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ABSTRACT 
 
Examination of Novel Cardiac Mechanisms Influencing Mitochondrial Proteomes 
during Diabetes Mellitus 
Walter A. Baseler 
 
 
Cardiac complications, including diabetic cardiomyopathy, are the leading cause of 
morbidity and mortality within diabetes mellitus.  Mitochondrial dysfunction has been suggested 
as an underlying factor in the initiation and progression of the pathology.  Cardiac mitochondria 
are characterized as two spatially distinct subpopulations within the myocyte including 
mitochondria located beneath the sarcolemma, termed subsarcolemmal mitochondria (SSM), and 
those located between myofibrils, termed interfibrillar mitochondria (IFM).  Mitochondrial 
subpopulations have been shown to respond differently to physiological and pathological stimuli 
with the IFM being the most impacted in a type 1 diabetic setting.  Proteomic evaluations within 
various models of diabetes have highlighted dynamic alterations of the mitochondrial proteome 
as a consequence of the pathology.  To date, no studies have identified how the proteomes of 
mitochondrial subpopulations are differentially impacted during a type 1 diabetic insult.  Further, 
the mechanisms involved in diabetes-driven mitochondrial proteomic alterations remain limited.  
Therefore, the goal of the present studies was to determine whether subpopulation-specific 
proteomes were altered with type 1 diabetes mellitus.  Further, we sought to identify mechanisms 
involved in mitochondrial proteomic dysregulation prevalent within diabetic cardiomyopathy.  
Type 1 diabetes mellitus was induced in 8 week old mice with multiple low dose (50mg/kg) 
injections of streptozotocin (STZ) administered for 5 days.  Five weeks post hyperglycemic 
onset, hearts were excised and mitochondrial subpopulations were isolated.   Proteomic analyses 
revealed that the proteome of diabetic IFM was significantly dysregulated compared to control 
with no changes within diabetic SSM compared to control.  Further, nuclear-encoded 
mitochondrial protein import was significantly decreased in the diabetic IFM, which correlated 
with decreased abundance of essential protein import constituent mitochondrial heat shock 
protein 70 (MtHsp70).  Because greater than 99% of proteins are of nuclear encoded origin and 
must be imported into the mitochondria, decrements to the import process may prove to be a 
novel mechanism of dysfunction within the diabetic IFM.  The inner mitochondrial membrane 
(IMM), the location of essential mitochondrial complexes including import translocases of the 
inner membrane (TIM), has been shown to be particularly prone to diabetes induced oxidative 
damage.  Reduction in oxidative damage within various pathologies has been shown to have 
beneficial effects upon mitochondrial functionality.  Therefore, we overexpressed antioxidant 
mitochondrial phospholipid hydroperoxide glutathione peroxidase (mPHGPx) to assess its 
impact upon the mitochondrial import process and proteomic makeup during a diabetic insult.  
Remarkably, nuclear-encoded mitochondrial protein import was corrected within the diabetic 
mPHGPx IFM, which correlated with restitution of a large proportion of mitochondrial proteins 
negatively impacted by diabetes mellitus including those involved in oxidative phosphorylation, 
the tricarboxylic acid cycle, fatty acid oxidation, and mitochondrial protein import.   MPHGPx is 
capable of scavenging mitochondrial lipid hydroperoxides specifically in mitochondrial 
membranes and hydrogen peroxide to a lesser extent. Overexpression of the antioxidant 
preserved or enhanced the protein content of essential mitochondrial import constituents 
translocase of the outer membrane 20 (Tom20), Tim23, Tim50, and MtHsp70 in mPHGPX 
diabetic IFM.  Therefore, we believe proteomic correction within mPHGPx diabetic IFM may be 
a consequence of preservation of mitochondrial protein import machinery.  These findings 
support the rationale for the use of mPHGPx as a mitochondrial-targeted therapeutic capable of 
protection in the diabetic heart.  Additional mechanisms of mitochondrial proteomic 
dysregulation within diabetes mellitus may exist including alterations to the 
transcriptional/translational regulators, microRNAs (miRNAs).   Therefore, we performed a 
broad scale miRNA analysis on control and STZ-treated mouse hearts 5 weeks post diabetic 
onset to determine the effect of diabetes mellitus on miRNA modulation.  Twenty nine miRNAs 
were shown to be dysregulated within the diabetic heart including miRNA-141 (miR-141), 
which was enhanced by 5 fold. miRNA targeting analyses (targetscan.org) revealed miR-141 
likely to regulated Slc25a3, the mitochondrial inorganic phosphate carrier.   Slc25a3 is essential 
for ATP production as it acts as conduit for inorganic phosphate to pass from the cytoplasm into 
the matrix, providing phosphate to fuel the ATP synthase.  IFM Slc25a3 protein content was 
decreased in the diabetic IFM, which correlated with decreased ATP synthesis rates. Similarly, 
overexpression of miR-141 decreased Slc25a3 protein content and ATP synthase activity within 
HEK293 cells.  These findings show, for the first time, miRNA modulation within diabetes 
mellitus has a direct impact upon mitochondrial proteomic makeup as well as mitochondrial 
functionality.   Further, miR-141 ablation may provide a protective benefit to mitochondria and 
subsequent cardiac function during a type 1 diabetic insult.  Taken together, the studies 
highlighted above prove that mitochondrial proteomic dysregulation prevalent within diabetes 
mellitus is a complicated process involving spatially distinct mitochondrial subpopulations and 
multiple mechanisms of action.  Targeted therapeutics aimed at the correction of one or more of 
these mechanisms may provide cardiac benefit from diabetic induced dysfunction via 
preservation of the mitochondrial proteome.    
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SPECIFIC AIMS 
 
 
Diabetic cardiomyopathy is the primary cause of heart failure in diabetes mellitus 
occurring independent of vascular pathogenesis.  It is characterized by contractile dysfunction 
leading to an increased risk of heart failure.  The hyperglycemic environment resulting from 
diabetes mellitus has been shown to be associated with mitochondrial dysfunction (2).  
Mitochondrial examinations are complicated by the fact that there are two mitochondrial 
subpopulations existing in the cardiomyocyte (3). The mitochondria are spatially distinct with 
the interfibrillar mitochondria (IFM) residing between myofibrils and the subsarcolemmal 
mitochondria (SSM) beneath the plasma membrane.  Nuclear encoded mitochondrial proteins, 
which make up 99% of the organelle’s proteome, are translated in the cytoplasm and must be 
imported into the mitochondria by a complex mechanism involving coordination between the 
outer and inner mitochondrial membranes (4, 6).   Recent proteomic analyses indicate decreased 
abundance of nuclear encoded proteins during a diabetic insult, including those essential for 
efficient mitochondrial import processes (1, 7).  Prior to this dissertation, mitochondrial protein 
import efficiency had not been studied in a pathology such as diabetes mellitus.   Specifically, it 
was unknown whether diabetes mellitus could cause cardiac mitochondrial protein import 
decrements and whether this is was mechanism of dysfunction in one or both mitochondrial 
subpopulations. 
 
Our long term goal is to better understand the mechanisms involved in the pathogenesis 
of diabetic cardiomyopathy as a prerequisite to the development of therapeutic interventions 
designed to lessen cardiac complications associated with diabetes mellitus.  The objective of this 
 xvi 
 
dissertation was to:  (1) to determine the effect of diabetic insult upon nuclear encoded protein 
import in mitochondria and identify key structural and functional differences seen in specific 
mitochondrial subpopulations; (2) to test the therapeutic benefit of overexpressing mitochondrial 
specific antioxidant mPHGPx on protein translocation into individual mitochondrial 
subpopulations during a diabetic insult;  (3)  to evaluate the effect of diabetes induced micro-
RNA (miRNA) modulation upon mitochondrial proteomic make-up. 
 
The central hypothesis of the dissertation was that type 1 diabetic insult would cause 
dysfunction of the mitochondrial protein import process, leading to a loss of key proteins 
required for adequate mitochondrial function and structure.  These effects being most 
pronounced in the IFM, influencing cardiac contractile processes.  The central hypothesis was 
based upon preliminary data produced in our laboratory indicating that cardiac mitochondria 
have decreased efficiency to import proteins following a diabetic insult.  Our rationale for the 
proposed research was based upon the notion that the understanding of mitochondrial 
subpopulation response and identification of key factors that contribute to mitochondrial 
dysfunction would aid in the development of therapeutics that can address specific mitochondrial 
subpopulations at greatest risk from diabetes.  We tested our central hypothesis by pursuing the 
following Specific Aims: 
 
Specific Aim I:  Determine the effect of type 1 diabetes insult on the mitochondrial protein 
import process and the presence of constituents involved in the import process.  Further, 
determine whether these effects are mitochondrial subpopulation-specific in response.     
 xvii 
 
To address Specific Aim I, we utilized a novel methodology in which a mitochondrial 
targeted protein was used to assess potential import deficiencies during a diabetic insult.  
Additionally, constituents involved in the mitochondrial protein import process as well as 
functional and structural parameters were analyzed.  Our working hypothesis was that type 1 
diabetic insult would be associated with dysfunction of the mitochondrial protein import process, 
as evidence by a decreased efficiency of mitochondrial protein import, and loss of key import 
process constituents. Further these effects were most pronounced in the IFM.   
 
Specific Aim II:  Evaluate the therapeutic potential of enhanced mPHGPx on the 
mitochondrial protein import process and mitochondrial proteome, following type 1 
diabetic insult.  Further, determine whether the effects of mPHGPx enhancement are 
mitochondrial subpopulation-specific in nature.   
mPHGPX is a unique  antioxidant that has the ability to reduce peroxidized acyl groups 
in phospholipids, fatty acid hydroperoxides, and cholesterol peroxides within subcellular 
membranes (5, 8).  Previous work from our laboratory has shown overexpression of mPHGPx to 
preserve mitochondrial inner membrane structure, decrease lipid peroxidations, and enhance 
ATP production in diabetic IFM subpopulation.    Overexpression of mPHGPx was employed to 
assess proteomic dysregulation, post translational modifications, and protein import efficiency 
during diabetic insult. Our working hypothesis was that enhanced mPHGPx content would lead 
to restitution of the mitochondrial protein import process and prevention of mitochondrial 
dysfunction associated with diabetic cardiomyopathy by reversing changes in proteomic loss 
including proteins essential for mitochondrial structure and function. Further, these effects were 
shown to be most pronounced in the IFM. 
 xviii 
 
 
Specific Aim III:   Determine the effect of type 1 diabetes insult on miRNA regulation 
within the diabetic heart.  Further, evaluate how alterations in miRNA presence influences 
essential proteins involved in mitochondrial function and structure.   
 To address aim III we performed a broad scale miRNA screening within the heart 
following type 1 diabetic insult to elucidate the effect of the pathology on miRNA modulation.  
The most relevant miRNAs, specifically miR-141, were further examined to determine their 
impact on essential mitochondrial processes.  Our working hypothesis was that miRNAs 
governing critical mitochondrial processes, such as ATP production, would be upregulated in the 
diabetic heart.  Further, these miRNAs negatively impacted mitochondrial functionality in a type 
1 diabetic setting.    
The research generated from this dissertation was innovative because it examined  
previously unexplored mechanisms of mitochondrial dysfunction associated with diabetes 
mellitus and employed the use of novel molecular techniques developed in our laboratory.  At 
the completion of these studies, we were able to determine protein import dysregulation in 
mitochondrial subpopulations, highlight specific areas at risk, and evaluate the role of miRNAs 
during a diabetic insult.  Our research concerning mPHGPx highlighted the potential therapeutic 
value of this critical antioxidant to the import process.  Further, the outcomes enhanced our 
understanding of pathogenic mechanisms involved with diabetic cardiomyopathy as well as 
provided insight into potential therapeutic interventions that will aid in the treatment of type 1 
diabetes mellitus.    
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BACKGROUND AND SIGNIFICANCE 
 
1.1 Diabetes Mellitus   
Diabetes mellitus (DM) is a pathological condition that is generally classified as two 
forms.  Type 1 diabetes, which constitutes 10% of total cases and Type 2 diabetes, which 
comprises 90% of cases (121). Both type 1 and type 2 diabetes, when left untreated, will lead to 
a hyperglycemic environment.  Two lesser known types of diabetes exist including gestational 
diabetes, which is a complication that arises in 2-10% of all pregnancies (20).  DM can also 
manifest from certain genetic conditions, surgeries, medications, infections, and pancreatic 
diseases as well, but these diagnoses account for less than 1% of total cases.  Generally, DM is 
diagnosed when fasting blood glucose levels are above 126 mg.dl-1 and insulin levels are less 
than 0.50 ng/ml (type 1 DM) (132).   
1.1a Type 1 diabetes mellitus 
Type 1 diabetes mellitus (T1DM) is characterized by the autoimmune destruction of 
pancreatic β-cells, severely depleting insulin levels in the body.  Briefly, there are several known 
autoantigens present within pancreatic islet cells, which promote their destruction through a β-
cell mediated mechanism including islet cell antigen, insulin and pro insulin, glutamic acid 
decarboxylase, and protein tyrosine phosphatase (94). T1DM is also referred to as juvenile-onset 
diabetes due to the majority of diagnoses occurring in children, adolescents, and young adults.   
The primary treatment for T1DM is regimented subcutaneous insulin injections prior to eating, 
allowing for proper cellular glucose transport and utilization.  Severe insulin deficiency, as seen 
in T1DM, increases ketone body production in the liver, causing lowered blood pH, which 
results in diabetic ketoacidosis, a condition known to be fatal if left untreated (29).   
 3 
 
Uncontrolled T1DM can cause a multitude of other ailments including heart disease, retinal 
detachment, renal failure due to diabetic nephropathy, nervous system damage, lower limb 
amputations, and periodontal disease (20).  Ultimately, these effects are directly associated with 
the hyperglycemic environment produced by DM.     
1.1b Significance 
Cardiac failure and heart disease is the leading cause of mortality among diabetic patients 
in the United States (52). Currently, over 171 million people worldwide are afflicted with DM 
with an estimate of 366 million by 2030 (113, 153).  In the United States alone, there are at least 
16 million diabetics, of which over 1 million are afflicted with T1DM (30).  DM is characterized 
as a hyperglycemic environment resulting from defects in insulin secretion or function.  Chronic 
hyperglycemia will lead to damage, dysfunction and ultimately failure of specific organs 
including the kidneys, eyes, nerves, blood vessels, and heart (156).  Increased oxidative damage, 
due to an imbalance between reactive oxygen species (ROS) and antioxidant defense, has been 
implicated with the onset and progression of diabetes-associated cardiac dysfunction such as 
diabetic cardiomyopathy.  Diabetic cardiomyopathy occurs independently of vascular 
dysfunctions such as atherosclerosis, coronary artery disease, or hypertension and is becoming an 
increasingly prevalent diagnosis in heart failure (6).  Diabetic cardiomyopathy affects the 
myocardium leading to changes in heart structure and function with symptoms ranging from 
cardiac hypertrophy, diastolic and systolic dysfunction, increased cardiac fibrosis, and elevated 
ROS levels due to increased glucose exposure (54, 69, 150).  Specifically, our laboratory and 
others have also shown mitochondrial dysfunction to be a component in diabetic 
cardiomyopathy, due to its role in ATP production for cardiac contractile function.  
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1.2 Diabetic Cardiomyopathy 
Vascular complications from diabetes such as atherosclerosis, coronary artery disease 
(CAD) and hypertension have been well studied (5, 57). However, cardiac dysfunction 
independent of vascular pathogenesis, such as diabetic cardiomyopathy, is becoming an 
increasingly prevalent diagnosis in heart failure (6).   Clinically, Rubler at al. were the first to 
diagnose patients with cardiomyopathies existing in the absence of the previously mentioned 
vascular abnormalities (46)  In a similar study, diabetic patients lacking CAD had increased left 
ventricular (LV) end diastolic pressure (EDP), decreased LV compliance, and decreased ejection 
fraction (108).  Characterizing the mechanistic properties of diabetic cardiomyopathy, 
researchers have generally shown cardiac contractile dysfunction, enhanced fibrosis, and 
enhanced oxidative stress as primary causative agents ultimately leading to the dysfunction seen 
within the pathology (44). 
1.2a Cardiac contractile dysfunction 
Diastolic dysfunction is the most common defect manifesting in diabetic 
cardiomyopathy, characterized by prolongation of relaxation and considerable slowing in 
relaxation velocity (12, 134).   Thirty diabetic male rats were analyzed and compared to controls 
in which the diabetics showed significant decreases in early to late diastolic mitral inflow 
velocity ratio and isovolumic relaxation time (39).  Based on the results, the group concluded 
diastolic dysfunction in the diabetic hearts may be related to uncoupling of the contractile 
apparatus without increases in chamber thickness.  Further, a similar study of young T1DM 
subjects without known CAD demonstrated reduced early peak mitral velocity, increased late 
peak mitral velocity, and prolonged deceleration time and isovolumic relaxation time compared 
to controls (116).  
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Animal studies have shown diabetic cardiomyopathy to be associated with systolic 
dysfunction including decreases in heart rate, systolic left ventricular blood pressure, and 
fractional shortening (61, 66, 157).  However, evidence of systolic dysfunction has not been 
uniformly reported in the literature (87, 109).  Those who report normal LV systolic  function 
within diabetics have also shown abnormalities during supine exercise, indicating systolic 
reserves may be reduced (142).  It should be noted that technical limitations may be the primary 
cause for no alterations seen pertaining to systolic dysfunction. Advancements in technology 
have allowed for more sensitive assessments of strain, strain rate, and myocardial tissue Doppler 
velocities (44, 45). 
1.2b Fibrosis 
 Structural changes to the diabetic myocardium have been reported, focusing on the 
understanding of enhanced fibrosis in the absence of CAD (10).  In a study of 9 diabetic hearts 
post mortem in which 6 died from heart failure, Regan et al. discovered elevated levels of 
interstitial fibrosis within the cardiac tissue (109).  Similarly, patients with mild diabetes and no 
symptoms of CAD showed significant increases in right ventricular myocardial cell volume and 
an increased percentage of interstitial fibrosis compared to controls (100).  The mechanisms 
involved in fibrosis accumulation within the diabetic heart are not entirely understood.  
Widyantoro et al. found elevated levels of plasma endothelin-1 (ET-1) within the vascular 
endothelium of mice, which is associated with the accumulation of cardiac fibroblasts in the 
diabetic hearts (151).  Further, increased fibrosis has been observed within the streptozotocin 
(STZ)-diabetic mouse heart in which it shares an association with enhanced protein kinase C 
beta-1 activation and decreased heart function (149).  Although the mechanisms involved remain 
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to be resolved, it is clear that fibrosis plays a critical role in diabetic induced cardiac dysfunction 
in animal and human.   
1.2c Oxidative stress 
Hyperglycemia is the primary causative agent for diabetic cardiomyopathy.  ROS, such 
as superoxide, are major contributors to hyperglycemic induced cellular damage to the heart 
primarily through the increased activity of four metabolic pathways.  Overproduction of 
superoxide causes increases in polyl pathway flux, advanced glycation end product (AGE) 
formation, hexosamine pathway flux and activation of protein kinase C leading to an imbalance 
between ROS and antioxidant defense known as oxidative stress (13, 41, 99).   Oxidative stress 
has been shown to alter myocyte morphology, function, protein content, and ion action leading to 
diabetic cardiomyopathy (13).  Hyperglycemia has been suggested to decrease cellular 
antioxidant levels within the heart increasing the susceptibility of ROS-induced damage (114).  
Mitochondria are the main source of ROS generation in cardiomyocyte.  Previous work from our 
laboratory shows STZ induced T1DM presents significantly increased levels of ROS produced 
from cardiac mitochondria (35).    
1.3 STZ Model of Diabetic Cardiomyopathy 
STZ, a nitrosourea derivative, was first used clinically to aid in the destruction of cancerous 
pancreatic β-cells in the early 1980’s (1).  Given the antibiotics unique propensity to target 
insulin-secreting islet cells, it was also successfully utilized as a method for type 1 diabetic 
induction within rodent models (1).  Structurally, STZ mimics glucose and is able to be 
transported into cells specifically through transport protein GLUT2.  STZ build up occurs within 
the pancreas because GLUT2 exists predominantly within pancreatic β-cells (148). 
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Mechanistically, STZ acts as an alkylating agent capable of causing DNA damage, which in turn 
leads to activation of ADP-ribosylation, depleting cellular NAD+ and ATP (119).  Further, STZ 
elicits enhanced ATP dephosphorylation leading to increased xanthine oxidase activity and 
elevated levels of superoxide production.  Finally, increased ROS accumulation within the 
pancreas will inevitably cause enhanced necrosis of β-cells and decreased insulin production 
within the organ (119).  Our laboratory performs multiple low dose intraperitoneal injections 
(50mg/kg) of STZ in FVB mice, which is the recommended protocol by the Animal Models of 
Diabetic Complications Consortium (AMDCC).  Typically, mice will develop fasting 
hyperglycemia (<250 mg/dl) and low levels of insulin (0.5 ng/ml) 7-14 days post STZ injection 
(15).  Our laboratory and others have shown STZ treatment will lead to diabetic cardiomyopathy, 
including alterations to diastolic and systolic function (35, 97, 134).  Specifically, we have 
shown significant decreases in rate of relaxation and contraction as well as enhanced developed 
pressure within 5 week diabetic STZ-treated mice (35).  A major advantage of STZ treatment is 
that it can be administered at any time point during rodent’s lifespan and can be used on any type 
of genetic background including transgenic animals.  Because of these aforementioned reasons, 
STZ is the most frequently used model of type 1 diabetes within rodent models (15).     
1.4 Mitochondrial Subpopulations 
Mitochondrial analyses are complicated primarily because two spatially distinct 
mitochondrial subpopulations exist in cardiac tissue, the subsarcolemmal mitochondria (SSM) 
and interfibrillar mitochondria (IFM). As shown in figure 1.1, SSM are located directly below 
the sarcolemma, have rod like morphology,  are larger, and more variable in shape with sizes 
reaching up to 4 µm (124).   It has been suggested that they function to create ATP which is 
utilized in active transport of electrolytes and metabolites through the sarcolemma (112, 124).  
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IFM are arranged in longitudinal rows tightly packed between myofibrils, are smaller than SSM, 
and elongated in size ranging up to 2µm (124).  It has been suggested that IFM create ATP 
chiefly for the fueling of muscle contraction (112).  Internal structure differs between 
subpopulations with lamelliform cristae in SSM and mainly tubular or mixed tubular/lamelliform 
in IFM (112).  Tubular cristae structure decreases intracristal space leading to a higher 
concentration of protons within the IFM, increasing adenosine triphosphate (ATP) synthase 
activity, and enhancing oxidative phosphorylation. It is well established that IFM also display 
increased oxidative rates (1.5 fold), ATP production (3 fold), and nuclear encoded protein import 
(3 fold) when compared with the SSM (16, 104, 112, 131). 
        
Fig 1.1 Mitochondrial Subpopulations 
Investigators has shown mitochondrial subpopulations can have differing responses to 
physiological or pathological stimuli including aging, Ischemia/Reperfusion (I/R), and diabetes 
mellitus (35, 67, 77, 111).  Pathological aging causes significant increases in oxidative stress 
levels, with elevations in manganese superoxide dismutase (MnSOD, SOD2), glutathione 
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peroxidase 1 (GPX1) as well as superoxide and hydrogen peroxide, exclusively in the IFM 
subpopulation (67).  IFM mitochondria isolated from diabetic mouse hearts have decreased 
respiratory function, elevated levels of superoxide, nitrotyrosine, and increased lipid 
peroxidation (35).  Interestingly, research evaluating skeletal muscle from type 2 diabetic 
patients demonstrated a decreased mitochondrial respiratory function with no change evident in 
the IFM subpopulation (111).  These results indicate that mitochondrial subpopulations respond 
differently to various pathological insults and locations highlighting the importance of examining 
the subpopulations in different muscles and pathologies. 
1.5 Mitochondrial Dysfunction 
The pathological mechanisms involving heart failure are multifactorial, however there is 
a multitude of data linking cardiac contractile abnormalities, as seen in diabetic cardiomyopathy 
to mitochondrial dysfunction (56, 133, 159).   Specifically, oxidative stress, mitochondrial 
calcium (Ca2+) handling, and mitochondrial proteomic remodeling are all factors involved in 
mitochondrial dysfunction within the diabetic heart. 
1.5a Mitochondrial dysfunction and oxidative stress 
ROS, such as superoxide and hydroxyl anions, are known to be heavily produced from 
the mitochondrial respiratory chain.  Mitochondrial driven ROS generation is thought to be a 
consequence of enhanced electron leakage, primarily from complex I and III of the electron 
transport chain (ETC) due to an increased flux of substrate fueling the mitochondria  (11, 128).  
ROS will damage mitochondria and cellular components through several mechanisms including 
direct oxidation of DNA and proteins, lipid peroxidations, and protein nitrations (14, 147).  
Enhanced ROS production from cardiac mitochondria has been shown within several different 
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T1DM animal models (35, 126).   Alloxane-treated T1DM rats display enhanced tyrosine 
nitration of energy metabolism including CoA:oxoacid CoA transferase and creatine kinase 
(136).  Further, overexpression of mitochondrial antioxidants such as catalase and MnSOD have 
shown to protect cardiac contractility and mitochondrial ETC function within the T1DM OVE26 
mouse model (123, 159).  In the STZ-T1DM mouse model, our laboratory utilized electron 
paramagnetic resonance spectroscopy, which demonstrated enhanced superoxide within the 
diabetic IFM isolated from the heart compared to control (35).  Further, the diabetic IFM also 
displayed enhanced nitrotyrosine content and lipid peroxidation byproducts malondialdehyde 
and 4-hydroxyalkenal implicating elevated levels of both reactive nitrogen species and hydroxyl 
anions (35). 
1.5b  Mitochondrial dysfunction and calcium handling 
Mitochondria are known to aid in the sequestering and emission of Ca2+ to help regulate 
excitation-contraction coupling within the heart (65).  Ca2+ also has additional functional roles 
within mitochondria including regulation of oxidative phosphorylation and activation of 
apoptosis through induction of the mitochondrial permeability transition pore (mPTP) (58).  
Indeed, decreased mitochondrial Ca2+ concentrations are shown in cardiomyocytes derived from 
T1DM hearts (75, 161).  Further, Oliveira et al. performed exogenous calcium administration 
experiments within isolated mitochondria from STZ-induced T1DM rats, which yielded 
decreases in Ca2+ retention as well as enhanced mPTP opening compared to control group (102).  
Similarly, our laboratory has shown enhanced rates of mPTP formation and cytochrome c release 
in IFM subpopulations isolated from STZ treated mice (154).  Taken together, the data suggests 
T1DM will lead to cardiac contractile dysfunction, in part, through a mechanism of 
mitochondrial Ca2+ mishandling and enhanced mitochondrial driven cellular apoptosis. 
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1.5c  Mitochondrial dysfunction and proteomic remodeling 
Broad scale proteomic analyses are becoming increasingly prevalent within various type 
1 diabetic models and are paramount to understanding mitochondrial dysfunction within the 
heart (4, 17, 60, 123, 136). Isolated mitochondria from STZ induced T1DM rats were subjected 
to two dimensional polyacrylamide gel electrophoreseis (2D-PAGE) coupled with matrix-
assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS). The 
results indicate 30 proteins were altered including increases in fatty acid oxidation (FAO) 
proteins, decreases in oxidative phosphorylation (OXPHOS)  complex I subunits, and reductions 
in mitochondrial heat shock proteins (Hsp60 and MtHsp70) within the diabetic group (136).  In a 
similar study model, Hamblin et al. analyzed cardiac tissue from eight week STZ-diabetic rats 
and found elevated FAO proteins as well as decreases in aldehyde dehydrogenase (ALDH-2) and 
3-mercaptopyruvate sulfurtransferase, proteins involved in antioxidant defense (60).  Utilizing 
iTRAQ proteomic labeling coupled with multidimensional protein identification technology 
mass spectrometry (MuDPIT MS/MS), Jüllig et al. examined STZ-treated rat cardiac 
mitochondria four months post-diabetes mellitus onset in which long chain fatty acid proteins 
were elevated in conjunction with reductions in catabolic short chain fatty acid enzymes, which 
could potentially explain enhanced lipotoxicity within type 1 diabetes mellitus (68).  In recent 
studies, Bugger et al. employed a label free approach in conjunction with selective mitochondrial 
sub compartment enrichment techniques to examine mitochondria in 12 week old type diabetic 
Akita mice from the kidney, liver, brain, and heart (17).  The results indicated increases in FAO 
proteins, with subsequent decreases in tricaboxylic acid proteins. OXPHOS proteins were 
differentially regulated with an increase in ATP synthase subunit and decreases in Complex I and 
IV subunits (17). 
 12 
 
Additionally, our laboratory examined proteomic differences in spatially distinct 
subpopulations of mitochondria within the STZ-induced diabetic heart through two separate 
methodologies, 2D-DIGE and iTRAQ coupled with MALDI-TOF-MS (4).  Interestingly, the 
protein alterations within the two mitochondrial subpopulations were vastly different with the 
IFM being the most adversely affected in the diabetic heart.  Specifically, proteins involved in 
FAO, OXPHOS subunits (complex I, IV, and V), TCA cycle intermediates, mitochondrial 
structure (mitofilin), and mitochondrial protein import (MtHsp70) were significantly decreased 
in the diabetic IFM compared to control with no change in the SSM.  Further, multidimensional 
protein identification technology (MudPIT) was used to identify post translational modifications 
(PTM) of proteins within the mitochondrial subpopulations from control and diabetic mouse 
hearts.  Diabetic IFM displayed the highest number of oxidations and deamidations to proteins 
including MtHsp70 and mitofilin, both proteins that were also reduced in abundance (4). 
1.6  Mitochondrial Protein Import 
Currently, there are an estimated 1500 proteins in the human mitochondrion, with only 13 
transcribed and translated in the organelle itself (2, 19, 105). The vast majority of proteins 
(>99%) are nuclear-encoded and imported into the mitochondrion through a complex mechanism 
of translocation (21).  Protein import into the matrix is a process involving direct interaction 
between the imported protein, the outer mitochondrial membrane (OMM), inner mitochondrial 
membrane (IMM), and the presequence translocase-associated motor (PAM) creating a 
“supercomplex”, which generates a singular avenue for translocation once the protein is 
delivered to the mitochondrion (23).   Proteins destined for the mitochondria are known as 
preproteins (48) and have specific targeting signals with cleavable N-terminal presequences 
being the most prevalent (48, 103).   
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1.6a Outer membrane protein import 
Nuclear-encoded preproteins are transported via cytosolic chaperones hsc70, hsp90, and 
mitochondrial import stimulation factor (MSF-L) to the translocase of the outer membrane 
(TOM) complex, which has multiple receptors that help recognize and guide preproteins to and 
through the OMM for  entrance into the mitochondrion  (43, 62, 158, 160).  Tom20 is the main 
receptor for N-terminal presequence recognition and subsequent binding to the cytosolic side of 
the OMM.  This protein has a binding groove for the hydrophobic face of the polypeptide 
presequence allowing for proper attachment to the mitochondrion.  Tom22 is negatively charged 
and cooperates with Tom20 to help keep the incoming protein unfolded by attaching itself to the 
positively charged presequence.  Finally, β-barrel protein Tom40, along with its three subunits 
Tom5, Tom6, and Tom7 (small Toms) form the import pore of the TOM complex through which 
translocating polypeptides are guided into the inner membrane space (Figure 1.2). 
1.6b Inner membrane protein import  
Once through the OMM, preproteins bind simultaneously to the inner membrane space 
domain of Tom22 and Tim50, as well as IMM protein Tim21, allowing for preproteins to be 
guided to the translocase of the inner membrane 23 (TIM23) complex. The TIM23 complex is 
the main mitochondrial import pore that allows entrance into and through the IMM (22, 96).  
Tim23 has a direct role in the translocation of preproteins into different areas of the 
mitochondrion including the inner membrane space, IMM, and matrix (22, 40).  The majority of 
preproteins that travel through the TIM23 complex are dependent upon mitochondrial membrane 
potential (ΔΨm) and the PAM complex.   MtHsp70 is an essential import protein and the central 
subunit of the PAM complex.  In a well-studied mechanism, MtHsp70 anchors to Tim44 on the 
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matrix side of the IMM binding itself to a translocating preprotein, “trapping” and “pulling” it 
through the IMM in an ATP-dependent manner (144).  Once into the mitochondrial matrix, the 
N-terminal presequence is subsequently cleaved by matrix processing peptidase (MPP) and the 
unfolded translocating protein is refolded into its native confirmation by co-chaperones hsp60 
and hsp10 (59, 125).  Below is a detailed schematic of matrix-targeted nuclear encoded protein 
import as described in the text.  
 
Fig 1.2 Mitochondrial Import of Matrix-Targeted Precursor Proteins 
Studies have shown that many matrix-targeted preproteins are not dependent on cytosolic 
molecular chaperones for import and it is believed MtHsp70 provides the force for unfolding of 
 15 
 
preproteins for protein import.  This requires that import occurs at contact sites where the inner 
and outer membrane come in close association to allow the protein to span both membranes 
being simultaneously inserted into the TOM complex and TIM23 complex (106). MtHsp70 has 
been reported to be responsive to cellular insults including thyroid hormone treatment, glucose 
deprivation, and myocardial I/R (60, 71, 83, 155).  Research from our laboratory using rat 
neonatal cardiac myocytes infected with an adenoviral vector expressing MtHsp70 has shown 
protection from simulated I/R injury which were associated with increased import of nuclear 
encoded antioxidant proteins (MnSOD) (155). 
1.6c Presequence translocase-associated motor complex 
MtHsp70 contains three key regions that include an ATPase domain, peptide binding 
domain, and a carboxy-terminal segment, all of which are essential for proper import 
functionality (74).  Mutations to MtHsp70 in multiple species have proven to have detrimental 
effects upon matrix-associated import.  As an example, a mutation to the Tim44 binding domain 
of MtHsp70 reduced mitochondrial translocation activity significantly (79).  Additionally, 
inactivation of ssc1 (MtHsp70 yeast equivalent) by temperature-sensitive mutation inhibited the 
unfolding, translocation, and subsequent folding of imported preproteins in vitro (51, 70).  
Interestingly, yeast cells containing low intrinsic ATP production from their mitochondria are 
still viable, however a deletion of Ssc1 causes complete death of the cell denoting the vast 
importance of this critical protein for not only the mitochondrial import process, but overall 
cellular viability (33). 
MtHsp70 driven protein import is regulated by the four other essential members of the 
PAM complex which include Tim44, Pam16 (Tim14), Pam18 (Tim16), GrpE (Mge1) and the 
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non-essential protein Tim17.  Tim44 is an adaptor protein that anchors itself to the IMM side of 
the mitochondrial matrix, serving as a pedestal for MtHsp70 (137).  Recent studies have 
highlighted Tim44 as a translocon with multiple functions including recruitment and 
coordination of PAM complex constituents, allowing for efficient protein translocation (118).  A 
mutation of the J-related segment of Tim44 in Saccharomyces cerevisiae significantly decreased 
mitochondrial protein import viability, presumably through dysfunctional Tim44-MtHsp70 
interaction (89). 
Matrix protein GrpE is the nucleotide exchange factor that promotes the release of ADP 
from MtHsp70.  Liberation of ADP disassociates the preprotein from MtHsp70 and allows for 
rapid binding of new ATP to further drive mitochondrial protein translocation (38).   
Examination of a conditional mutant allele of Mge1 (eukaryotic GrpE homolog) demonstrated 
decreased MtHsp70 binding efficiency to translocating preproteins and enhanced binding of fully 
imported preproteins highlighting the importance of GrpE regulatory effect upon MtHsp70 (76). 
MtHsp70 is also regulated by j-like protein Pam16 and j-protein Pam18, which function 
collectively to regulate protein import activity.  Pam18 uses its j-domain to stimulate the ATPase 
activity of MtHsp70 and is critical for proper PAM complex function.  Additionally, Pam16 acts 
as a negative regulator of Pam18 by forming a heterodimer which controls its ability to interact 
with the presequence translocase and is known to affect the formation of the MtHsp70-Tim44 
complex (34, 49).  Further, the destabilization of the Pam16-Pam18 complex not only exhibited a 
decrease in mitochondrial protein import, but also had lethal effects upon yeast cell viability (34, 
92).  Finally, although not essential for cell viability, a sixth member of the complex has been 
identified as Pam17.  Genetic and biochemical analyses indicated that Pam17 interacts with 
Tim44 in a complementary manner to assist in protein import (64, 117).  Also, Pam17 has been 
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shown to interact with several other PAM complex proteins, including Tim23, prior to preprotein 
translocation and its interaction is required for proper Pam16-Pam18 complex formation (139).  
Interestingly, mitochondria lacking Pam17 has shown impaired mitochondrial protein import and 
PAM complex formation, although import itself was not completely abolished (139).  With 
multiple proteins comprising the PAM complex, some with multiple regulatory functions, 
MtHsp70 driven mitochondrial protein import is one of the more complicated processes that 
occur inside the mitochondrion. 
1.6d Brownian ratchet versus power stroke models 
Functionally, MtHsp70 is characterized as the primary motor subunit which aids in the 
unfolding, transport, and refolding of mitochondrially-targeted proteins containing N-terminal 
presequences through the mitochondrial IMM to target destinations.  The vast majority of 
mitochondrial matrix proteins are imported through a MtHsp70-dependent mechanism.  
However, the motor subunit has also been shown to aid in the import of mitochondrial IMM and 
IMS proteins as well.  Oxidase assembly 1 (oxa1), a mitochondrial IMM translocase, was proven 
to be imported into the matrix via MtHsp70 and subsequently reinserted back into the 
mitochondrial IMM (8).  Likewise, IMS space proteins containing bipartite signaling sequences 
(matrix and IMS), such as cytochrome b2, are partially pulled into the matrix while being 
actively unfolded by MtHsp70. The bipartite signaling sequences are subsequently cleaved 
allowing the functional portion of the protein to stay in the IMS where it is actively folded into 
its native confirmation (53). 
Although MtHsp70 is widely accepted as an essential constituent for mitochondrial 
protein import, how it exerts its effect upon translocating proteins is still unclear.  There are two 
 18 
 
different models proposed for MtHsp70 mechanism of action; the Brownian ratchet model and 
the power stroke model (Figure 1.3) (95).   Specifically, the Brownian ratchet mechanism 
proposes the N-terminal preprotein of the polypeptide is translocated into the matrix initially by 
the pulling force of ΔΨm.  Once through the IMM, the preprotein binds to MtHsp70, ATP 
hydrolysis occurs, and MtHsp70 is released from the import docking subunit Tim44.  MtHsp70 
acts to “trap” the translocating protein by preventing its retrograde movement back into the IMM 
(82, 101). Additional MtHsp70/Tim44 complexes bind to deeper segments of the incoming 
polypeptide further assisting in the movement of the protein into the matrix.  Nucleotide 
exchange factor GrpE, catalyzes the release of adenosine diphosphate (ADP) from MtHsp70, 
facilitating the disassociation of the motor subunit from the protein (82, 101).  This mechanism 
alleviates the dependence upon ΔΨm for mitochondrial protein import (129). 
The power stroke model begins in a similar fashion with MtHsp70 attached to the 
docking subunit Tim44.  However, MtHsp70 does not dissociate from Tim44, rather it undergoes 
a conformational change fueled by binding to the incoming polypeptide followed by ATP 
hydrolysis, which actively propels the protein through the IMM and into the matrix.  GrpE again 
functions as a nucleotide exchange factor, facilitating the release of MtHsp70 from the 
translocating protein.  This method indicates that multiple molecules of MtHsp70 would be 
needed to thrust the protein into the mitochondrial matrix (24).  Indeed, blue native complex 
analyses of arrested TIM-TOM-PAM supercomplexes estimate 6-7 MtHsp70 molecules are 
available per imported protein at any given time (37).  Below is a diagram depicting the 
predicted differences between the Brownian ratchet and power stroke model. 
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Fig 1.3 Power Stroke verse Brownian Ratchet Models 
Recent literature supports the notion that there is not a singular mechanism of action 
pertaining to the motor function of MtHsp70. It is likely both models are employed in 
conjunction depending on what protein in being imported (72).   As an example, preproteins 
must be in an unfolded confirmation to fit through the pores of the OMM and IMM.  MtHsp70 
will exert the necessary amount of force needed to push the N-terminal portion of the imported 
protein into the matrix.  This motion actively unfolds C-terminal hydrophobic domains at the 
OMM pore during the import process allowing for linear movement into the target destination 
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(143).  MtHsp70 is the likely driving force for the linearization of proteins due to the absence of 
unfolding enzymes present at the OMM (145).  Additionally, the unfolding of proteins during 
mitochondrial import is accelerated when the presequence is long enough to span the IMM and 
OMM, thereby contacting MtHsp70 for expedited entry into the matrix (86).  In this scenario, the 
power stroke model is the most logical mechanism of import for tightly folded proteins due to a 
large amount of force needed to linearize the protein prior to translocation.  However, proteins 
lacking tightly folded domains do not need to be forcefully straightened.  Therefore, the 
Brownian ratchet model would seem to be the most efficient mechanism of action (152).  Thus, 
the mechanism by which MtHsp70 exerts itself upon mitochondrial protein import likely 
depends upon the composition of the translocating protein itself. 
1.7 Antioxidant Defense 
Increased oxidative damage, due to an imbalance between reactive oxygen species (ROS) 
and antioxidant defense, has been implicated with the onset and progression of multiple disease 
states including I/R, aging, and diabetes-associated cardiac dysfunction such as diabetic 
cardiomyopathy.  ROS production is regulated by multiple antioxidant enzyme families 
including the superoxide dismutases (SOD) and glutathione peroxidases (GPx).   
1.7a Superoxide dismutase 
Superoxide dismutases are a family of enzymes that catalyze the dismutation of 
superoxide into oxygen and hydrogen peroxide (50, 88).  There are multiple isoforms of SOD, 
however, the most prominent are the cytoplasmic copper zinc SOD (CuZnSOD, SOD1) and 
mitochondrial specific MnSOD (9, 130).  Due to the high quantity of superoxide produced within 
mitochondria, MnSOD remains a key factor in oxidant regulation.  Overexpression of MnSOD 
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within the type 1 diabetic heart elicits reduced oxidative damage, improved ETC functionality, 
and protects against diabetic induced decreases in mitochondrial mass (122).  Further, a genetic 
knockout of MnSOD within mice caused severe dilated cardiomyopathy and was lethal within 
days of birth, presumably through a mechanism of enhanced oxidative stress (78). 
1.7b Glutathione peroxidase 
The GPx’s are a selenoprotein dependent family of enzymes that use reduced glutathione 
(GSH) to catalyze the reduction of hydrogen peroxide and lipid peroxides.  GPx1, the most 
characterized enzyme of the family, is ubiquitously expressed within almost all tissues (25-27).  
T1DM, induced through STZ injection in male Wistar rats show increased abundance of GPx1 
within the liver that coincided with increased oxidative stress present within the organ (115).  
Other members of the family exist predominantly in specific areas of the body including GPx2 
(gastrointestinal tract) and GPx3 (kidney) (31, 131).   
The GPx4 family exists in three different isoforms, which target the enzyme to different 
locations within the cell including the nucleus (nGPx4), cytoplasm (GPx4), and mitochondria 
(mPHGPx).  GPx4 is unique to other GPx family members in that it exists as a monomeric 
structure and has the ability to reduce peroxidized acyl groups in phospholipids, fatty acid 
hydroperoxides, and cholesterol peroxides within subcellular membranes (93).  Functionally, the 
selenoanalate anion is oxidized by a hydroperoxide to selenic acid and subsequently reduced in 
its active state with two molecules of GSH (Fig 1.4A) (138).  Further, in the absence of GSH, 
GPx4 is able to turn into a thiol peroxidase and oxidize thiol groups within proteins (Fig 1.4B). 
A detailed schematic below highlights mPHGPx mechanism of action.    
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Fig. 1.4 Glutathione Peroxidase 4 Catalysis (32) 
MPHGPx, primarily located within and around the mitochondrial inner membrane 
(IMM), has been shown to be protective against apoptosis, oxidants, DNA-damaging agents, and 
glucose deficiency (84).  Additionally, our laboratory has shown mPHGPx overexpression to be 
protective of cardiac contractile function through a mechanism of reduced lipid peroxidations 
and preservation of the mitochondrial ETC complex following I/R injury (36).  Further, we have 
also shown overexpression of mPHGPx to preserve mitochondrial inner membrane structure, 
decrease lipid peroxidations, and enhance ATP production in diabetic IFM subpopulation 
through a mechanism of cardiolipin preservation.     
1.8  Micro-RNA (miRNA) 
miRNAs are novel post transcriptional regulators discovered in the early 1990’s.  
Originally described in the nematode C. elegans, miRNAs are ubiquitous among many species 
including all vertebrates (146).  To date, there are over 677 known human miRNAs located 
primarily around intergenic regions, introns, and to a lesser extent, exons of protein coding 
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genes.  In the nucleus, RNA Polymerase II is chiefly used to transcribe miRNAs producing a 
“pri-miRNA” transcript that has a hairpin loop, capped 5’ end and polyadenylated tail all of 
which can be thousands of basepairs in length.  Nuclear located RNase III enzyme, Drosha, will 
then cut the pri-miRNA into the intermediate form “pre-miRNA”, which still contains the hairpin 
loop but is significantly smaller in size (approximately 70 basepairs in length).  Pre-miRNA are 
exported out of the nucleus into the cytoplasm by nuclear membrane protein exportin-5 with the 
help of ran-guanosine triphosphate.  Once into the cytoplasm, pre-miRNA are cut again by 
another RNase III enzyme, Dicer, resulting in the mature double stranded miRNA, ranging from 
20-25 base pairs (85).  The final stage of processing involves the formation of the RNA Induced 
Silencing Complex (RISC).  Briefly, Dicer is able to unravel the miRNA from its complementary 
sequence leaving only the single stranded functional miRNA present.  Dicer, along with 
cofactors transactivating response RNA binding protein and protein activator of interferon 
induced protein kinase help to bring the miRNA to a member of the argonaute family (AGO1-4) 
forming the RISC (107).  AGO proteins function in miRNA repression by inhibiting protein 
synthesis when artificially tethered to the mRNA 3’ UTR (47).   The miRNA will then target the 
RISC, AGO in particular, to a specific mRNA for binding and subsequent inhibition.  miRNA 
have a 2-7 base pair “seeding region” which binds directly to the target mRNA.  Once bound, the 
complex will cause translational repression, deadenylation, or endonucleolytic cleavage causing 
mRNA degradation (80).  Below is a diagram depicting the general mechanism of miRNA 
biogenesis and function. 
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Fig 1.5 miRNA Biogenesis and Function (140) 
1.8a miRNAs in pathologies 
miRNAs have been researched most extensively to determine their role in regulating  
basic cell function and oncogenesis in studies including colorectal neoplasia, chronic 
lymphocytic leukemia, and human B cell lymphomas (18, 42, 90).  However, the effect of 
miRNA dysregulation upon a multitude of other pathophysiological states is becoming a topic of 
interest.  Broad scale miRNA array analyses upon I/R injury in mouse hearts post insult had a 
significant increase in 33 miRNA compared to control (135). In a similar study, closer 
examination of  miR-320 dysregulation affected targeting to Hsp20, denoting its potential 
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importance as a therapeutic target for ischemic heart disease (110).  Genetic overexpression of 
miR-375 lead to reduced pancreatic β-cell number and viability highlighting this miRNA as an 
important modulator of β-cell function (146).   Finally, Nishi et al. identified miR-15b as a 
regulator of mitochondrial ATP production in cardiomyocytes through its inhibition of ADP-
ribosylation factor-like 2, a protein essential for adenine nucleotide transporter function (98). 
1.8b Circulating miRNAs  
 miRNAs exist in all parts of the body and seem to be implicated in virtually all cellular 
processes currently known (120).  Further, miRNAs seem to be completely stable as well as 
resistant to nuclease digestion within the blood stream and can circulate to target areas of the 
body given the proper physiological or pathophysiological stimulus.  Due to this discovery, 
scientists are now pursuing miRNAs within the circulation as clinical biomarkers for multiple 
diseases and disease states (55).  Hung et al. examined cell-free circulating fetal nucleic acids, 
such as placental miRNAs, which could be examined for non-invasive prenatal diagnoses (63).  
Additionally, many laboratories have explored the regulation of miRNAs within different types 
of cancer.  As an example, miR-141, known to be highly upregulated within epithelial cells in 
prostate cancer, was also shown to be significantly increased concurrently within blood serum. 
Therefore, Mitchell et al. believe miR-141 can potentially be used as a viable circulating 
biomarker for blood-based detection of human prostate cancer (91).  Similar to cancers, miRNA 
expression levels within the blood are starting to be utilized as potential biomarkers in heart 
disease.  miR-1 is traditionally known as the most abundant miRNA within the heart.  However, 
acute myocardial infarction induced in rats through a coronary ligation exhibited increases in 
miR-1 isolated from blood serum (28).  Elevated serum levels of miR-1 was further confirmed in 
patients with acute myocardial infarctions as well yielding similar results across species (28).  To 
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date, there have been no published studies on the influence of circulating miRNAs in T1DM and 
their impact as biomarkers for the disease.   
1.8c miRNAs within the heart 
 miRNA regulation within the heart has been extensively characterized in the last decade 
playing an intricate role in essential cardiac functions including cardiomyocyte differentiation, 
cardiac development, and ventricular hypertrophy (3).  miR-1 has been shown to regulate 
essential helix-loop-helix transcription factor HAND2, which controls cardiomyocyte growth 
specifically within the right ventricle (127).  Pertaining to ventricular development, it has been 
shown that miR-133a has a critical role.  Indeed, deletion of miR-133a is lethal in over 50% of 
mice after 1 day of birth, which is associated with ventricular septal defects (81).  Further, mice 
that survive to adulthood display severe systolic dysfunction, enhanced cardiomyocyte 
proliferation, and apoptosis, demonstrating the critical regulatory effect miR-133a has upon 
cardiac development (81).  
  Perhaps the most effort put forth within the field has been in the understanding of 
miRNA dysregulation within ventricular hypertrophy and congestive heart failure.  Multiple 
miRNAs have been identified as key regulators including let-7c, miR-23a, miR-100, miR-103, 
miR-1, miR-133, miR-208, and miR-29 (3).  As an example, ligations of the left anterior 
descending coronary artery of mice revealed significant decreases in miR-29 expression within 
the heart (141).  Further, knockdown of miR-29 enhanced cardiac fibrosis, suggesting miR-29 
has an essential role in collagen gene expression following a myocardial infarction.  In a 
fascinating study, van Rooij et al. examined miR-208 and its regulation upon myosin heavy 
chain (MHC) expression (140). Pathological hypertrophic growth in the heart will lead to 
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downregulation of α-MHC and an upregulation of β-MHC.  It was determined that miR-208 is 
encoded within an intron of α-MHC and is a regulator of β-MHC.  Therefore, in stress conditions 
such as heart failure, α-MHC and miR208 expression are both decreased, allowing for elevated 
β-MHC expression altering contractility within the heart.  Taken together, it is clear miRNAs 
have critical roles in the development and function of the heart within physiological and 
pathophysiological conditions.   
1.8d miRNAs within mitochondria 
 Most recently, researchers have begun identifying miRNAs within organelles, including 
mitochondria, in which their functional role at this point remains undefined.  Influential research 
by Kren et al. identified 15 miRNAs residing within rat liver mitochondria (73).  Utilizing 
bioinformatics approaches such as MiRanda and TargetScan algorithms, they determined 
mitochondrial miRNAs are likely involved in regulation of apoptosis, cell proliferation, and 
differentiation.  Further, this group inferred miRNAs may serve as reservoirs that can release 
miRNA given certain stimulus to aid in the regulation of various cellular processes.  In a similar 
study to determine whether unique subpopulations of miRNAs exist within mitochondria, Bian et 
al. isolated highly purified RNA from liver tissue and liver mitochondria followed by miRNA 
microarray analysis (7).  Interestingly, the highest expressed miRNAs within mitochondria, such 
as miR-451, miR7b, and mir-26a, were not present within liver fractions.  Further, another group 
of mice were treated with STZ to induce TIDM in which the STZ treated liver mitochondria 
miRNAs were compared to control mitochondria miRNA.  The results show increased levels of 
miR-494, miR-202-5p, and miR-134 within the STZ mitochondria.  Bioinformatics analyses 
highlighted several mitochondrial-specific gene targets including tryptophanyl-tRNA synthetase 
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and transcription factor A.  Taken together, both studied show the distinct possibility of unique 
miRNA subpopulations within mitochondria. 
1.9 Summary 
 As of 2011, 25.8 million people (8.3% of the population) within the United States alone 
have diagnosed or undiagnosed diabetes mellitus.  It also appears that this number will only 
increase in the years ahead.  Understanding the mechanisms involved within the etiology is 
absolutely essential for better diagnoses and therapeutic treatment programs.  Dysregulation of 
the mitochondrial proteome seems to be a critical factor within the pathology of diabetic 
cardiomyopathy.  Therefore, the goal of the studies presented was to determine whether nuclear 
encoded mitochondrial protein import is a potential mechanism for proteomic dysregulation 
within the diabetic IFM and to evaluate whether overexpression of a targeted antioxidant 
(mPHGPx) will preserve import function.  Further, we assessed how miRNAs are regulated 
within the heart in context to T1DM and determined how specific miRNAs can influence the 
mitochondrial proteome.   
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ABSTRACT 
Diabetic cardiomyopathy is associated with increased risk of heart failure in type 1 diabetic 
patients.  Mitochondrial dysfunction is suggested as an underlying contributor to diabetic 
cardiomyopathy. Cardiac mitochondria are characterized by their subcellular spatial locale 
including mitochondria located beneath the sarcolemma, subsarcolemmal mitochondria (SSM), 
and mitochondria situated between the myofibrils, interfibrillar mitochondria (IFM).   The goal 
of this study was to determine whether type 1 diabetic insult in the heart influences proteomic 
make-up of spatially-distinct mitochondrial subpopulations and to evaluate the role of nuclear-
encoded mitochondrial protein import.  Utilizing multiple proteomic approaches (iTRAQ,  and 
2D-DIGE), IFM proteomic make-up was impacted by type 1 diabetes mellitus to a greater extent 
than SSM as evidenced by decreased abundance of fatty acid oxidation and electron transport 
chain proteins.  Mitochondrial phosphate carrier and adenine nucleotide translocator, inner 
membrane translocases, were decreased in the diabetic IFM (p<0.05 for both).  Mitofilin, a 
protein involved in cristae morphology, was diminished in the diabetic IFM (p<0.05). Post-
translational modifications, including oxidations and deamidations, were most prevalent in the 
diabetic IFM.  Mitochondrial heat shock protein 70 (mtHsp70) was significantly decreased in 
diabetic IFM (p<0.05).  Mitochondrial protein import was decreased in the diabetic IFM with no 
change in the diabetic SSM (p<0.05).  Taken together, these results indicate that mitochondrial 
proteomic alterations in the type 1 diabetic heart are more pronounced in the IFM.  Further, 
proteomic alterations are associated with nuclear-encoded mitochondrial protein import 
dysfunction and loss of an essential mitochondrial protein import constituent, mtHsp70, 
implicating this process in the pathogenesis of the diabetic heart. 
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INTRODUCTION 
Cardiovascular complications, including diabetic cardiomyopathy, are the leading cause of 
mortality among type 1 diabetic patients.  A number of studies have indicated that mitochondrial 
dysfunction underlies and is a central contributor to the dysfunction seen in the type 1 diabetic 
heart (11, 13, 36, 39).   An increasing amount of evidence suggests that mitochondrial 
subcellular location influences the pathogenesis of dysfunctional mitochondria in the type 1 
diabetic heart (11, 24).  Cardiac mitochondria are characterized by different spatial location 
within the cell including mitochondria located at the sarcolemma, subsarcolemmal mitochondria 
(SSM), and mitochondria situated between the myofibrils, interfibrillar mitochondria (IFM).  We 
and others have shown that these two spatially distinct subpopulations of mitochondria are 
differentially affected with various pathological insults (11, 24, 26, 27, 32, 37, 43).  Specifically, 
we have demonstrated that the IFM display greater dysfunctional profiles with type 1 diabetic 
insult, as evidenced by enhanced oxidative stress, diminished ETC function and decreased 
cardiolipin content (11).   
Proteomic evaluations have played an important role in furthering our understanding of 
mitochondrial dysfunction in the diabetic heart.  Several proteomic studies have been undertaken 
in various diabetic models in an effort to clarify the nature of the proteomic changes associated 
with the diabetic heart (5, 15, 21, 39, 41).  Turko et al. identified 30 altered mitochondrial 
proteins in isolated mitochondria from STZ-induced type 1 diabetic rat hearts (41).  In particular, 
they observed enhanced fatty acid oxidation (FAO) proteins and reduction of several oxidative 
phosphorylation (OXPHOS) protein subunits.  Utilizing an iTRAQ™ labeling method, Jullig et 
al. identified 65 proteins significantly changing in the STZ-induced type 1 diabetic rat heart as 
compared to control (21).  The most significant changes were increased levels of FAO enzymes 
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and decreased proteins involved in OXPHOS.  In a recent study using label free proteome 
expression analyses, Bugger et al. examined mitochondrial proteomes of several tissues from the 
Akita mouse (kidney, liver, brain and heart) (5).  Their results indicate that FAO proteins were 
less abundant in liver mitochondria, whereas FAO protein content was induced in mitochondria 
from all other tissues. In addition, levels of OXPHOS subunits were coordinately increased in 
liver mitochondria, whereas mitochondria from other tissues were unaffected (5).  Taken 
together, these data suggest that the cardiac mitochondrial proteome is impacted during type 1 
diabetes mellitus, though a number of variables may contribute to conflicting results.  To date no 
one has examined proteomic differences in spatially distinct subpopulations of mitochondria in 
the type 1 diabetic heart which may offer further insight into the nature of this dynamic process 
in the type 1 diabetic heart.    
Studies examining mechanisms underlying or contributing to the proteomic alterations in the 
diabetic heart are limited (16).  Potential mechanisms of proteomic dysregulation may include 
pathological alterations in gene expression, increases in post-translational modifications (PTMs) 
of proteins, or upregulation of post-translational regulators such as microRNAs (miRNAs).  
Alternatively, dysfunctional nuclear-encoded mitochondrial protein import could also disturb the 
proteomic composition of the mitochondrion.  Currently, there are approximately 1200 known 
proteins in the human mitochondrion (38), and an estimated 1500 proteins (6).  Of this number 
only 13 proteins are transcribed and translated inside the organelle itself.  As a result, the vast 
majority of proteins (~99%) must be imported into mitochondrion through a complex mechanism 
of translocation involving interaction between protein targeting signals and mitochondrial 
translocases (7).  To date, no study has examined the impact of type 1 diabetes mellitus on 
spatially distinct mitochondrial proteomes in the diabetic heart or offered insight into the 
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mechanisms influencing specific proteomic profiles.  The goal of this study was to determine 
whether proteomic differences exist in subpopulations of mitochondria as well as to evaluate the 
role of nuclear-encoded mitochondrial protein import in the type 1 diabetic heart. 
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MATERIALS AND METHODS 
Experimental Animals and Diabetes Induction  
The animal experiments in this study conformed to National Institutes of Health (NIH) 
Guidelines for the Care and Use of Laboratory
 
Animals and were approved by the West Virginia 
University Animal Care and Use Committee. Male FVB mice (Charles River Laboratories, 
Wilmington, MA) were housed in the West Virginia University Health Sciences Center animal 
facility.  Mice were given unlimited access to a rodent diet and water.  Type 1 diabetes mellitus 
was induced in 8-wk-old mice following the protocol of the Animal Models of Diabetic 
Complications Consortium using multiple low-dose streptozotocin (STZ; Sigma, St. Louis, MO) 
injections.   Injections of 50 mg/kg body weight STZ dissolved in sodium citrate buffer (pH 4.5) 
were performed daily for 5 consecutive days after 6 hours of fasting.  Mice that served as vehicle 
controls were given the same volume per body weight of sodium citrate buffer. One week post-
injections, hyperglycemia was confirmed by measuring urinary glucose levels (Chemstrip 2GP 
Urine test strips, Roche Diagnostics, Indianapolis, IN).  Five weeks post hyperglycemia onset, 
animals were sacrificed for further experimentation.  To characterize the diabetic phenotype, 
blood glucose (Bayer, Mishawaka, IN) and plasma insulin (ALPCO, Salem, NH) levels were 
determined using commercially available kits. 
 
Preparation of Individual Mitochondrial Subpopulations  
At 5 weeks post hyperglycemia onset, FVB mice and their littermate controls were sacrificed, 
and the hearts were excised.  Hearts were rinsed in phosphate buffered saline (PBS, pH 7.4), then 
blotted dry.  SSM and IFM were isolated as previously described following the methods of 
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Palmer et al. (31) with minor modifications (11, 12, 43).  Protein concentrations were determined 
using the Bradford method with bovine serum albumin (BSA) as a standard (3). 
 
iTRAQ Labeling 
Pooled SSM and IFM subpopulations (N=4) from diabetic and control hearts were lysed and 
precipitated overnight in acetone at -20°C and pellets were resuspended in 20 μL of 0.5 M 
triethylammonium bicarbonate (TEAB; pH 8.5) as previously described (10).  Protein contents 
were determined using a 2-D Quant Kit (Amersham, Piscataway, NJ) and 100 μg of each pooled 
sample was than denatured with 0.1% SDS and reduced with 5mM tris-(2-carboxyethyl) 
phosphine (TCEP).  After incubation for 1 hour at 60°C, cysteines were blocked with 10 mM 
methyl methane thiosulfonate (MMTS) in isopropanol, and the samples were incubated at room 
temperature for 10 minutes.  Addition of 10 μL of sequencing grade trypsin (Applied 
Biosystems, Foster City, CA) was added in a trypsin/protein ratio of 1:20, and the samples 
incubated at 37°C overnight.  Digested samples were labeled with the iTRAQ™ reagents 
following the protocol provided by the vendor (Applied Biosystems, Foster City, CA).  
After digestion and iTRAQ labeling, the ultra-complex protein digests were combined to create a 
400 µg pooled protein digest sample that contained equal fractions of each of the four labeled 
samples for subsequent Multi Dimensional Protein Identification Technology (MudPIT) analysis 
(28).   After lyophilization, the digest mixture was reconstituted in strong cation exchange (SCX) 
loading buffer (5mM ammonium formate in 20% acetonitrile; pH 3.0) to be fractionated with 
SCX SpinTips (Protea Biosciences, Morgantown, WV) per the manufacturer’s protocol.  Briefly, 
the sample solution was loaded centrifugally onto the SCX SpinTip.  The non-adsorbing solution 
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that passed through the SCX SpinTip was collected.  Eight different elution solutions were used 
to fractionate the peptides (20, 60, 100, 150, 200, 250, 400, and 500 mM ammonium formate in 
10% acetonitrile) in a step-wise manner, for a total of nine sample fractions.  The collected 
fractions were cleaned by repeated lyophilization and reconstituted in a 0.1 M acetic acid 
solution, and then lyophilized to dryness.  The fractions were then submitted for LC-MALDI 
TOF/TOF mass spectral analysis for protein identification, characterization, and differential 
expression analysis.  
 
Mass Spectrometry (MS) Analyses with iTRAQ™ Labeling 
The LC-MALDI mass spectrometry system utilized was an ABI Tempo LC MALDI spotter with 
Tempo LC MALDI v.2.00.09 data acquisition and processing software.  Lyophilized SCX 
sample fractions were reconstituted in LC aqueous run buffer (0.1% trifluoroacetic acid, 2% 
acetonitrile) and injected onto a Zorbax C18 chromatographic column, 150 x 0.3 mm (Agilent 
Technologies, Wilmington, DE).  The peptides were eluted from the column using an 
acetonitrile/trifluoroacetic acid gradient (2-72% acetonitrile in 35 minutes) and spotted directly 
onto a MALDI plate in 6 second spot fractions.  The MALDI spots were analyzed using an ABI 
4800 MALDI TOF/TOF analyzer operated with 4000 Series Explorer software.  The MS 
acquisition was in positive ion reflector mode with 400 laser shots per spectrum performed.  The 
15 strongest precursors per spot were chosen for MS/MS and the MALDI spot was interrogated 
until at least 4 peaks in the MS/MS, spectra achieved a S/N ≥ 70.   
The resulting MS/MS spectra were analyzed using ABI Protein ProteinPilot software 2.0 
(Applied Biosystems, Foster City, CA).  The spectral data was searched against the mouse 
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protein database (NCBI nr.fasta database customized to select for all mouse proteins) for 
identification of the peptides and corresponding proteins.  In ProteinPilot, the sample type was 
selected as iTRAQ 4Plex for retrieval of the isotopic tag information from the mass spectra.  
After database correlation analysis, the proteins were grouped, scored, and normalized against 
one of four isotope correction factors.  The Pro Group algorithm of ProteinPilot generated a 
protein score (ProtScore) that is a cumulative score from each of the peptides used by the 
algorithm in the protein identification.  ProtScores above 2.0, 1.0, and 0.47 expressed the percent 
confidence levels of >99, >90, and >66%, respectively.  Each peptide match showed the iTRAQ 
isotopic labels, MMTS labeled cysteines, and other PTMs present as mass spectral shifts 
identified during the database correlation analysis.  Each protein identified also showed the 
differential protein expression compared against the other iTRAQ labeled samples for relative 
quantitation. 
 
2D-Differential In-Gel Electrophoresis (2D-DIGE) 
Sample Preparation 
 Isolated mitochondrial subpopulations were placed in lysis buffer (7 M urea, 2 M 
thiourea, 30 mM Tris, 5 mM magnesium acetate, 4% CHAPS, and 58 mM DTT) in a 1:10 ratio.  
Protein concentration of the samples was determined using a 2-D Quant Kit (Amersham 
Biosciences, Piscataway, NJ).  
  
2D-DIGE and Differential-display Proteome Analyses 
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100 µg of each mitochondria subpopulation from both diabetic and control was lysed with 
labeling buffer (7 M urea, 2 M thiourea, 4% CHAPS, 30 mM Tris, 5 mM magnesium acetate).  
One third of each sample was removed and combined into a separate tube to serve as an internal 
standard.  50 μg of the remaining samples were labeled separately with 400 pmol of Cy3 or Cy5 
NHS-ester minimal labeling reagents for 30 minutes on ice and in the dark.  The samples were 
then quenched with 2 μl of 10 mM lysine for 10 minutes on ice in the dark.   50 μg of the 
combined sample was also labeled with 400 pmol of Cy2 and than quenched with 10 μl of 10 
mM lysine.  Individual Cy3- and Cy5-labeled samples were combined with the same amount of 
the Cy2-labeled internal standard.  Each gel contained one control and one diabetic sample from 
individual mitochondrial subpopulations, and the Cy3 and Cy5 dyes were alternated to account 
for dye labeling variability.  The samples were separated by standard 2D gel electrophoresis 
utilizing a manifold-equipped IPGphor first dimension isoelectric focusing unit and 24 cm 3-10 
immobilized pH gradient (IPG) strips.  The initial separation was followed by a second-
dimension 12% SDS-PAGE homogenous on hand-cast gels.  The Cy2 (mixed standard), Cy3 and 
Cy5 components of each gel were visualized separately at 100 μm resolution with mutually-
exclusive excitation/emission wavelengths using a Typhoon 9400 Variable Mode Fluorescence 
Imager (GE Healthcare, Piscataway, NJ).  A Sypro Ruby protein post-stain (Invitrogen, 
Carlsbad, CA) was used to extract protein from the gels.  Gel images were submitted to Ludesi 
2D Analysis (Ludesi, Malmo, Sweden, http://www.ludesi.com) for spot detection, matching, and 
analysis. Control:standard and diabetic:standard normalized volume ratios were calculated for 
each protein on every gel, and the internal standards were used to normalize and compare these 
ratios across the 10 2D-DIGE gels.  This method allowed for the calculation of average 
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abundance changes and Student’s T-test p-values for the variance of these ratios for each protein-
pair across all 10 individual gels.   
 
Mass Spectrometry and Database Analysis 
 Proteins that were changing were excised and digested in gel with trypsin protease and 
the resulting peptides analyzed using a Micromass MALDI micro MX TOF Spectrometer 
(Waters, Milford, MA).  The resulting peptide mass maps were compared to sequences present in 
the SWISS-PROT and NCBInr databases to generate statistically significant identifications of 
proteins using GPS Explorer software (Applied Biosystems, Foster City, CA) running the 
MASCOT search algorithm.   Searches were performed without constraining protein molecular 
weight or isoelectric point, with complete carbamidomethylation of cysteine, partial oxidation of 
methionine residues, and one missed cleavage also allowed in the search parameters.  Molecular 
Weight Search (MOWSE) scores from database interrogation above 58 (p<0.05), number of 
matched ions, number of matching sequence coverage, and correlation of gel region with 
predicted MW and pI were considered for each protein identification.   
 
Protein Import 
Plasmid Construction  
The fusion protein construct pAcGFP1-Mito (Clontech Laboratories, Mountain View, CA) 
containing the precursor subunit VIII of human cytochrome C oxidase and the green fluorescent 
protein from Aequorea coerulescens (AcGFP1) was cloned into pIVEX2.3d (Roche Applied 
Science, Indianapolis, IN) at restriction sites Not I and blunted Nco I/Nhe I creating 
pMITOGFP1 (Supplemental Figure 1S).  The correct sequence was confirmed by 
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dideoxynucleotide sequencing.  pMITOGFP1 was grown to a concentration of 500 ng/µl and 
isolated using mini prep plasmid DNA isolation (Qiagen, Valencia, CA).   
 
In Vitro Synthesis of Mitochondrial Protein 
In vitro transcription and translation of MitoGFP1 was performed using the S30 T7 protein 
expression system (Promega, Madison, WI) as per the manufacturer’s protocol.  Additionally, 
fluorescent labeling of MitoGFP1 was performed using the FluoroTect GreenLys tRNA in vitro 
labeling system (Promega, Madison, WI) as per the manufacturer’s protocol. MitoGFP1 and 
fluorescent MitoGFP1 lysates were subsequently used as substrates for the in vitro protein 
import process. 
 
Mitochondrial Protein Import 
The mitochondrial protein import procedure was performed following the protocol from 
Stojanovski et al. (40) with modifications.  Briefly, 40 µg of mitochondria was resuspended in 
100 µl of import buffer (250 mM Sucrose, 80 mM KCl, 5 mM MgCl2, 2 mM KH2PO4, 10 mM 
MOP-KOH, pH 7.2) with addition of 2 mM ATP and 10mM Na-Succinate.  1-5 µl of bacterial 
lysate containing MitoGFP1 protein was added and protein import performed at increasing time 
intervals of 2, 5, and 10 minutes at 25°C.  2 µM valinomycin was added to stop the import 
reaction, and samples were centrifuged at 12,000 x g for 5 minutes at 4°C.  The supernatant was 
discarded and the pellet resuspended in SEM buffer (250 mM Sucrose, 1 mM EDTA, 10 mM 
MOP-KOH, pH 7.2) containing 25 µg/ml trypsin, on ice.  Trypsin was subsequently inhibited by 
protease inhibitor cocktail (BioVision, Mountain View, CA).  Samples were centrifuged again at 
12,000 x g for 5 min at 4°C.  Pellets were then resuspended in lysis buffer (BioVision, Mountain 
View, California), subjected to SDS-PAGE, and subsequent Western blot analyses performed. 
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Quantification of blots was performed using Pierce ECL Western Blotting Substrate (Pierce 
Biotech, Rockford, IL).  The primary antibody was an anti-GFP monoclonal antibody raised in a 
mouse host (Clontech Laboratories, Mountain View, CA).   The secondary antibody was an anti-
mouse IgG horseradish peroxidase conjugate (Sigma, St. Louis, MO).  Quantification of 
chemiluminescent signals were detected using a G:BOX (Syngene, Frederick, MD), and data 
expressed as arbitrary optical density units.  Additionally, visualization of imported fluorescent 
MitoGFP1 was performed using a Typhoon 9400 Variable Mode Fluorescence Imager (GE 
Healthcare, Piscataway, NJ) with a 532nm excitation.  Control for protein loading was confirmed 
using Ponceau staining. 
 
Western Blot Analyses 
 SDS polyacrylamide gel electrophoresis (SDS-PAGE) was run on 4-12% gradient gels as 
previously described (25, 43) with equal amounts of protein loaded for each study treatment. 
Relative amounts of subpopulation-specific mitochondrial heat shock protein 70 (mtHsp70), 
translocases of the outer membrane 40 and 20 (Tom40 and Tom20), translocases of the inner 
membrane 23 and 44 (Tim23 and Tim44), were analyzed using the following primary antibodies; 
anti-mtHsp70 mouse antibody (Product# SPA-825; Stressgen, Ann Arbor, MI ), anti-Tom40 goat 
antibody (Product# sc-11025; Santa Cruz Biotech, Santa Cruz, CA), anti-Tom20 mouse antibody 
(Product # 612278; BD Biosciences, San Jose, CA), anti-Tim23 mouse antibody (Product # 
611222; BD Biosciences, San Jose, CA), and anti-Tim44 mouse antibody (Product # 612582, 
BD Biosciences, San Jose, CA).  The secondary antibodies used in the analyses were donkey 
anti-goat IgG HRP conjugate (Product #sc-2020; Santa Cruz Biotech, Santa Cruz, CA) for 
Tom40, and goat-anti mouse conjugate (Product# 31430; Pierce Biotech, Rockford, IL) for 
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mtHsp70, Tom20, Tim23 and Tim44.  Detection of signal was performed according to the 
manufacturer’s instructions as above.  Quantification of chemiluminescent signals and data 
analysis were performed as above.  Control for protein loading was confirmed using Ponceau 
staining. 
 
mRNA Analyses 
 30 mg of tissue was excised from control and diabetic hearts for mRNA extraction using 
an RNeasy mini kit per manufacturer’s protocol (Qiagen, Valencia, CA) and reverse transcribed.   
Equal amounts of cDNA from the hearts of control and diabetic mice were subjected to real-time 
PCR.  Custom primers were designed for target genes adenine nucleotide translocator 4 (ANT4), 
ATP synthase subunit alpha (ATP5A1), and ATP synthase subunit beta (ATP5B).  SYBR Green 
I was used for quantification of respective cDNA replicates (Qiagen, Valencia, CA).  Data were 
normalized by gene expression relative to the levels of GAPDH. 
 
Mitochondrial Membrane Potential (ΔΨm) 
 Mitochondrial membrane potential (ΔΨm) was measured by flow cytometry using the 
ratiometric dye 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazol carbocyanine iodide (JC-1) 
(Molecular Probes, Carlsbad, CA), which is a lipophilic cation that enters selectively into 
mitochondria, as previously described (43).  Values are expressed as the mean orange 
fluorescence divided by the mean green fluorescence of 20,000 mitochondrial events per 
individual mitochondrial sample. 
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Statistics 
Means and standard errors (SEM) were calculated for all data sets.  Data were analyzed with a 
one-way analysis of variance (ANOVA) method to evaluate the main treatment effect, diabetes 
induction (GraphPad Software Inc., La Jolla, CA).  Fisher’s Least Significant Difference (LSD) 
post hoc tests were performed to determine the significant differences among means.  When 
appropriate a Student’s T-test was employed.  p<0.05 was considered significant. 
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RESULTS 
Diabetes Mellitus Phenotype 
 The diabetes mellitus phenotype was characterized five weeks following STZ treatment 
by assessing blood glucose and plasma insulin levels.  Blood glucose levels were significantly 
elevated in diabetic mice as compared to control (Control, 140±5 mg/dL vs. Diabetic, 548±22 
mg/dL; P<0.05).  Further, plasma insulin levels were significantly reduced in diabetic mice as 
compared to control (Control, 1.92±0.17 ng/mL vs. Diabetic, 0.47±0.06 ng/mL). 
 
Proteomic Analyses 
To determine whether type 1 diabetes mellitus differentially impacts spatially distinct 
mitochondrial subpopulation proteomes, we utilized both iTRAQ and 2D-DIGE approaches.  
iTRAQ enables simultaneous identification and relative quantification of mitochondrial proteins 
through isobaric peptide tagging, while 2D-DIGE analysis is a quantitative technique that 
enables multiple protein samples to be separated on the same 2-D gel, thereby greatly reducing 
the introduction of potential artifacts due to gel-to-gel variations.  Figure 2.1 is an example of an 
MS/MS fragment ion (spectra) for a peptide that was used to identify a protein, mtHsp70.  
Located below the spectra is an example of an iTRAQ tag mass spectral signature (m/z 114, 115, 
116, and 117) used to make a relative quantification of mtHsp70 within the four labeled sample 
groups (see Figure 2.1 legend for groups).  Figures 2.2A-D are representative 2D gels from four 
mitochondrial samples, (A) control IFM, (B) diabetic IFM, (C) control SSM, and (D) diabetic 
SSM, labeled with different Cy dyes.  In this example, an individual spot, identified as mtHsp70, 
is indicated by the red arrows, and the quantitative differences assessed by examination of peak 
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densities which are shown in each individual representative gel image (Figures 2.2A-D).  
MtHsp70 peak density was significantly decreased (p<0.02) in the diabetic IFM as compared to 
control IFM, with no changes in diabetic SSM as compared to control SSM. 
Proteins of Fatty Acid Oxidation (FAO).  FAO proteins were significantly altered in both 
diabetic SSM and diabetic IFM as compared to control using both iTRAQ and 2D-DIGE 
methods.  In contrast to our previous study in a type 2 diabetes mellitus model (10), iTRAQ 
analysis revealed 8 of 10 proteins involved in FAO which were decreased in the diabetic IFM, 
while 4 of 10 were decreased in the diabetic SSM (Table 2.1).  Interestingly, carnitine 
palmitoyltransferase-1 (CPT-1), an outer mitochondrial membrane protein that mediates 
transport of long-chain fatty acids across the membrane, was significantly increased in the 
diabetic SSM while diminished in the diabetic IFM (Table 2.1).  Further, 2D-DIGE analysis 
identified 6 FAO proteins that were also significantly decreased in the diabetic IFM, while 2 of 6 
were decreased in the diabetic SSM (Table 2.2).  Taken together, both proteomic analyses 
suggest that FAO proteins are impaired in both diabetic SSM and IFM, with the effect being 
greatest in the IFM.  
Proteins of the Mitochondrial Respiratory Chain. Utilizing both iTRAQ and 2D-DIGE, a 
number of proteins of the mitochondrial respiratory chain were significantly altered in both 
diabetic SSM and diabetic IFM as compared to control.  With iTRAQ, 9 of 23 respiratory chain 
proteins identified were significantly decreased in the diabetic IFM as compared to control, while 
1 of 23 respiratory chain proteins identified were decreased in expression in the diabetic SSM as 
compared to control (Table 2.1).  Interestingly, 5 of 23 respiratory chain proteins identified were 
increased in the SSM as compared to control.  In the diabetic IFM, all 4 proteins identified from 
complex V (ATP synthase) were decreased, while 2 of 6 proteins from complex I, and 1 of 4 
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were from complex IV were decreased (Table 2.1).  In the diabetic SSM, one protein each from 
complexes I, III, IV and V, respectively, were significantly increased as compared to control 
SSM (Table 2.1).  Similar to the iTRAQ analysis, 2D-DIGE analysis revealed 16 proteins of the 
respiratory chain decreased in the diabetic IFM, with 3 proteins increased in the diabetic SSM 
(Tables 2.1 and 2.2).   Proteins that were decreased in the diabetic IFM were from all respiratory 
complexes including complexes I, II, III, IV and V with the greatest number of decreased 
proteins occurring at complex I.  Similar to the iTRAQ analysis, several respiratory proteins 
were increased in the diabetic SSM suggesting a possible compensatory mechanism to prevent 
dysfunction. 
Proteins of the Citric Acid Cycle (TCA).  iTRAQ and 2D-DIGE analyses of proteins involved in 
the TCA revealed significant changes in both the diabetic SSM and IFM as compared to control.  
In the diabetic IFM, 2 of 5 TCA proteins were decreased, while 3 of 5 proteins were increased in 
the diabetic SSM (Table 2.1). Of particular interest was the observation that isocitrate 
dehydrogenase 2 (NADP+) displayed increased content in the diabetic SSM yet decreased 
content in the diabetic IFM (Table 2.1).  Similar to the iTRAQ analysis, 2D-DIGE analysis 
reported 6 TCA proteins decreased in the diabetic IFM, and 3 proteins increased in the diabetic 
SSM (Table 2.2).  These data suggest again that TCA proteins and other proteins necessary for 
energy production are increased in the diabetic SSM, yet decreased in the diabetic IFM. 
Transport Proteins.  Proteins involved in transport of proteins and or substrates across the inner 
mitochondrial membrane (IMM) were preferentially decreased in the diabetic IFM as compared 
to control IFM as evidenced by a decreased content in 3 of 4 proteins, with no changes in the 
SSM (Table 2.1).  Mitochondrial phosphate carrier, a protein that is involved in transport of 
phosphate groups from the cytosol to the mitochondrial matrix, was significantly decreased in 
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diabetic IFM as compared to control (Table 2.1).  Another translocase required for exchange of 
ADP and ATP across the IMM, adenine nucleotide translocator 1 (ANT1), was also significantly 
decreased in the diabetic IFM as compared to control (Table 2.1).  Interestingly, mtHsp70 (a.k.a 
glucose-regulated protein 75; Grp75), a heat shock protein and a constituent of the mitochondrial 
import process essential for import of proteins into mitochondria, was also significantly 
decreased only in diabetic IFM as compared to control (Tables 2.1 and 2.2).  Western blot 
analyses of mtHsp70 (Figure 2.5C), provided confirmation of both the iTRAQ and 2D-DIGE 
results observed.  Another heat shock protein involved in folding and protein import into the 
mitochondrion, Hsp60, was also significantly decreased only in the diabetic IFM as revealed by 
2D-DIGE analysis (Table 2.2). 
Structural Proteins.  With both iTRAQ and 2D-DIGE analyses, alterations to proteins involved 
in mitochondrial structure were apparent in only the diabetic IFM as compared to control with no 
changes in diabetic SSM.  In particular, mitofilin, a transmembrane IMM protein that regulates 
mitochondrial cristae morphology (cristae density) (19), was significantly decreased only in 
diabetic IFM as indicated by both iTRAQ and 2D-DIGE analysis (Tables 2.1 and 2.2).  Further, 
prohibitin-2, a protein involved in mitochondrial chaperone functions which may impact 
mitochondrial morphology as well as maintenance of mitochondrial DNA (1), was significantly 
decreased in the diabetic IFM with 2D-DIGE analysis (Table 2.2).  These data are consistent 
with our previously published data suggesting that mitochondrial internal complexity is 
decreased in the diabetic IFM (11). 
  
Post-translational Modifications (PTM) 
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Utilizing MudPIT technology to assess PTM, 42 proteins were identified as having a PTM in the 
diabetic IFM while 23 proteins were identified in the diabetic SSM (Table 2.3).  Interestingly, 11 
of the 42 proteins in the diabetic IFM contained oxidations on various amino acid residues.  In 
particular, 3 proteins of complex III, 2 proteins of complex V and 1 protein of complex I were 
oxidized in the diabetic IFM.  Further, mtHsp70 and mitofilin were also only oxidized in the 
diabetic IFM.  Additionally, 13 proteins in the diabetic IFM and 8 proteins in the diabetic SSM 
involved in the ETC presented with some sort of PTM including acetylations, deamidations and 
methylations.  Of greatest interest was that the majority of the modified proteins were IMM 
proteins, suggesting that this locus may be specifically impacted and as a result, play a key role 
in the pathogenesis of cardiac dysfunction associated with type 1 diabetes mellitus. 
 
Mitochondrial Protein Import Construct 
The MITOGFP1 cDNA was inserted as a Not I, Nhe I blunt fragment into the PIVEX2.3d 
plasmid (Figure 2.3).  PIVEX2.3d has all necessary components for efficient protein production 
in a cell free bacterial protein expression lysate system including a T7 promoter, ribosomal 
binding site, and poly A tail.  The MITOGFP1 gene consists of an N-terminal mitochondrial 
targeting sequence derived from cytochrome C oxidase subunit VIII (targeted to the matrix) 
fused with AcGFP.  Translated MitoGFP1 protein was incubated with isolated mitochondria to 
allow for proper import.  Mitochondria were subsequently cleaned of non-imported protein, 
lysed, and a Western blot analysis was performed probing for AcGFP.  Isolated cardiac 
mitochondria alone does not produce a signal on the blot, (Figure 2.4, lane 1) whereas pure 
protein lysate from the bacterial expression system does produce the full length 31 kDa band 
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containing the N-terminal presequence (Figure 2.4, lane 2).  Addition of total mitochondria and 
lysate together produce a similar 31 kDa band, which is the precursor protein in transit through 
the mitochondrial outer and inner membrane yet to be completely imported into the 
mitochondrial matrix.  Additionally, there is a 27 kDa band representing the mature MitoGFP1 
protein in which the precursor sequence has been cleaved and properly imported into the 
mitochondrial matrix (Figure 2.4, lane 3).  Presequence cleavage of our target protein by 
mitochondrial processing peptidase will not occur until the protein is pulled into the matrix.  
Therefore, the smaller mature sequence was quantified for import analysis.  
 
Mitochondrial Protein Import 
Utilizing Western blot analysis, Figures 2.5A and C show increasing amounts of protein 
abundance at 2, 5, and 10 minutes, respectively, of the mature 27 kDa MitoGFP1 in the control 
SSM and diabetic SSM subpopulations with no statistical difference between the samples.  
Conversely, a significant decrease (40%) in the amount of MitoGFP1 imported into the diabetic 
IFM compared to control IFM is shown at all three time points (Fig 2.5B and D).  Additionally, 
fluorescent labeling and subsequent import of MitoGFP1 was performed to confirm our Western 
blot findings (Figures 2.5A and B).  The 31 kDa band is also decreased in the diabetic IFM 
compared to control denoting lesser amounts of precursor proteins in transit to the matrix.   
 
Protein Import Machinery 
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Several outer and inner mitochondrial membrane translocases essential for proper mitochondrial 
protein import were also analyzed by Western blot analysis.  There were no significant 
differences observed in the protein expression of Tom20, Tom40, Tim23, or Tim44 in either the 
diabetic SSM or diabetic IFM as compared to control (Figure 2.6A).  It should be noted that 
Tim44 protein content showed a trend for decrease in the diabetic IFM, but the difference was 
not significant (p=0.07).  In contrast, the essential mitochondrial protein import motor, mtHsp70, 
was significantly decreased in only the diabetic IFM subpopulation  compared to control (Figure 
2.6C) with no change in the diabetic SSM compared to control (Figure 2.6B).  These results 
indicate that of the several mitochondrial protein import constituents examined, only mtHsp70 is 
significantly decreased in abundance during type 1 diabetic insult and this phenomenon is 
specific to the IFM subpopulation.    
 
mRNA Analyses 
 Expression of mitochondrial IMM (ANT4) and matrix (ATP5B and ATP5A1) transcripts 
were evaluated to determine if proteomic alterations (Tables 2.1 and 2.2) were preceded by 
transcriptional dysregulation in the diabetic heart.  Our results indicated in Table 2.4, show no 
significant decreases in the gene expression of diabetic vs. control for these three specific 
proteins (ANT4, ATP5A1, and ATP5B), suggesting that diabetes induced proteomic decreases to 
IFM proteins were not a consequence of decreased mRNA presence for these particular proteins. 
 
Mitochondrial Membrane Potential (ΔΨm) 
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 ΔΨm is essential for protein translocation across the IMM.  Therefore, ΔΨm was 
analyzed in freshly isolated mitochondrial subpopulations by flow cytometry using JC-1.  No 
significant differences in ΔΨm were observed in SSM control vs. diabetic (Figure 2.7A).  
However, there was a 19% reduction in diabetic IFM ΔΨm as compared to control (Figure 2.7B).   
Additionally, baseline ΔΨm was higher in IFM compared with SSM, which is in agreement with 
previous reports (34, 43).  These data suggest that IFM ΔΨm is decreased relative to control 
during diabetic insult, whereas SSM ΔΨm remains unaffected. 
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DISCUSSION 
A significant amount of data supports the notion that mitochondrial dysfunction plays a critical 
role in the pathogenesis of diabetic cardiomyopathy.  Despite the growing evidence for 
mitochondrial abnormalities underlying diabetic cardiomyopathy, the mechanisms involved in 
this dysfunction are not entirely clear.  Evidence suggests that mitochondrial dysfunction varies 
depending on subcellular location, with those mitochondria located between the myofibrils being 
affected to a greater extent in the type 1 diabetic heart (11, 43).  Data also suggests that 
dysfunction manifests via disturbance to the IMM as evidenced by diminished ETC complex 
activities, an enhanced oxidative environment and depletion of cardiolipin, an essential 
phospholipid required for proper mitochondrial function (11, 33).  The goal of this study was to 
build upon our previous findings and determine whether mitochondrial subpopulation-specific 
proteomes are altered with type 1 diabetes mellitus in the heart.  In an effort to elucidate 
mechanism, we examined whether mitochondrial import of nuclear-encoded proteins is 
decreased resulting in mitochondrial proteome dysregulation.   
Proteomic analyses have played an integral role in furthering our understanding of mitochondrial 
dysfunction in the diabetic heart.  Several proteomic studies, in a variety of diabetic models, have 
been employed to assess proteomic changes associated with the diabetic heart (5, 10, 15, 21, 39, 
41).  However, to date no examination of subpopulation-specific proteomic make-up has been 
performed in a type 1 diabetic model.  Proteomic profile comparisons of mitochondrial 
subpopulations from diabetic and control mouse hearts revealed that the majority of proteins 
changing were in the IFM and that almost all of these changes were decreases in protein 
abundances.  Utilizing iTRAQ and 2D-DIGE methodologies afforded a number of advantages 
over the use of a single proteomic methodology including the ability to confirm experimental 
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results and accuracy by essentially comparing results from each method.  By using MudPIT 
analysis combined with iTRAQ labeling, the limitations associated with 2D-DIGE, such as 
solubility and separation, were bypassed.  Further, the iTRAQ approach enabled comparison of 
total protein levels, which can be more difficult using 2D-DIGE separation, where PTMs such as 
phosphorylation can alter pIs and hence gel migration (21).  Utilizing 2D-DIGE allowed us to 
examine proteins that may be in less abundance and as a result, less likely to show up with 
iTRAQ analyses.  Because each method has its own unique set of advantages, the combined use 
of both techniques enhanced our level of confidence in the reported findings.  
The majority of proteins identified as changing with both 2D-DIGE and iTRAQ approaches in 
the diabetic IFM were FAO and ETC proteins.  In contrast to previous studies (21, 41), proteins 
involved in FAO (transport and/or utilization of fatty acids) were decreased in abundance in the 
diabetic IFM to a greater extent than in diabetic SSM.  It is not entirely clear why the disparity in 
findings was observed.  One could speculate that differences in animal models employed (mouse 
vs. rat), timing of examinations, STZ protocols utilized (single dose vs. multiple dose), 
mitochondria examined (total vs. subpopulations), or a combination of these variations in study 
designs may have contributed to the dissimilarity in findings.  It is important to point out that in 
the current study, both proteomic platforms seemed to yield similar results.  Nevertheless, the 
findings are interesting and warrant further investigation.  In addition, though only a few fatty 
acid utilization enzymes were decreased in diabetic SSM, CPT-1 a transporter of fatty acids into 
the mitochondrion, was upregulated which is consistent with other proteomic studies utilizing an 
STZ-induced diabetic model (21).  One could hypothesize that the diminished ability to utilize 
fatty acids within the diabetic IFM may have hampered its ability to produce ATP which in turn, 
contributed to an overall decrease in cardiac contractile function as reported previously (11, 42).  
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Additionally, ETC complexes and translocases within the IMM act as key contributors to overall 
oxidative phosphorylation and energy production within the mitochondrion.  In total, we 
identified 9 ETC proteins from iTRAQ analyses and 16 ETC proteins from 2D-DIGE analyses as 
being decreased in the diabetic IFM.  Jullig et al. reported decreases in ETC constituents that are 
involved in oxidative phosphorylation in total mitochondria (21), which is somewhat different 
from our current study examining mitochondrial subpopulations.  Further, translocases located 
within the IMM that are essential for energy production through synthesis (mitochondrial 
phosphate carrier) and transport of ATP (ANT1) were also significantly decreased only in the 
diabetic IFM.  Interestingly, Jullig et al. did not report changes in ANT1 or the mitochondrial 
phosphate carrier which may have resulted from their analyses being performed on total 
mitochondria as opposed to our study examining subpopulations of mitochondria.  Our 
proteomic data are consistent with previous reports of decreased respiratory capacity in the 
diabetic heart as well as functional data indicating down-regulation of ETC activities, 
specifically in the IFM (11, 24, 39).  Down-regulation of multiple components of the oxidative 
phosphorylation machinery and FAO proteins suggests that mitochondria in the type 1 diabetic 
mouse heart, specifically IFM, may be less efficient in producing ATP required for contraction 
and calcium homeostasis. 
 Mitochondrial morphological abnormalities have been reported with both type 1 and type 
2 diabetes mellitus (4, 23, 39).  Previous reports suggest that IFM morphology is specifically 
impacted by diabetes mellitus (11, 23).  We reported previously that IFM were smaller and less 
complex in the type 1 diabetic heart with no changes in the SSM (11).  Both 2D-DIGE and 
iTRAQ analyses indentified mitofilin, a protein critical for proper cristae morphology (19), as 
being decreased only in the diabetic IFM.  It is conceivable that diminished mitofilin, along with 
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our previous reports of depleted cardiolipin may have been a contributing factor to the altered 
IFM morphology reported previously (11).  
To date, no attempts have been made to define the mechanisms accounting for mitochondrial 
proteomic dysregulation in the diabetic heart.   Many potential mechanisms of proteomic 
dysregulation exist, including alterations in gene expression, enhanced PTMs, or upregulation of 
regulators such as miRNAs (22, 30).  To start to dissect some of these potential mechanisms we 
examined a small subset of mRNAs encoding for nuclear-encoded mitochondrial proteins whose 
contents were decreased in diabetic IFM.  Our results indicate that despite significant decreases 
in the IFM protein contents for these proteins (ANT4, ATP5A1, and ATP5B), no significant 
decreases in mRNAs encoding for these proteins was observed.  Though the subset is small, our 
results suggest that decreased mRNA abundance does not necessarily account for the decreased 
IFM protein contents observed, and suggest that other mechanisms may be involved such as 
protein import deficiencies and/or enhanced PTMs.  In the present study, PTMs identified 
included oxidations, deamidations, deacetylations and methylations, with oxidations and 
deamidations being the most prevalent.  Interestingly, the diabetic IFM displayed the greatest 
number of oxidatively-modified proteins.  These findings complement previous studies 
suggesting that enhanced mitochondrial ROS formation during type 1 diabetic insult may 
precipitate oxidative damage to mitochondrial constituents (2, 11, 39).  Also in agreement are the 
results from our previous study reporting increased superoxide formation in the type 1 diabetic 
IFM and the associated enhancement of protein oxidation (nitrotyrosine) within the 
mitochondrion (11).  Another PTM that was prevalent in the diabetic IFM was deamidation.  It 
has been suggested that deamidation of asparaginyl and glutaminyl residues within proteins 
causes structural and biological alterations to peptide and protein structure (35).  Though the 
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contribution of deamidation and oxidation to protein dysfunction is somewhat unclear, these 
PTMs may alter protein structure/function making the protein more susceptible for degradation 
by the proteasome system (17, 35).  In addition, several proteins that were decreased in the 
diabetic IFM also contained oxidations and deamidations within their structure.  Interestingly, 
mtHsp70, mitofilin and several components of complex V were decreased in abundance with 
both proteomic technologies and contained oxidations and deamidations within their structures.  
It is plausible that these modifications may have contributed to altered functionality and 
subsequent proteasomal degradation, all of which may have contributed to the morphological 
and oxidative phosphorylation deficiencies present in the type 1 diabetic heart.  
Given that the majority of mitochondrial proteins are nuclear-encoded and must be imported into 
the mitochondrion, it is possible that defects in this complicated process may underlie proteomic 
dysregulation in the diabetic heart.  Nuclear-encoded mitochondrial proteins constitute 99% of 
the organelle’s proteome (7).  These proteins are translated outside the mitochondrion and must 
be imported into the mitochondrion via an intricate mechanism involving coordination between 
the outer and inner mitochondrial membranes (8).  The two membranes come together to form a 
“supercomplex”, which creates a singular avenue for translocation of the imported protein into 
the IMM and matrix (8).  Given the considerable importance of this process, protein import 
decrements resulting from pathological conditions could represent a mechanism for 
mitochondrial dysfunction in the diabetic heart.  Hence, a major goal of this study was to gain 
insight into whether diabetes mellitus causes protein import deficiencies in the mitochondrion 
and determine whether this phenomenon manifests differently in mitochondrial subpopulations.  
Utilizing a novel mitochondrial protein import methodology that eliminated the use of protein 
radiolabeling, we observed dysfunction of the IFM protein import process without effect to the 
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SSM.  Previous literature examining mitochondrial protein import in the skeletal muscle of aging 
mice revealed enhanced cytoplasmic protein degradation, as opposed to protein import 
decrements as the contributing source of the mitochondrial dysfunction (16).  It is unclear why 
the differences were observed but they may be due in part to the different pathologies and tissue 
types examined.   In addition, movement of preproteins into the IMM is aided by ΔΨm.  Our 
results indicate that a 5 week diabetic insult caused a modest decrease (19%) in IFM ΔΨm 
suggesting that mitochondrial protein import deficiencies in diabetic IFM could be at least 
partially due to mitochondrial ΔΨm deficiencies.  However, previous studies examining aged 
skeletal muscle have indicated that as much as a 50% decrease in ΔΨm had no impact on 
mitochondrial protein import mechanics (16).  Therefore, it’s possible that reduced ΔΨm, as 
reported in our study, may still be sufficient to allow for proper mitochondrial protein import. 
Mitochondrial protein import dysfunction has been attributed in part to cardiolipin loss (20).  
Cardiolipin is known to surround and stabilize protein import complexes including Tim23, the 
major pore forming unit essential for protein translocation.  Studies examining a mutation of 
cardiolipin that leads to loss of the phospholipid, caused reduced ΔΨm and decreased 
mitochondrial protein import (18). Another potential mechanism of mitochondrial import 
dysfunction is PTMs to proteins essential for protein translocation.  As indicated above, we 
observed multiple modifications to mtHsp70 in the diabetic IFM subpopulation.  MtHsp70 is a 
heat shock protein and the central subunit of the presequence translocase-associated motor 
complex (PAM) that binds to a translocating polypeptide chain and drives its movement through 
the IMM into the matrix by a reaction cycle that requires hydrolysis of ATP (7).  Previous 
literature examining inactivation of yeast mtHsp70 revealed a near complete inhibition of 
oxidase assembly 1 protein translocation through the IMM (14).  Additionally, cardiac 
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mitochondria in senescent mice were shown to have elevated mtHsp70 protein content as well as 
increased protein import of a mitochondrial matrix protein, malate dehydrogenase (9).  In our 
study, we show a marked decrease in mtHsp70 protein content coinciding with decreased protein 
import in the diabetic IFM subpopulation, suggesting that mtHsp70 protein content is associated 
with protein import capacity.  Our examination of several other key translocases that play a 
major role in mitochondrial protein import including translocase of the outer membrane Tom20, 
outer membrane pore Tom40, inner membrane pore Tim23, and docking subunit Tim44 
indicated that none of these mitochondrial protein import constituents were significantly 
decreased in the diabetic heart.  It should be noted that our examination of Tim44 protein content 
revealed a trend for decrease in the diabetic IFM (p=0.07).  This result is of interest in that 
previous studies have suggested a protective role for Tim44 overexpression in multiple tissue 
types following diabetic insult (29, 44).  Additional experimentation regarding Tim44 and the 
diabetic heart are warranted. 
 
Perspectives and Significance 
With the dramatic increase in diabetes mellitus incidence elucidation of the mechanisms 
contributing to the pathogenesis of diabetic cardiomyopathy are critical.  An increasing amount 
of evidence suggests that mitochondrial dysfunction in the diabetic heart does not manifest in a 
homogeneous fashion.  Rather, mitochondrial dysfunction occurs in a heterogeneous fashion 
with specific impact on mitochondria located in distinct subcellular locales and dependent upon 
the pathology (type 1 diabetes mellitus vs. type 2 diabetes mellitus).  In the current study, we 
observed that type 1 diabetic insult differentially influenced spatially distinct cardiac 
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mitochondrial proteomes, with the greatest impact occurring to those mitochondria located 
between the myofibrils (IFM).  Further, changes in IFM proteomic make-up were associated 
with dysfunction to the nuclear-encoded mitochondrial protein import process, which may 
account in part, for the more pronounced loss of proteins in this specific mitochondrial 
subpopulation.  Finally, loss of key mitochondrial protein import constituents in the IFM may 
underlie protein import deficiencies during type 1 diabetic insult in the heart.  The results support 
a paradigm in which changes in mitochondrial subpopulation-specific proteomic make-up 
underlie mitochondrial dysfunction, necessitating the study of the underpinnings of the complex 
and coordinated process of nuclear-encoded mitochondrial protein import during diabetes 
mellitus.  In addition, these findings continue to emphasize the importance of incorporating 
subcellular spatial locale into the study of diabetic mitochondria which may be of particular 
relevance for the future development of diagnostics and therapeutic interventions.  
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Fig 2.1 
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Figure 2.1. Representative iTRAQ spectra.  Isolated mitochondrial subpopulations from 
control and diabetic hearts were labeled with iTRAQ reagents 114 (diabetic SSM), 115 (diabetic 
IFM), 116 (control SSM), 117 (control IFM) and combined for analysis with mass spectrometry.  
(A) Representative spectra of simultaneous quantitation of a mtHsp70 peptide in control and 
diabetic mitochondrial subpopulations.  (B) MS/MS spectra for the reporter groups of the iTRAQ 
reagents (114,115,116 and 117) from a mtHsp70 peptide. These spectra were used along with 
other peptides to simultaneously quantify mtHsp70 control and diabetic mitochondrial 
subpopulations.   
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Fig 2.2 
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Figure 2.2. Representative 2D-DIGE gels. Samples were labeled with either Cy3 or Cy5 
alternating between control and diabetic SSM and IFM.  A control and treated were run on the 
same gel and an internal standard was labeled with Cy2 and run on every gel for gel to gel 
comparisons. (A) A representative gel showing Cy3 labeled control IFM and (B) is the same gel 
showing Cy5 labeled diabetic IFM.  (C) A representative gel showing Cy3 labeled control SSM 
and (D) is the same gel showing Cy5 labeled control SSM.  Below the gel images are individual 
spots that were identified as mtHsp70, (indicated by the red arrow) and quantitative differences 
were assessed by examination of peak density. 
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Fig 2.3 
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Figure 2.3. pMITOGFP1 construct.  The pMITOGFP1 plasmid was generated and inserted 
into a bacterial cell free protein expression system to produce MitoGFP1 protein.  The 
MITOGFP1 gene consists of an N-terminal mitochondrial targeting sequence derived from 
cytochrome C oxidase subunit VIII (red) fused with AcGFP1 (green).  The MITOGFP1 gene 
was cloned into pIVEX2.3d at restriction sites Not I and blunted Nco I/Nhe I sites.  The correct 
sequence was confirmed by dideoxynucleotide sequencing. 
 
 
 
 
 
 
 
 
 92 
 
Fig 2.4 
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Figure 2.4. MITOGFP1 protein import.  Western blot analysis of MitoGFP1 protein import 
into isolated cardiac mitochondria probed for AcGFP in samples containing 40µg of 
mitochondria only (lane 1), 0.05 µl of MitoGFP1 protein lysate (lane 2), or combined 
mitochondria and lysate (3µl) (lane 3).   The upper 31 kDa band represents the full length 
precursor MitoGFP1 in transit and yet to be processed while the lower 27 kDa band represents a 
mature cleaved MitoGFP1 protein residing within the mitochondrial matrix.    
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Fig 2.5 
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Figure 2.5.  Mitochondrial protein import.   Effect of type 1 diabetes mellitus on MitoGFP1 
import in SSM and IFM subpopulations. Cardiac mitochondrial subpopulations from control and 
diabetic mice were isolated and incubated with 3µl of MitoGFP1 protein lysate at 2, 5, and 10 
minute time points.  Representative Western blots and fluorescent images from (A) SSM and (B) 
IFM protein import assay.  Graphical representation of mitochondrial protein import performed 
in (C) SSM and (D) IFM control and diabetic subpopulations.   The relative amount of imported 
MitoGFP1 was determined by densitometry. The highest value was set to 100% to determine 
percent import at each time point (Control 10 min).  Control for protein loading was confirmed 
by Ponceau staining.  N=8 per group.   
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Fig 2.6 
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Figure 2.6. Western blot analysis of protein import constituents.  Key proteins involved in 
mitochondrial protein import were assessed using Western Blot analyses. (A) Control SSM 
(lanes 1-2), Diabetic SSM (lanes 3-4), Control IFM (lanes 5-6), Diabetic IFM (lanes 7-8); 
translocases of the outer mitochondrial membrane Tom20, Tom40 and inner mitochondrial 
membrane Tim23, Tim44 protein expression.  Representative Western blots and densitometry 
analysis for mtHsp70 protein expression in (B) SSM, and (C) IFM from control and diabetic 
hearts. Values are represented as mean ± SEM.  All values presented indicate a significant 
difference of at least *p<0.05 for control vs. diabetic groups.  Control for protein loading was 
confirmed with Ponceau staining.  N=5 for each group. 
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Fig 2.7 
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Figure 2.7.  Mitochondrial subpopulation membrane potential.  Isolated mitochondrial 
subpopulations were incubated with JC-1, and 20,000 gated events were analyzed per sample.  
Control and diabetic SSM (A) and IFM (B) samples were analyzed.  Values are represented as 
mean ± SEM.  All values presented indicate a significant difference of at least *p<0.05 for 
control vs. diabetic groups.  N=4 for each group.   
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Table 2.1 
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Table 2.1. iTRAQ Proteomic analysis of mitochondrial subpopulations from control and 
diabetic hearts.  iTRAQ analysis of proteins identified and significantly changing, categorized 
into groups consisting of fatty acid oxidation (FAO), mitochondrial respiratory chain, citric acid 
cycle (TCA), transport proteins, structural and miscellaneous proteins in isolated SSM and IFM 
from control and diabetic hearts.  Cells highlighted in red represent decreased protein expression 
in the diabetic mitochondria compared to control, while cells highlighted in green are increased 
in diabetic vs. control.  All values presented indicate a significant difference of at least p<0.05 
for control vs. diabetic groups, while NS represents no significant differences between any 
groups.  N=4 for each group. 
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Table 2.2 
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Table 2.2. 2D-DIGE proteomic analysis of mitochondrial subpopulations from control and 
diabetic hearts. 2D-DIGE analysis of proteins identified and significantly changing, categorized 
into groups consisting of fatty acid oxidation (FAO), mitochondrial respiratory chain, citric acid 
cycle (TCA), amino acid metabolism, oxidative stress related, transport proteins, and structural 
proteins in isolated SSM and IFM from control and diabetic hearts.  Cells highlighted in red 
represent decreased protein expression in the diabetic mitochondria compared to control, while 
cells highlighted in green are increased in diabetic vs. control.  All values presented indicate a 
significant difference of at least *p<0.05 for control vs. diabetic groups, while NS represents no 
significant differences between any groups.  N=4 for each group. 
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Table 2.3 
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 107 
 
Table 2.3 
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Table 2.3 
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Table 2.3 
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Table 2.3. Post-translational modifications (PTM) in mitochondrial subpopulations from 
control and diabetic hearts.   Multidimensional protein identification technology (MudPIT) 
was used to identify post-translational modifications (PTM) of proteins from SSM and IFM from 
control and diabetic mitochondria.  Peptides presented represent only those peptides that have 
PTMs in the diabetic SSM or diabetic IFM and not present in the control group. 
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Table 2.4 
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Table 2.4. Relative gene expression compared to IFM protein expression from control and 
diabetic hearts.  Myocardial gene expression of ANT4, ATP5B and ATP5A1 in control and 
diabetic mice as compared to respective protein expression levels in IFM.  Values represent 
cellular mRNA transcript levels and IFM protein expression in diabetic compared to control.  
mRNA expression was normalized to GAPDH.  All protein values presented indicate a 
significant difference of at least *p<0.05 for control vs. diabetic groups.  N=4 for each group. 
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ABSTRACT 
Mitochondrial dysfunction is a contributor to diabetic cardiomyopathy. Previously, we observed 
proteomic decrements within the mitochondrial inner membrane (IMM) and matrix of diabetic 
cardiac interfibrillar mitochondria (IFM) correlating with dysfunctional mitochondrial import. 
The goal of this study was to determine whether overexpression of mPHGPx, an antioxidant 
capable of scavenging membrane-associated lipid peroxides, could preserve the mitochondrial 
proteome and import process. mPHGPx transgenic mice and controls were made diabetic by 
multiple low-dose streptozotocin. Proteomic analyses revealed mPHGPx overexpression 
preserved proteins decreased within the diabetic IFM. Posttranslational modifications, including 
oxidations and deamidations, were reversed within mPHGPx diabetic IFM.  Ingenuity Pathway 
Analyses indicated that OXPHOS, TCA, and FAO processes most influenced in diabetic IFM 
were preserved by mPHGPx overexpression (P<0.05). IMM proteins were the most highly 
preserved (63%) followed by matrix proteins (34%).  Specific mitochondrial protein networks 
were preserved including those of Complex I and II, structure (mitofilin), and mitochondrial 
import.  Mitochondrial protein import was also preserved in the mPHGPx diabetic IFM (P<0.05) 
which correlated with increases in protein import constituents. Mitochondrial import translocases 
Tom20, Tim23, Tim50, and MtHsp70 were all preserved within mPHGPx diabetic IFM 
(P<0.05).  The results indicate overexpression of mPHGPx can protect the mitochondrial 
proteome and may provide cardioprotective benefits to the diabetic heart. 
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INTRODUCTION 
 
Cardiac failure and heart disease are the leading cause of morbidity and mortality among 
type 1 diabetic patients (15).  Multiple studies have specifically implicated mitochondrial 
dysfunction as an underlying mechanism for cardiac dysfunction seen in the type 1 diabetic heart 
(12, 15, 46).  Mitochondrial analyses are complicated primarily because two spatially distinct 
mitochondrial subpopulations exist in cardiac tissue, subsarcolemmal (SSM) and interfibrillar 
mitochondria (IFM). Literature suggests mitochondrial subpopulations are differentially affected 
within various pathological insults (2, 12, 23, 29, 36).  Specifically, we have shown cardiac IFM 
exhibit the greatest dysfunctional profile within the type 1 diabetic insult including enhanced 
oxidative stress, decreased OXPHOS, and diminished nuclear-encoded mitochondrial import (2, 
12). 
Broad scale proteomic analyses are becoming increasingly prevalent within various type 
1 diabetic models and are paramount to understanding mitochondrial dysfunction within the 
heart (2, 6, 18, 38, 41).  In general, diabetes mellitus leads to significant alterations to proteins 
directly involved in mitochondrial energy production, including processes such as fatty acid 
oxidation (FAO), oxidative phosphorylation (OXPHOS), and the tricarboxylic acid cycle (TCA).  
Further, proteins involved in mitochondrial antioxidant defense, nuclear-encoded mitochondrial 
import, and protein folding were also highlighted as key loci affected by diabetes mellitus (2, 24, 
41). Specifically, our laboratory examined proteomic differences in spatially distinct 
subpopulations of mitochondria in which cardiac IFM displayed decrements to proteins involved 
in FAO, OXPHOS, the TCA cycle, mitochondrial structure (mitofilin) and nuclear-encoded 
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mitochondrial protein import.  Post translational modifications (PTM), such as oxidations and 
deamidations, were also elevated within the diabetic IFM (2). 
Potential mechanisms as to why mitochondrial proteomic dysregulation occurs within the 
diabetic heart remain limited.  Mitochondrial dysfunction has been shown to be directly 
correlative with enhanced mitochondrial derived reactive oxygen species (ROS) generation and 
oxidative damage within the organelle.  Multiple proteins and lipids within the inner 
mitochondrial membrane (IMM) are known targets of reactive oxygen species damage, which 
may potentially elucidate a mechanism of proteomic dysregulation. Phospholipid hydroperoxide 
glutathione peroxidase (PHGPx; GPx4) is an antioxidant that exists as a monomeric structure 
and has the ability to reduce peroxidized acyl groups in phospholipids, fatty acid hydroperoxides, 
and cholesterol peroxides within subcellular membranes (32).  The mitochondrial specific 
isoform, mPHGPx, is primarily located within the inner membrane space (IMS) and has been 
shown to be protective against apoptosis, oxidants, DNA-damaging agents, and glucose 
deficiency (31).  mPHGPx overexpression was shown to be protective of cardiac contractile 
function through a mechanism of reduced lipid peroxidations preservation of essential 
mitochondrial phospholipid cardiolipin, and protection of the mitochondrial ETC complex 
following Ischemia/Reperfusion (I/R) injury (13).  Cardiolipin is known to surround essential 
mitochondrial complexes such at the ETC and Tim23 protein import complex (16, 22, 35).  To 
date, no study has examined how antioxidant overexpression within the diabetic heart influences 
mitochondrial proteomic makeup and essential processes within the organelle.   
Currently, there are an estimated 1500 proteins residing within the human mitochondrion, 
with only 13 proteins transcribed and translated in the organelle itself (1, 7, 34). The vast 
majority of proteins (>99%) are nuclear-encoded and must be imported into the mitochondrion 
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through a complex mechanism of translocation (8). Mutations or deletions to essential protein 
import constituents, specifically mitochondrial heat shock protein 70 (MtHsp70), have been 
shown to drastically reduce nuclear encoded mitochondrial import into the mitochondrial matrix 
and has been proven lethal within yeast cells (10, 14, 25).  Our laboratory has previously shown 
decreased nuclear-encoded mitochondrial protein import correlated with the loss of MtHsp70 
within the diabetic IFM (2).    
It is known type 1 diabetes mellitus will cause widespread proteomics irregularities 
within cardiac mitochondria, however the mechanism of action as well as targeted therapeutics to 
preserve proteomic integrity remain limited.  The goal of this manuscript was to assess the 
influence mPHGPx overexpression has on mitochondrial proteomic integrity and evaluate its 
impact on essential processes such as nuclear-encoded mitochondrial protein import in a diabetic 
setting.  We hypothesize mPHGPx overexpression will preserve essential constituents of the 
protein import process, which will lead to restoration of nuclear-encoded mitochondrial import 
and potentially elucidate a mechanism of mitochondrial proteomic protection within the 
mPHGPx diabetic mouse model.     
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METHODS 
Experimental Animals and Diabetes Induction  
The animal experiments in this study conformed to National Institutes of Health (NIH) 
Guidelines for the Care and Use of Laboratory
 
Animals and were approved by the West Virginia 
University Animal Care and Use Committee. Mixed sex FVB mice were housed in the West 
Virginia University Health Sciences Center animal facility. Mice were given unlimited access to 
a rodent diet and water. MPHGPx transgenic mouse lines were generated as previously described 
(13, 19, 20).  Briefly, the pCAGGS vector places the mPHGPx gene under the control of the 
human cytomegalovirus (CMV).  All littermante control and transgenic mice were generated 
using an FVB background, and experimental procedures were performed on animals of 
approximately 8 weeks of age.  Type 1 diabetes was induced in 8-wk-old mice following the 
protocol of the Animal Models of Diabetic Complications Consortium using multiple low-dose 
streptozotocin (STZ; Sigma, St. Louis, MO) injections. A multiple low-dose STZ protocol was 
chosen because previous reports (21) have indicated that this model limits the body weight losses 
associated with diabetic protocols. Injections of 50 mg/kg body wt STZ dissolved in sodium 
citrate buffer (pH 4.5) were performed daily for 5 consecutive days after 6 h of fasting. Mice that 
served as vehicle controls were given the same volume per body weight of sodium citrate buffer. 
One week postinjection, hyperglycemia was confirmed by measuring urinary glucose (Chemstrip 
2GP Urine test strips, Roche Diagnostics, Indianapolis, IN), where >250 mg/dl was considered 
diabetic.  Five weeks after the onset of hyperglycemia, animals were sacrificed for further 
experimentation. 
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Preparation of Individual Mitochondrial Subpopulations  
At 5 wk post hyperglycemia onset, FVB control, diabetic, MPHGPx, and MPHGPx 
diabetic mice were killed, and their hearts excised.  Hearts were rinsed in PBS (pH 7.4), then 
blotted dry.  IFM were isolated as previously described following the methods of Palmer et al. 
(33) with minor modifications (2, 11, 12).  Protein concentrations were determined using the 
Bradford method with BSA as a standard (5).   
 
iTRAQ™ Labeling 
Pooled IFM (n=4) from control, diabetic, mPHGPx, and mPHGPx diabetic mice were 
lysed and precipitated overnight in acetone at -20°C and pellets were resuspended in 20 μL of 
0.5 M triethylammonium bicarbonate (TEAB; pH 8.5).  Protein contents were determined using 
a 2-D Quant Kit (Amersham, Piscataway, NJ) and 100 μg of each pooled sample was than 
denatured with 0.1% SDS and reduced with 5mM tris-(2-carboxyethyl) phosphine (TCEP).  
After incubation for 1 hour at 60°C, cysteines were blocked with 10 mM methyl methane 
thiosulfonate (MMTS) in isopropanol, and the samples were incubated at room temperature for 
10 minutes.  Addition of 10 μL of sequencing grade trypsin (Applied Biosystems, Foster City, 
CA) was added in a trypsin/protein ratio of 1:20, and the samples incubated at 37°C overnight.  
Digested samples were labeled with the iTRAQ™ reagents following the protocol provided by 
the vendor (Applied Biosystems, Foster City, CA).  
After digestion and iTRAQ™ labeling, the ultra-complex protein digests were combined 
to create a 400 µg pooled protein digest sample that contained equal fractions of each of the four 
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labeled samples for subsequent Multi Dimensional Protein Identificiation Technology (MudPIT) 
analysis (30).   After lyophilization, the digest mixture was reconstituted in strong cation 
exchange (SCX) loading buffer (5mM ammonium formate in 20% acetonitrile; pH 3.0) to be 
fractionated with SCX SpinTips (Protea Biosciences, Morgantown, WV) per the manufacturer’s 
protocol.  Briefly, the sample solution was loaded centrifugally onto the SCX SpinTip.  The non-
adsorbing solution that passed through the SCX SpinTip was collected. Eight different elution 
solutions were used to fractionate the peptides (20, 60, 100, 150, 200, 250, 400, and 500 mM 
ammonium formate in 10% acetonitrile) in a step-wise manner, for a total of nine sample 
fractions.  The collected fractions were cleaned by repeated lyophilization and reconstituted in a 
0.1 M acetic acid solution, and then lyophilized to dryness.  The fractions were then submitted 
for LC-MALDI TOF/TOF mass spectral analysis for protein identification, characterization, and 
differential expression analysis.  
 
Mass Spectrometry (MS) Analyses with iTRAQ™ Labeling 
The LC-MALDI mass spectrometry system utilized was an ABI Tempo LC MALDI 
spotter with Tempo LC MALDI v.2.00.09 data acquisition and processing software.  Lyophilized 
SCX sample fractions were reconstituted in LC aqueous run buffer (0.1% trifluoroacetic acid, 
2% acetonitrile) and was injected onto a Zorbax C18 chromatographic column, 150 x 0.3 mm 
(Agilent Technologies, Wilmington, DE).  The peptides were eluted from the column using an 
acetonitrile/trifluoroacetic acid gradient (2-72% acetonitrile in 35 minutes) and spotted directly 
onto a MALDI plate in 6 second spot fractions.  The MALDI spots were analyzed using an ABI 
4800 MALDI TOF/TOF analyzer operated with 4000 Series Explorer software.  The MS 
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acquisition was in positive ion reflector mode with 400 laser shots per spectrum performed.  The 
15 strongest precursors per spot were chosen for MS/MS and the MALDI spot was interrogated 
until at least 4 peaks in the MS/MS, spectra achieved a S/N ≥ 70.   
The resulting MS/MS spectra were analyzed using ABI Protein ProteinPilot software 2.0 
(Applied Biosystems, Foster City, CA).  The spectral data was searched against the mouse 
protein database (NCBI nr.fasta database customized to select for all mouse proteins) for 
identification of the peptides and corresponding proteins.  In ProteinPilot, the sample type was 
selected as iTRAQ 4Plex for retrieval of the isotopic tag information from the mass spectra.  
After database correlation analysis, the proteins were grouped, scored, and normalized against 
one to four isotope correction factors.  The Pro Group algorithm of ProteinPilot generated a 
ProtScore that is a cumulative score from each of the peptides used by the algorithm in the 
protein identification.  Protein scores (ProtScore) above 2.0, 1.0, and 0.47 expressed the percent 
confidence levels of >99, >90, and >66%, respectively.  Each peptide match showed the 
iTRAQ™ isotopic labels, carbamidomethylated cysteines, and other post-translational 
modifications present as mass spectral shifts identified during the database correlation analysis.  
Each protein identified also showed the differential protein expression compared against the 
other iTRAQ™ labeled samples for relative quantitation. 
 
Canonical Pathways and Molecular Network Analysis 
After protein identification/quantification of diabetic IFM and mPHGPx diabetic IFM 
proteomes through iTRAQ proteomic analyses, the accession numbers and fold changes of the 
differentially expressed proteins were tabulated in Microsoft Excel and imported into IPA 
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(Ingenuity Systems, www.ingenuity.com) for canonical pathway analyses. The statistical 
significance of each pathway was determined by IPA using a Fisher Exact test p <0.05 and 
visualized as a bar graph. IPA was also used to construct interacting protein networks identified 
within diabetic IFM and mPHGPx diabetic IFM groups obtained through iTRAQ proteomic 
analyses. IPA contains a database that uses the most current knowledge available on genes, 
proteins, disease processes, signaling and metabolic pathways needed for protein network 
construction.    
Protein Import 
Plasmid Construction  
The fusion protein pAcGFP1-Mito (Clontech Laboratories, Mountain View, CA) 
containing the precursor subunit VIII of human cytochrome C oxidase and the green fluorescent 
protein from Aequorea coerulescens (AcGFP1) was cloned into pIVEX2.3d (Roche Applied 
Science, Indianapolis, IN) at restriction sites NotI and blunted NcoI/NheI creating pMitoGFP1.  
The correct sequence was confirmed by dideoxynucleotide sequencing.  pMitoGFP1 was grown 
to a concentration of 500 ng/µl and isolated using mini prep plasmid DNA isolations (Qiagen, 
Valencia, CA).   
 
In Vitro Synthesis of Mitochondrial Protein 
In Vitro transcription/ translation of mitoGFP1 was performed using the S30 T7 protein 
expression system (Promega, Madison, WI) per manufacturer’s protocol.  MitoGFP1 lysate was 
subsequently used as substrates for the in Vitro protein import process. 
 
Mitochondrial Protein Import 
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The mitochondrial protein import procedure was performed following the protocol from 
Stojanovski et al. (40) with modifications.  Briefly, 40 µg of mitochondria was resuspended in 
100 µl of import buffer (250 mM Sucrose, 80 mM KCl 5 mM MgCl2, 2 mM KH2PO4 10 mM 
MOP-KOH, pH 7.2) with addition of 2 mM ATP and 10 mM Na-Succinate.  1-5 µl lysate 
containing MitoGFP1 protein was added, and protein import was performed at increasing time 
intervals of 1 and 2 minutes at 25°C.  Valinomycin (2 µM) was added to stop the import 
reaction, and samples were centrifuged at 12,000 x g for 5 min at 4°C.  The supernatant was 
discarded, and the pellet resuspended in SEM buffer (250 mM Sucrose, 1 mM EDTA, 10 mM 
MOP-KOH, pH 7.2) containing trypsin, on ice.  Trypsin was subsequently inhibited by protease 
inhibitor cocktail (BioVision, Mountain View, CA). Samples were centrifuged again at 12,000 x 
g for 5 min at 4°C.  Pellets were then resuspended in lysis buffer (Biovision, Mountain View, 
California), subjected to SDS-PAGE, and subsequent Western blot analyses. Quantification of 
blots was performed using Pierce ECL Western Blotting Substrate (Pierce Biotech, Rockford, 
IL).  The primary antibody was an anti-GFP monoclonal antibody raised in a mouse host 
(Clontech Laboratories, Mountain View, CA).   The secondary antibody was an anti-mouse IgG 
horseradish peroxidase conjugate (Sigma, St. Louis, MO).  Quantification of chemiluminescent 
signals were detected using a G:BOX (Syngene, Frederick, MD), and data expressed as arbitrary 
optical density units.   
 
Western Blot Analyses 
 SDS polyacrylamide gel electrophoresis (SDS-PAGE) was run on 4-12% gradient gels as 
previously described (28, 44) with equal amounts of protein loaded for each study treatment. 
Relative amounts of subpopulation-specific mitochondrial MtHsp70 (MtHsp70), translocase of 
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the outer membrane 20 (Tom20), translocases of the inner membrane 23 (Tim23) and 50 
(Tim50) were analyzed using the following primary antibodies; anti-MtHsp70 mouse antibody 
(Product # SPA-825; Stressgen, Ann Arbor, MI), anti-TOM20 mouse antibody (Product # 
612278; BD Biosciences, San Jose, CA), anti-Tim23 mouse antibody (Product # 611222; BD 
Biosciences, San Jose, CA) .  The secondary antibodies used in the analyses were donkey anti-
goat IgG HRP conjugate (Product # sc-2020; Santa Cruz Biotech, Santa Cruz, CA) for TIM50, 
goat-anti mouse conjugate (Product # 31430; Pierce Biotech, Rockford, IL) for TOM20, TIM23, 
and MtHsp70.  Detection of signal was performed according to the manufacturer’s instructions, 
using Pierce ECL Western Blotting Substrate (Pierce Biotech, Rockford, IL).  Autoradiographic 
signals were assessed using a G:Box Bioimaging System (Syngene, Frederick, MD), and the data 
captured and analyzed using GeneSnap/GeneTools software (Syngene, Frederick, MD). 
 
Blue Native Gel 
To assess MtHsp70 abundance within the PAM complex, Native Polyacrylamide Gel 
Electrophoresis (NativePAGE) was performed in control, diabetic, mPHGPx, and diabetic 
mPHGPx IFM according to manufacturer’s protocol (Invitrogen, Carlsbad, CA).  Briefly, 20 µg 
of isolated mitochondria was solubilized with 1% digitonin for 15 minutes on ice.  After addition 
of 1.25 µl of Coomassie G-250, samples were run in 4-16% NativePAGE gels at 120 V for 90 
minutes in room temperature.  Gels were transferred to PDVF membranes and subsequently 
probed with mtHSP70 antibody previously described.   
 
 125 
 
Statistics 
Means and standard errors (SEM) were calculated for all data sets.  Data were analyzed 
with a one-way analysis of variance (ANOVA) method to evaluate the main treatment effect, 
diabetes induction and mPHGPx transgene presence (GraphPad Software Inc., La Jolla, CA).  
Fisher’s Least Significant Difference (LSD) post hoc tests were performed to determine the 
significant differences among means.  When appropriate a Student’s T-test was employed.  
P<0.05 was considered significant. 
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RESULTS 
 
Proteomic Analyses 
To determine how mPHGPx overexpression impacts the proteomic makeup of IFM 
during a type 1 diabetic insult, iTRAQ labeling followed by MALDI-TOF/TOF mass 
spectrometry was performed.  iTRAQ allows for identification and quantification of unique 
polypeptide sequences through isobaric tagging.  Only proteins that were statistically significant 
as a result of diabetes mellitus in control or mPHGPx overexpressed animals were reported.   
Proteins of the Mitochondrial Respiratory Chain.  
  As previously reported, multiple mitochondrial respiratory chains proteins were 
significantly decreased in the IFM by diabetes mellitus (2).  The greatest influence was upon the 
NADH dehydrogenase complex (complex I) with 5 proteins significantly decreased.  To a lesser 
extent, the other respiratory chain complexes were also decreased including 2 proteins from 
complex II, 3 proteins from complex III, 1 protein from complex IV, and 2 proteins from the 
ATP synthase itself (TABLE 3.1).  Interestingly, overexpression of mPHGPx within the diabetic 
IFM lead to the preservation of 9 OXPHOS proteins significantly decreased in the diabetic IFM 
group including those from complex I, II, III, and V (Table 3.1).  Further, mPHGPx diabetic IFM 
displayed enhanced protein content of 9 OXPHOS proteins that weren’t decreased in the diabetic 
IFM (Table 3.1).  The results indicate that mPHGPx has the specific ability to protect the 
mitochondrial respiratory chain during a type 1 diabetic insult.    
Proteins of Lipid Metabolism 
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 Because of the inability to utilize glucose within the diabetic heart, preservation of lipid 
metabolism is paramount for proper energy production and utilization.  Three mitochondrial 
proteins involved in lipid metabolism, acyl carrier protein, hydroxyacyl-coenzyme A 
dehydrogenase, and short-chain specific acyl-CoA dehydrogenase were significantly decreased 
when comparing control and diabetic IFM (Table 3.1).  Interestingly, 2 of these proteins as well 
as other lipid metabolism constituents including enoyl-CoA hydratase were significantly 
increased in the mPHGPx diabetic transgenic IFM compared to diabetic counterpart (Table 3.1).   
Proteins of the Citric Acid Cycle (TCA).   
Two proteins of the TCA cycle were significantly decreased in the IFM of the diabetic 
animals compared to control including isocitrate dehydrogenase 3 (IDH3) (Table 3.1).  
Conversely, mPHGPx diabetic IFM show highly significant increases in IDH3 (3.5 fold) when 
compared to the diabetic phenotype.  Interestingly, mPHGPx was able to preserve or elevate 4 
additional TCA cycle proteins that were not influenced by diabetes mellitus.  These proteins 
include aconitate hydratase, citrate synthase, and malate dehydrogenase (Table 3.1).  Because 
mPHGPx is thought to predominantly exist within the inner membrane space, we did not 
anticipate its effects upon the mitochondrial matrix. 
Transport Proteins  
Multiple mitochondrial transport proteins were decreased including mtHsp70, the key 
constituent of the presequence translocase-associated motor (PAM) complex essential for all 
mitochondrial matrix import and to a lesser extent, IMM transport.  Following trend, mtHsp70 
protein content was preserved in the IFM mPHGPx diabetic group compared to the diabetic 
group (Table 3.1).  The IMM transporter essential for phosphate transport into the mitochondrial 
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matrix, Phosphate carrier protein, was also decreased in the diabetic IFM and rescued in the 
MPHGPx transgenic animal.  ADP/ATP translocase 1 was also preserved within the mPHGPx 
diabetic IFM (Table 3.1).  Outer mitochondrial membrane (OMM) channel, voltage dependent 
anion selective channel 1 was also enhanced within the mPHGPx diabetic IFM, highlighting the 
ability of mPHGPx to preserve proteins within the OMM as well. 
Miscellaneous  
  D-beta-hydroxybutyrate dehydrogenase was significantly decreased in the diabetic IFM 
compared to control and increased by 2.45 fold in the mPHGPx transgenic compared to diabetic 
(Table 3.1).  Antioxidant peroxiredoxin-5, which is capable of reducing hydrogen peroxide and 
alkyl hydroperoxides was significantly decreased within the diabetic IFM compare to control.  
mPHGPx diabetic mice show a trending increase in peroxiredoxin-5 when compared with 
diabetic IFM, however not statistically significant (Table 3.1).  MPHGPx diabetic IFM show 
increases in amino acid metabolism protein aspartate aminotransferase as well as ketone 
metabolism protein succinyl-CoA:3-ketoacid-coenzyme A transferase 1 when compared to 
diabetic IFM (Table 3.1). 
Diabetic mPHGPx IFM vs mPHGPx IFM 
 Analyses were conducted analyzing diabetic mPHGPx IFM and control mPHGPx IFM, 
which are shown in Table 3.1.  Interestingly, the majority of proteins (34 out of 46) were not 
significantly changed between mPHGPx diabetic IFM and mPHGPx IFM indicating a 
preservation of these proteins within a diabetic setting (Table 3.1). Further, diabetic mPHGPx 
IFM displayed enhanced protein content in 12 out of 46 proteins identified when compared to 
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mPHGPx IFM, including MtHsp70 (Table 3.1).  Western blot data confirms elevated levels of 
MtHsp70 protein content in diabetic mPHGPx IFM compared to mPHGPx IFM (Fig 3.5C).   
Posttranslational Modifications (PTM) 
Utilizing MudPIT technology to examine PTM, we identified 68 peptide sequences of 44 
different protein that were modified through oxidations, acetylations or deamidations, within the 
diabetic IFM, which were reversed in the diabetic mPHGPx transgenic (Table 3.2).  All proteins 
analyzed were within the IMM or matrix.  Nine proteins were no longer oxidized in the diabetic 
mPHGPx IFM including 3 from the ETC, 2 from the TCA cycle, and 2 FAO proteins (Table 
3.2).  Interestingly, 16 IMM proteins and 21 matrix protein identified no longer displayed 
deamidations within the mPHGPx diabetic IFM group including essential mitochondrial import 
protein MtHsp70 (Table 3.2). 
Proteomic Analyses 
To begin to understand the impact of mPHGPx overexpression upon diabetic IFM, we 
evaluated proteins in three categories; unique proteins decreased only in the diabetic IFM, unique 
protein only upregulated within the diabetic mPHGPx IFM, or common proteins (decreased in 
diabetic IFM, restored in mPHGPx diabetic IFM).  Analyses revealed a total of 25 proteins 
statistically decreased within the diabetic IFM compared to control.  Of those, 9/24 
mitochondrial proteins were uniquely decreased in the diabetic IFM alone without correction in 
the mPHGPx diabetic group (Fig. 3.1B).  Conversely, the remaining 15/24 proteins (62.5%) were 
shown to be significantly decreased in the diabetic IFM and subsequently preserved within the 
diabetic mPHGPx IFM group.   Interestingly, there are an additional 20 unique proteins that were 
not changed in the diabetic verse control IFM but were significantly increased within the diabetic 
 130 
 
mPHGPx group (Fig. 3.1B).  These results indicate that the majority of proteins negatively 
impacted by type 1 diabetes mellitus are preserved with mPHGPx overexpression.   
Mitochondrial Subcompartment Targeting 
Because mitochondria are double membrane organelles, they contain various sub 
compartments including the OMM, IMS, IMM, and matrix.  To determine the sub-mitochondrial 
location most targeted by mPHGPx overexpression within diabetic IFM, we analyzed the 
percentage of proteins preserved within the various compartments.  As shown in Fig. 3.1A, 
proteomic protection via mPHGPx overexpression predominantly occurred within the 
mitochondrial IM (61%), followed by the mitochondrial matrix (36%), and then OMM (3%).   
Canonical Pathways  
We utilized Ingenuity based software (IPA) in conjunction with iTRAQ proteomics to 
predict canonical pathways within mitochondria that were most negatively impacted by a 
diabetic insult and subsequently preserved through mPHGPx overexpression.  As expected, Fig. 
3.2 demonstrates OXPHOS, FAO, the TCA cycle and fatty acid elongation pathways were the 
most negatively affected (green) by diabetes mellitus within IFM.  Interestingly, mPHGPx 
overexpression within diabetic IFM not only corrected but enhanced (red) proteins involved 
within all four of these major pathways within the diabetic IFM (Fig. 3.2).  Further, mPHGPx 
was also shown to influence proteins involved in pyruvate metabolism within the diabetic 
mPHGPx IFM.  The results suggest that mPHGPx overexpression is able to preserve and even 
potentially bolster essential mitochondrial processes negatively influenced by diabetes mellitus. 
Common Molecular Networks 
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IPA software was able to identify essential mitochondrial molecular networks that were 
damaged within diabetic IFM and preserved within the mPHGPx diabetic IFM.  Of the 6 
networks identified, 5 were of IMM origin including ETC complexes I and II networks, ATP-
sensitive K+ channel network, structural protein mitofilin network, and mitochondrial protein 
import network (Fig 3.3).  Finally, a hydrogen peroxide (H2O2) network was also identified and 
shown to be preserved within the diabetic mPHGPx (Fig 3.3).  mPHGPx is capable of  directly 
scavenging H2O2.    
Mitochondrial Protein Import 
In vitro mitochondrial protein import was evaluated by quantifying the amount of mature 
MitoGFP1 protein within mitochondrial subpopulations of control, mPHGPx, diabetic, and 
mPHGPx diabetic hearts as previously described (2).  Western blot analyses highlighted 
increasing amount of MitoGFP1 at 1 and 2 minutes, respectively, of the mature 27-kDA band in 
all IFM groups.  MitoGFP1 protein import was significantly decreased in the diabetic IFM when 
compared to control, which is in agreement with previous findings from our laboratory (2) (Fig. 
3.4, A and B).  Further, MitoGFP1 import was restored back to control levels in the mPHGPx 
diabetic group indicating mPHGPx overexpression is protective against diabetes induced 
mitochondrial import decrements within the IFM (Fig. 3.4, A and B).  SSM protein import was 
not significantly altered in any of the groups examined (Appendix 7.1).   
Protein Import Machinery 
To determine the impact of mPHGPx overexpression upon key mitochondrial import 
constituents, we evaluated the protein abundance of OMM translocase Tom20, IMM translocases 
Tim23 and Tim50, and essential PAM complex constituent MtHsp70 in control, mPHGPx, 
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diabetic, and mPHGPx diabetic IFM (Table 3.1, Fig. 3.5).  MtHsp70 protein content was 
significantly decreased in the diabetic IFM group and significantly increased in the mPHGPx 
diabetic group, which is in agreement with our iTRAQ data (Fig. 3.5C).  Further, Tom20, Tim23, 
and Tim50 were all significantly increased in the diabetic mPHGPx IFM compared to diabetic 
IFM (Fig. 3.5, A, B and D).  MtHsp70 also had a trending increase (P < 0.07) in the mPHGPx 
diabetic SSM group compared to all other SSM groups (Appendix 7.2). The results indicate 
mPHGPx has a direct ability to protect and enhance nuclear-encoded mitochondrial protein 
import constituents.   
MtHsp70 Complexing 
During moments of import into the mitochondrial matrix, MtHsp70 will complex with 
inner membrane anchor protein Tim44 to form the functional element of the PAM complex.  To 
examine the ability of MtHsp70 to complex with Tim44, we performed BN-PAGE analyses on 
isolated IFM in control, diabetic, MPHGPx, and diabetic MPHGPx mouse hearts (Fig. 3.6, A and 
B).  Similar to the Western blot results, diabetic IFM displayed a significant decrease in 
MtHsp70-Timm44 protein complexing compared to all other groups and diabetic mPHGPx IFM  
was restored to control levels (Fig. 3.6, A and B).  The results indicate that diabetic mPHGPx 
IFM are able to adequately form the functional PAM complex, which was decreased in the 
diabetic IFM.   
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DISCUSSION 
Mitochondrial dysfunction plays a critical role in the progression and pathogenesis of 
type 1 diabetes mellitus and diabetic cardiomyopathy.  Although multiple studies highlight 
mitochondrial abnormalities within the pathology, the underlying mechanisms involved with 
dysfunction remain limited.  Further complicating studies of this nature are that mitochondria 
exist in two spatially distinct subpopulations within the heart, the SSM and IFM.  Interestingly, 
literature suggests the two subpopulations respond differently to pathological insults. As an 
example, our laboratory has shown type 1 diabetic IFM to produce elevated levels of ROS, have 
enhanced oxidative damage and decreased cardiolipin content compared to IFM control (12).  
Further, we found that the proteomic makeup of IFM was significantly altered, presumably 
through a mechanism of enhanced post translational modifications and altered nuclear-encoded 
mitochondrial protein import mechanism (2).   Mitochondrial proteomic decrements 
predominantly occur within the IMM locale.  Because so many critical complexes exist within 
the IMM such as the ETC, the ATP synthase, and mitochondrial protein import TIM complex, 
preservation of this critical locale is essential for correction of the dysfunction present within 
mitochondria during a type 1 diabetic insult.  MPHGPx is a unique antioxidant capable of 
scavenging phospholipid hydroperoxides, and is critical for the preservation of the IMM.  
Therefore, the goal of the study was to determine whether overexpression of mPHGPx will lead 
to protection of the IFM proteome and preservation of essential mitochondrial processes such as 
nuclear-encoded mitochondrial import during a diabetic insult.    
Proteomic analyses are excellent tools for furthering our understanding of how 
mitochondrial proteins are influenced globally within the diabetic heart.  Utilizing iTRAQ 
methodologies, we confirmed previous research from our laboratory highlighting decreases in 
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essential mitochondrial proteins governing processes such as OXPHOS, TCA cycle, FAO, and 
transport proteins of the diabetic IFM (2).  A rather compelling finding from the proteomic 
analysis was that mPHGPx was able to preserve a significant portion of the proteins decreased in 
the diabetic IFM (62.5%) from all the mitochondrial processes highlighted above (Table 3.1).  
Further, the majority of proteins preserved or elevated within the diabetic mPHGPx IFM resided 
within the IMM.  The results seem logical because mPHGPx resides predominantly within the 
mitochondrial IMS allowing for proximal scavenging membrane lipid hydroperoxides of the 
IMM (31, 32).   However, it is important to point out that nearly one third of proteins protected 
or elevated within the diabetic mPHGPx IFM resided within the matrix.  Because mPHGPx is 
not endogenous to this submitochondrial region, this data was unexpected. ETC Complexes I and 
III, the principle sites for electron leakage, were highly preserved within the mPHGPx diabetic 
IFM potentially decreasing total ROS production and subsequent damage of matrix proteins (9).   
Our PTM data supports this notion by highlighting decreases in oxidations and deamidations in 
IMM and matrix proteins from mPHGPx diabetic IFM (Table 3.2).  Further, mPHGPx is capable 
of scavenging ROS hydrogen peroxide, potentially further decreasing the oxidative environment 
seen within the mitochondria and highlighting another possible mechanism for proteomic 
protection seen within the matrix of mPHGPX diabetic IFM (42).  However, further studies 
elucidating exact mechanisms of mPHGPx protection of mitochondrial matrix proteins is 
warranted.   
Ingenuity Pathways Analysis (IPA) software is critical for the identification of key IFM 
canonical pathways and networks that are directly influenced by diabetes mellitus and preserved 
within mPHGPx diabetic IFM.  From our results, we were able to validate the major processes 
negatively impacted by diabetes mellitus are OXPHOS, TCA, and FAO (Fig. 3.2).  Interestingly, 
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mPHGPx overexpression preserved all three of these canonical pathways highlighting the 
antioxidants ability to protect the exact areas of dysfunction within the diabetic IFM.    Delving 
further into IPA’s capabilities, we analyzed molecular networks directly influenced by enhanced 
mPHGPx in diabetic IFM.  MPHGPx overexpression preserved biological networks originating 
within the IMM that are involved in OXPHOS (Complex I and II), ATP-sensitive K+ channel 
function, mitochondrial structure (mitofilin), and nuclear-encoded mitochondrial protein import.  
Some of the networks analyzed validate previous results from our laboratory and others as areas 
of dysfunction within diabetic IFM such as complex I and II of the ETC (12, 26, 27).   
Interestingly, mPHGPx overexpression was able to correct networks relatively unexplored within 
a diabetic setting, including structural networks through the preservation of known mitochondrial 
scaffolding protein mitofilin.  Deeper analysis into how the mitofilin network is influenced by 
diabetes mellitus may lead to novel mechanisms of dysfunction within the pathology.   
Most importantly, IPA was able to identify a central linkage, connecting all other 
common networks displayed, the mitochondrial protein import network.    Currently, there are an 
estimated 1500 proteins in the human mitochondrion, with only 13 transcribed and translated in 
the organelle itself (1, 7, 34). The vast majority of proteins (>99%) are nuclear-encoded and 
imported into the mitochondrion through a complex mechanism of translocation (8).  
Mitochondrial import of proteins into the matrix involved a coordinated effort between the 
translocases of the OMM (TOM), IMM (TIM), and the PAM complex, which create a 
“supercomplex”, generating a singular avenue for translocation once the protein is targeted to the 
mitochondria.   Because mitochondrial protein import is absolutely essential for mitochondrial 
morphology and structure, preservation of this process may be paramount within pathologies 
involving mitochondrial dysfunction, such as diabetes mellitus.   
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Interestingly, key mitochondrial import protein and main component of the PAM 
complex, MtHsp70, was decreased in the diabetic IFM and preserved within the diabetic 
mPHGPx IFM in our proteomic analysis, which also was confirmed through Western blot 
analysis (Fig. 3.5C).  Further, BN-PAGE was utilized to determine the level of MtHsp70 within 
the PAM complex.  Similar to Western blot results, MtHsp70 content within the complex was 
decreased in the diabetic IFM and preserved within the mPHGPx diabetic group (Fig. 3.6B).    
Functionally MtHsp70 assists in the import of preproteins into various mitochondrial 
subcompartments including the inner membrane space, IMM, and matrix (4, 37, 43).  Previously, 
we have shown decreased MtHsp70 content within the diabetic IFM, which correlated with 
decreased ability of the mitochondria to import preproteins into the mitochondrial matrix (2).  
Therefore, we hypothesized that MtHsp70 preservation through mPHGPx overexpression could 
lead to correction of import decrements seem within the diabetic IFM and potentially elucidate a 
mechanism of proteomic protection within the diabetic mouse.  Confirming previous 
experimentation, in vitro import of mitochondrial matrix targeted mitoGFP1 was significantly 
decreased in the diabetic IFM compared to control IFM.  Further, mitoGFP1 import into the 
diabetic mPHGPx IFM was significantly higher (back to control level) when compared to 
diabetic IFM import, indicating restoration of matrix import within the diabetic mPHGPx IFM 
(Fig. 3.4).  Further highlighting the positive effects upon nuclear-encoded mitochondrial protein 
import, key import constituents Tom20, Tim23, and Tim50 were all significantly increased 
within diabetic mPHGPx IFM compared to diabetic IFM (Fig 3.5 A, B, D).  A number of reports 
have recently identified mitochondrial import decrements when one or more of these essential 
translocases are disturbed.  Mutations to or inactivation of MtHsp70 was shown to inhibit 
unfolding, translocation, and subsequent folding of mitochondrial preproteins imported into yeast 
 137 
 
mitochondria (3, 14, 25) Singh et al. examined mitochondrial protein import in a model of 
skeletal muscle disuse through unilateral peroneal nerve denervation (39).  Interestingly, in vitro 
import of TCA cycle protein malate dehydrogenase 2 was decreased coinciding with significant 
decreases to MtHsp70, Tim23, and Tom20 protein content (39).  Further, research from our 
laboratory using rat neonatal cardiac myocytes infected with an adenoviral vector overexpressing 
MtHsp70 enhanced protein content of Tom20 and antioxidant MnSOD compared to control 
myocytes (45).  Recently, Gevorkyan-Airepetov et al. mutated the binding region of Tim23 and 
Tim50, destabilizing the interaction between the translocases (17).  In vitro import of both IMM 
and matrix bound proteins were inhibited in the mutant yeast indicating the importance of Tim50 
for the transport of numerous proteins within these mitochondrial locales. Overall, mPHGPx 
overexpression was able to preserve key translocases of the mitochondrial import process, which 
lead to restoration of mitochondrial protein import within the diabetic IFM subpopulation.  
In conclusion, the data presented indicates for the first time that enhanced antioxidant 
defense via mPHGPx overexpression lead to protection of the IFM proteome within the diabetic 
heart.  IPA analysis was utilized to highlight specific areas of dysfunction and preservation 
within diabetic and mPHGPx diabetic IFM respectively.  Further, nuclear-encoded mitochondrial 
protein import function was corrected within the mPHGPx diabetic mice and may provide a 
mechanism for proteomic protection seen within the transgenic animal.  These finding provide 
further rationale for the use of mPHGPx as a therapeutic protectant against type 1 diabetic-
induced cardiac injury.   
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Fig 3.1 
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Figure 3.1.  Proteomic alterations in diabetic and mPHPGx diabetic IFM.  (A)  Breakdown 
in approximate percentages of protein contents preserved in the mPHGPx diabetic heart IFM.  
(B) total amount of proteins decreased solely in the diabetic IFM (left), common proteins 
decreased in diabetic IFM and preserved within mPHGPx diabetic IFM (middle), and proteins 
increased solely within the mPHGPx diabetic IFM.  OMM, outer mitochondrial membrane; 
IMM, inner mitochondrial membrane.   
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Fig 3.2 
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Figure 3.2.  Mitochondrial canonical pathways.  Identification of essential mitochondrial 
canonical pathways negatively influenced in diabetic IFM and preserved within mPHGPx 
diabetic IFM.  Oxidative phosphorylation, Citrate cycle, fatty acid metabolism, and fatty acid 
elongation were negatively affected (green) by diabetes mellitus.  Conversely, these pathways as 
well as pyruvate metabolism were preserved (red) within the mPHGPx diabetic IFM. 
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Fig 3.3 
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Figure 3.3. Mitochondrial protein networks.  Identification of mitochondrial proteomic 
networks negatively influenced in diabetic IFM and preserved within mPHGPx diabetic IFM.  
Six networks including ETC complexes I and II, H2O2 production, Structure, ATP-sensitive K+ 
channel, and mitochondrial protein import were identified.  Mitochondrial protein import 
network is the central node linking all other networks. Green indicates proteins preserved within 
mPHGPx diabetic IFM. Red indicates proteins positively enhanced in mPHGPx diabetic IFM. 
White indicates proteins unchanged by diabetes mellitus but are part of their respective networks.    
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Fig 3.4 
 
 
 
 151 
 
Figure 3.4.  Mitochondrial protein import.   Effect of type 1 diabetes mellitus and mPHGPx 
overexpression on MitoGFP1 import in IFM. Cardiac mitochondrial subpopulations from 
control, diabetic, mPHGPx, and diabetic mPHGPx mice were isolated and incubated with 2µl of 
MitoGFP1 protein lysate at 1 and 2 minute time points.  Representative Western blots from IFM 
(A) protein import assay.  Graphical representation of mitochondrial protein import performed in 
control (C), diabetic (STZ), mPHGPx (M),  and diabetic mPHGPx IFM (M + STZ) (B).  The 
relative amount of imported MitoGFP1 was determined by densitometry. Dashed line denotes 
control levels.  Import efficiency was based off of percent control at the 1 and 2 minute time 
points.  Both time point percentages were then averaged to show total import efficiency.  Control 
for protein loading was confirmed by Ponceau staining.  Values are presented as means ± SE; *P 
< 0.05 for IFM STZ vs. all IFM groups.  N=5 per group.   
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Fig 3.5 
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Figure 3.5.  Mitochondrial protein import constituents.  Western blot 
analysis of protein import constituents.  Key proteins involved in 
mitochondrial protein import were assessed using Western blot analysis.  
Representative Western blot and densitometry analysis for Tom20 (A), 
Tim50 (B), MtHsp70 (C), and Tim23 (D) from control, mPHGPx, 
diabetic and diabetic MPHGPx IFM. Control for protein loading was 
confirmed by Ponceau staining. Values are presented as means ± SE; *P 
< 0.05 for IFM STZ vs. all groups; +P < 0.05 for IFM mPHGPX 
diabetic vs. all groups; $P < 0.05 for IFM MPHGPx STZ vs. IFM 
diabetic.  N=4 per group.   
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Fig 3.6 
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Figure 3.6.  MtHsp70 protein complexing.  Isolated mitochondrial subpopulations from 
control, diabetic, mPHGPx, and diabetic mPHGPx hearts were partially lysed in digitonin buffer 
and subjected to BN-PAGE.  Protein complexes were transferred to nitrocellulose membrane and 
probed for MtHSP70.  A complex of MtHsp70 and Timm44 exists at 119 kD (A).  MtHsp70 
content was analyzed through densitometric analysis (B).   *P < 0.05 for IFM STZ vs. all IFM 
groups.  N=4 per group.   
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Table 3.1  
 
Protein IFM Diab/IFM Control IFM MPHGPx Diabetic/IFM Diabetic IFM MPHGPx Diabetic/IFM MPHGPx
Oxidative Phosphorylation
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10 0.77 1.53 NC
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6 NC 1.63 NC
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7 0.77 NC NC
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8 NC 1.57 1.3
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 0.63 NC NC
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6 0.61 1.6 NC
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7 NC 2.28 NC
NADH dehydrogenase [ubiquinone] iron-sulfur protein 2 NC 1.75 1.46
NADH dehydrogenase [ubiquinone] iron-sulfur protein 3 NC 1.41 1.32
NADH-ubiquinone oxidoreductase 75 kDa subunit 0.83 1.42 NC
Succinate dehydrogenase [ubiquinone] flavoprotein subunit 0.86 1.37 1.21
Succinate dehydrogenase [ubiquinone] iron-sulfur subunit 0.84 1.25 NC
Cytochrome b-c1 complex subunit 1 0.79 1.31 NC
Cytochrome b-c1 complex subunit 2 0.82 1.56 NC
Cytochrome b-c1 complex subunit 8 0.73 NC NC
Cytochrome b-c1 complex subunit Rieske NC 1.42 NC
Cytochrome c oxidase subunit 6 0.88 NC NC
Cytochrome c1, heme protein NC 1.37 NC
ATP synthase protein 8 0.55 1.95 NC
ATP synthase subunit alpha NC 1.57 NC
ATP synthase subunit epsilon NC 1.92 1.74
ATP synthase subunit O 0.76 NS NC
Electron transfer flavoprotein subunit beta 0.80 1.62 NC
Lipid Metabolism
Acyl carrier protein 0.82 1.87 NC
Enoyl-CoA hydratase NC 1.91
Hydroxyacyl-coenzyme A dehydrogenase 0.71 2.06
Short-chain specific acyl-CoA dehydrogenase 0.69 NC
3-ketoacyl-CoA thiolase NC 1.31 1.46
TCA cycle
Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex0.75 NC NC
Aconitate hydratase NC 1.80 1.37
Citrate synthase NC 2.07 NC
Isocitrate dehydrogenase 3 (NAD+) 0.74 3.5 2.43
Malate dehydrogenase NC 1.39 NC
NAD(P) transhydrogenase NC 1.47 1.25
Transport
60 kDa heat shock protein NC 1.39 NC
ADP/ATP translocase NC 1.59 NC
Mitochondrial heat shock protein 75 0.69 1.77 1.21
Mitochondrial inner membrane protein 0.55 1.7 NC
Phosphate carrier protein 0.81 1.66 NC
Voltage-dependent anion-selective channel 1 NC 1.58 NC
Prohibitin-2 0.59 NC NC
Amino Acid Metabolism
Aspartate aminotransferase NC 1.98 1.29
Oxidation/Reduction
D-beta-hydroxybutyrate dehydrogenase 0.57 2.45 1.99
Ketone Metabolism
Succinyl-CoA:3-ketoacid-coenzyme A transferase 1 NC 2.05 NC
Oxidative stress related
Peroxiredoxin-5 0.73 NC NC
 157 
 
Table 3.1. iTRAQ Proteomic analysis of mitochondrial subpopulations from control, 
diabetic, and mPHGPx diabetic IFM.  iTRAQ analysis of proteins identified and significantly 
changing, categorized into groups consisting of oxidative phosphorylation, citric acid cycle 
(TCA), structural, glycolysis, lipid metabolism, and transport proteins isolated form isolated IFM 
from control, diabetic, and diabetic mPHGPx hearts.  Cells greater than 1.0 denote increased 
protein expression (green) and cells less than 1.0 denote decreased protein expression (red) in the 
control vs diabetic, diabetic mPHGPx vs diabetic groups, and diabetic mPHGPx vs mPHGPx 
group.  All values presented indicate a significant difference of at least p<0.05 for control vs 
diabetic and diabetic mPHGPx vs diabetic groups, while NS represents no significant differences 
between any groups.  N=4 for each group. 
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Table 3.2 
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Table 3.2 
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Table 3.2 
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Table 3.2 
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Table 3.2.  Posttranslational modifications (PTM) present within diabetic IFM and 
reversed within mPHGPX diabetic IFM.  Multidimensional protein identification technology 
(MudPIT) was used to identify PTMs of proteins from diabetic IFM that were reversed in 
mPHGPx diabetic IFM subpopulation.  Peptides presented represent only those peptides that 
have PTMs in the diabetic IFM and not present in the mPHGPx diabetic group.   
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ABSTRACT 
Cardiac complications, such as diabetic cardiomyopathy are the leading cause of morbidity and 
mortality among diabetic patients. Dysfunctional mitochondria are central in the pathogenesis of 
diabetic cardiomyopathy. Mitochondrial proteomic alterations during diabetes mellitus have been 
reported however, the mechanisms responsible are unknown. The goal of this study was to 
determine whether miRNAs play a role in diabetes-induced mitochondrial proteomic 
dysregulation. RTQ-PCR miRNA screening in diabetic mice following multiple low-dose 
streptozotocin treatment revealed a significant increase in the expression of 26 miRNAs in the 
diabetic heart compared to control, including microRNA-141 (mir-141) (P<0.05). miRNA target 
predication analyses identified miR-141 as a potential regulator of the inner mitochondrial 
membrane phosphate transporter, solute carrier family 25 member 3 (Slc25a3), which provides 
inorganic phosphate to mitochondrial matrix and is essential for ATP production.  Using a 
luciferase reporter construct with Slc25a3 3’ UTR target sequence, overexpression of miR-141 
down-regulated luciferase activity levels confirming miR-141/Slc25a3 3’ UTR binding.  
miRNA-141 overexpression in HEK 293 cells elicited a decrease in Slc25a3 protein content 
similar to the diabetic phenotype (P<0.05).  ATP synthase activity was decreased in miRNA-141 
overexpressed HEK293 cells (P<0.05).  Diabetic interfibrillar mitochondria (IFM) displayed 
decreased Slc25a3 protein content inversely correlating with increased miR-141 expression.  
Further, diabetic IFM ATP synthase activity was also decreased (P<0.05).   Together these 
results indicate that miR-141 could be a potential regulator of slc25a3 protein expression in the 
diabetic heart. Further, diabetes-induced miRNA modulation may influence mitochondrial 
proteomic make-up and alter functional processes such as mitochondrial ATP production.   
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INTRODUCTION 
Cardiac complications, including diabetic cardiomyopathy, are the leading cause of 
morbidity and mortality among type 1 diabetic patients.  Mitochondrial dysfunction has been 
shown to have a causal role in the role in cardiac abnormalities present during a type 1 diabetic 
insult (9, 13, 30, 34).  Cardiac mitochondria are characterized as two spatially distinct 
mitochondrial subpopulations, located beneath the sarcolemma, termed subsarcolemmal 
mitochondria (SSM), and between myofibrils, termed interfibrillar mitochondria (IFM).  
Mounting evidence suggests that mitochondrial subpopulations are differentially affected in 
multiple pathologies (4, 9, 10, 18, 19, 27, 32, 40).  Our laboratory has shown IFM to be 
dysfunctional in type 1 diabetes mellitus through mechanisms of enhanced oxidative stress, 
decreased oxidative phosphorylation, decreased cardiolipin content, and decreased nuclear-
encoded mitochondrial protein import (4, 9).  Further, ourselves and others have shown dynamic 
alterations of the type 1 diabetic mitochondrial proteome, however the mechanism/mechanisms 
involved remain unclear (6, 14, 34, 35).  A large proportion of the dysregulated proteins reside 
within the inner mitochondrial membrane (IMM) altering essential functions such as oxidative 
phosphorylation and fatty acid synthesis. 
A specific protein that appears to be a target of interest is IMM phosphate carrier protein 
termed “Slc25a3”, which has been shown to be decreased in abundance during a type 1 diabetic 
insult (4).  This transmembrane protein is essential for ATP production as it acts a conduit for 
inorganic phosphate to pass from the inner membrane space into the matrix, providing phosphate 
to fuel the ATP synthase (16).  Decrements to Slc25a3 have shown to have deleterious effects 
upon ATP production and cellular viability (2, 25, 29).  Clinically, patients with a homozygous 
mutation to Slc25a3 presented with exercise intolerance, proximal muscle weakness and 
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cardiomyopathy (24).  However, how Slc25a3 is regulated within type 1 diabetes mellitus has yet 
to be elucidated.  One potential explanation for this phenomenon includes alterations to 
gene/protein expression by way of microRNA (miRNA) regulation. 
miRNAs are 21-23 nucleotide non-coding RNA capable of post transcriptional 
regulation.  Originally described in the nematode C. elegans, miRNAs are ubiquitous among 
many species including all vertebrates (38).  Functionally, with the help of the RNA induced 
silencing complex, miRNAs will aid in the degradation of or inhibit the translational efficiency 
of the target mRNA (20).  The mode of action is thought to largely depend on the binding 
efficiency of the miRNA to the target mRNA.  miRNAs exist in all parts of the body and seem to 
be implicated in virtually all cellular processes currently known (33).  miRNAs have been 
extensively studied in context to cancer, heart failure, and cellular homeostasis (7, 36).  The 
miR-200 family (miR-200a, 200b, 200c, 141, 429) has been shown to modulate E-cadherin 
transcriptional repressors ZEB1 and SIP1, critical factors in epithelial to mesenchymal transition 
and tumor metastasis.  Interestingly, miR-141 and miR-200c were shown to be up regulated in an 
acute hindlimb ischemic model of hypoxia, presumably through a mechanism of enhanced 
reactive oxygen species (ROS) production (21).   
In this current study, we evaluated the impact type 1 diabetes mellitus has upon miRNA 
regulation within the heart. Further, we assessed how changes in this process may lead to 
specific mitochondrial proteomic detriments seen within a type 1 diabetic insult.  
Experimentally, we isolated total RNA from control and diabetic mouse hearts and performed 
broad scale quantitative real time polymerase chain reaction (RTQ-PCR) analyses on 375 of the 
most highly characterized mouse miRNAs within the groups.  We found miR-141 was the most 
significantly increased miRNA within the diabetic heart.  Further, through miRNA target 
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prediction analyses (miRbase, TargetScan, PicTar), we were able to determine Slc25a3 as a 
likely target for regulation by miR-141.  Therefore, we hypothesized that enhanced expression of 
miR-141 would negatively regulate Slc25a3 within cardiac mitochondria during a diabetic insult.  
Further, loss of Slc25a3 would lead to diminished mitochondrial ATP synthesis rates.   
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METHODS 
Experimental Animals and Diabetes Induction  
The animal experiments in this study conformed to National Institutes of Health (NIH) 
Guidelines for the Care and Use of Laboratory Animals and were approved by the West Virginia 
University Animal Care and Use Committee. Male FVB mice (Charles River Laboratories, 
Wilmington, MA) were housed in the West Virginia University Health Sciences Center animal 
facility.  Mice were given unlimited access to a rodent diet and water.  Type 1 diabetes mellitus 
was induced in 8-wk-old mice following the protocol of the Animal Models of Diabetic 
Complications Consortium using multiple low-dose streptozotocin (STZ; Sigma, St. Louis, MO) 
injections.   Injections of 50 mg/kg body weight STZ dissolved in sodium citrate buffer (pH 4.5) 
were performed daily for 5 consecutive days after 6 hours of fasting.  Mice that served as vehicle 
controls were given the same volume per body weight of sodium citrate buffer. One week post-
injections, hyperglycemia was confirmed by measuring fasting blood glucose levels using a 
commercially available kit (Bayer, Mishiwaka, IN).  Blood glucose levers greater than 250 
mg/dL were considered diabetic.  Five weeks post hyperglycemia onset, animals were sacrificed 
for further experimentation. 
 
Preparation of Individual Mitochondrial Subpopulations  
At 5 weeks post hyperglycemia onset, FVB mice and their littermate controls were 
sacrificed, and the hearts were excised.  Hearts were rinsed in phosphate buffered saline (PBS, 
pH 7.4), then blotted dry.  SSM and IFM were isolated as previously described following the 
methods of Palmer et al. (26) with minor modifications (9, 10, 39).  Mitochondrial subpopulation 
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pellets were resuspended in sucrose based SEM buffer (250 mM Sucrose, 1 mM EDTA, 10 mM 
MOP-KOH, pH 7.2) or mitochondrial extraction buffer (Biovision, Mountain View, CA).  
Mitochondrial protein concentrations were determined using the Bradford method and bovine 
serum albumin as a standard (5).   
 
Western Blot Analyses 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) was run on 4-12% gradient gels as 
described (17), with equal amounts of protein loaded.  Relative amounts of Slc25a3 were 
quantified in isolated mitochondrial subpopulations and HEK293 cells using anti-Slc25a3 goat 
antibody (Product # sc-1661226, Santa Cruz Biotechnology, Santa Cruz, CA) and anti-Slc25a3 
mouse antibody (Product # ab67121, Abcam, Cambridge, MA) respectively.  The secondary 
antibodies used in the analyses were donkey anti-goat IgG HRP conjugate (Product # sc-2020) 
and goat-anti mouse conjugate (Product # 31430, Pierce Biotechnology, Rockford, IL).  
Quantitation of chemiluminescent signals were detected using a G:BOX (Syngene, Frederick, 
MD), and data were expressed as arbitrary optical density units.  Control for protein loading in 
isolated mitochondria was confirmed using Ponceau staining.  Control for protein loading in 
HEK293 cells was confirmed using ant-GAPDH mouse antibody (Product # ab8245, Abcam, 
Cambridge, MA) in conjunction with the secondary mouse antibody described above.   
 
RNA Isolation 
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Hearts were rinsed in phosphate buffered saline (PBS, pH 7.4) then snap frozen with 
liquid nitrogen.  Total RNA (small and large) was isolated from heart (25 mg) tissue using 
miRNeasy mini kit per manufacturer’s protocol (Qiagen, Valencia, CA).  Total RNA 
quantification and purity was assessed using a Nanodrop (ND-1000) and stored at -80 °C. 
 
miRNA RTQ-PCR Array 
For miRNA RTQ-PCR analyses, Enriched miRNA was converted to cDNA using the RT² 
miRNA First Strand Kit.  cDNA samples were then used in the SABiosciences RT2 MicroRNA 
PCR Whole Genome Array system, which allowed for simultaneous detection of 378 mouse 
miRNAs, representing functional miRNAs, appropriate housekeeping genes (Rnu6, snoRNA, 
PPC), and RNA quality controls (SABiosciences, Frederick, MD). We performed the assay 
according to the manufacturer's protocol using a Taqman 7900HT system (Applied Biosystems, 
Foster City, CA) utilizing sequence detection systems software version 2.3 (SDS 2.3).  Threshold 
cycles (Ct) were used to determine miRNA copy number and levels of respective miRNAs.  
Relative qPCR expression was normalized to the expression of housekeeping genes using  ΔΔCt 
methodology. 
 
Cell Cultures, Transfections, and Plasmids 
HEK293 cells were grown at 37 °C in a humidified atmosphere of 5% CO2, 95% air.  
HEK293 cells were maintained in Dulbecco’s Modified Eagle Medium (Cellgro, Manassas, VA) 
with 10% fetal bovine serum (Sigma, St. Louis, MO).    miRNA Expression plasmids (pCMV-
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MIR) housing the mouse precursor sequence of miR-141 (5’- 
GGGUCCAUCUUCCAGUGCAGUGUUGGAUGGUUGAAGUAUGAAGCUCCUAAC 
ACUGUCUGGUAAAGAUGGCCC, mature sequence in black) and human miR-200c precursor 
sequence (5’ CCCUCGUCUUACCCAGCAGUGUUUGGGUGCGGUUGGGAGUCUCU 
AAUACUGCCGGGUAAUGAUGGAGG, mature sequence in black ) were purchased from 
Origene and used for transfection studies (Origene, Rockville, MD).  2 µg of plasmids was used 
per well for transfections, which were performed using FuGENE 6 transfection kit per 
manufacturer’s protocol (Promega, Madison, WI) into 6-well culture plates. An Empty pCMV-
MIR plasmid was used as a negative control (Origene, Rockville, MD).   72 hours post 
transfection, cells were washed with phosphate-buffered saline (PBS) and harvested in either 1X 
RIPA Buffer (Sigma, St. Louis, MO) for protein based experimentation or RNA lysis buffer for 
RNA isolation. 
 
miRNA Target Luciferase Assay 
Mouse Slc25a3 3’ UTR target region, 5’– TTTAAACTAGCGG 
CCGCTAGTCTTTATCTGCTTGTTGATCAGTGTTGTATATATTCTAGA (target sequence 
in black), was duplexed (Integrated DNA Technologies, Coralville, IA), cut by Pme1/Xba1 and 
ligated into pmirGLO Dual-Luciferase miRNA Target Expression Vector for miRNA binding 
analyses.  500 ng of Slc25a3 PmirGLO vector was co-transfected as described above with 500 ng 
of mouse miR-141, human miR-200c, or scrambled control vector in triplicate in 12-well culture 
plates.  24 hours post transfection, luciferase activities were assayed with the Dual-Luciferase 
Reporter Assay System (Promega, Madison, WI) per manufacturer’s protocol using a Flexstation 
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3 luminometer (Molecular Devices, Sunnyvale, CA).   Luciferase activity was quantified as a 
ratio of firefly luciferase to renilla luciferase.   
 
RTQ-PCR Analyses 
Isolated total RNA from HEK293 cells was converted to cDNA using miRNA first strand 
cDNA synthesis kit (Origene, Rockville, MD) per manufacturer’s protocol.  15ng of cDNA 
sample, 0.5 µM human miR-141 primer pairs (Origene, Rockville, MD), and 2X SYBR Green I 
qPCR master mix (Origene, Rockville, MD) were used to perform RTQ-PCR analysis using a 
Taqman 7900HT system.  RTQ-PCR was performed as follows:  Activation 50° C for 2 min, 
Pre-soak 95°C for 10 min. Followed by 42 cycles: Denaturation 95°C for 15 sec, Annealing 
55°C for 10 sec, Extension 72°C for 30 sec.  Threshold cycles (Ct) were used to determine 
miRNA copy number and levels of miR-141.  Relative qPCR expression of miR-141 and 
Slc25a3 was normalized to the expression of RNU6 using ΔΔCt method.   
 
Mitochondrial ATP Synthase Activity 
ATP synthase activity was measure in mitochondrial subpopulations and cellular lysate 
as oligomycin-sensitive ATPase activity using an assay coupled with pyruvate kinase which 
converts the ADP to ATP and produces pyruvate from phosphoenolpyruvate as previously 
described (8, 12, 28, 31).  Protein content was assessed as described above (5) with final values 
expressed as nanomoles consumed per minute per milligram of protein, which was equal to the 
nanomoles of NADH oxidized per minute per milligram of protein.   
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Statistics 
Means and standard errors (SEM) were calculated for all data sets.  Data were analyzed 
with a one-way analysis of variance (ANOVA) method to evaluate the main treatment effect, 
diabetes induction (GraphPad Software Inc., La Jolla, CA).  Fisher’s Least Significant Difference 
(LSD) post hoc tests were performed to determine the significant differences among means.  
When appropriate a Student’s T-test was employed.  p<0.05 was considered significant. 
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RESULTS 
miRNA Dysregulation within the Diabetic Heart 
To give a better understanding of how type 1 diabetes mellitus affects miRNA regulation 
within the heart, we performed a broad scale RTQ-PCR analysis of 375 mouse miRNAs in STZ 
treated and control mice (Fig 4.1A).   Interestingly, STZ treated hearts saw significant increases 
in 26 miRNAs and significant decreases in 3 miRNAs when compared to control (Fig 4.1A).  
miR family members miR-141 (5 fold) and miR-200c (2.9 fold) were among the most highly 
upregulated miRNA within the diabetic hearts (Fig 4.1B).    Further, a significant increase in 
miR-208b, known to modulated cardiac hypertrophy, was also shown in the diabetic heart 
compared to control (Fig 4.1B).   
 
Slc25a3 is a Target of miR-141 
Because miR-141 elicited the highest fold change in STZ treated mice, we decided to 
analyze genes that were likely to be regulated by this specific miRNA.  Through the utilization 
of known miRNA target predictor programs (MirBase, Target Scan, PicTar), we were able to 
identify mitochondrial phosphate carrier, Slc25a3, as a primary target of miR-141.  Examination 
of Slc25a3 mRNA revealed two potential target sites of miR-141 within Slc25a3 3’ UTR.  Fig 
4.2A highlights the putative recognition site of miR-141 and Slc25a3 3’UTR.  Further, the 
binding site of the miR-141 seeding sequence to Slc25a3 3’ UTR was highly conserved within 
multiple vertebrate species including mouse, rat, human, and guinea pig (Fig 4.2B).  Multiple 
target sites and conserved vertebrate seeding regions are both positive indicators of potential 
miR-141 targeting and regulation of Slc25a3. 
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In order to determine whether miR-141 was able to effectively bind the 3’ UTR of 
Slc25a3, we performed a cell-based luciferase reporter assay in which Slc25a3 3’ UTR binding 
region of miR-141 was cloned downstream of the Firefly luciferase gene in the pMIR-GLO 
plasmid.  To determine specificity of miR-141, the luciferase reporter plasmid was co-transfected 
into HEK293 cells with miR-141, miR-200c, or pCMV-MIR control.  miR-200c contains a 
slightly different seed region than miR-141 (Fig 4.3A), therefore was not expected to bind with 
the 3’ UTR of Slc25a3.  As shown in Fig 4.3B, miR-141 was able to significantly reduce 
luciferase activity by 30%, whereas the control miR plasmid and miR-200c could not (Fig 4.3B).  
These results indicate that Slc25a3 is a potential target of miR-141.  Further, miR-141 recognizes 
the putative recognition site in the 3’ UTR of Slc25a3. 
 
Slc25a3 is Decreased in Type 1 Diabetic IFM 
We next analyzed Slc25a3 mRNA level and protein content within isolated mitochondrial 
subpopulations from control and diabetic mouse hearts to determine if miR-141 upregulation 
correlated with decreased in Slc25a3 content.  Interestingly, mRNA levels of Slc25a3 were 
unchanged in control and diabetic groups (Fig 4.4A).  Western blots analyses of mitochondrial 
subpopulations revealed a significant decrease of Slc25a3 within diabetic IFM compared to 
control (Fig 4.4C) with no significant change in the SSM subpopulations (Fig 4.4B).  The results 
suggest that if miR-141 regulates Slc25a3, it is through a mechanism of translational repression, 
not transcriptional degradation.   
We then examined whether loss of Slc25a3 would inhibit the mitochondria functionally 
through analysis of ATP synthase activity.  The ATP synthase is able to create ATP by utilizing 
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essential  substrates ADP and phosphate, which are translocated into the mitochondrial matrix 
through adenine nucleotide transporter (ANT) and Slc25a3 respectively (Fig 4.5A).  Correlating 
with decreased Slc25a3 levels, ATP synthase activity within the diabetic IFM was significantly 
decreased compared to control (Fig 4.5C).  Diabetic SSM ATP synthase activity was not 
significantly changed when compared to control (Fig 4.5B).    
 
miR-141 Directly Regulates Slc25a3  
To determine whether miR-141 directly regulates Slc25a3 expression, we performed 
miR-141 overexpression studies within HEK293 cells.   Lipofectamine based transient 
transfections increased miR-141 mRNA expression by 9 fold compared to control in HEK293 
cells (Fig 4.6A).  miR-141 overexpression did not change Slc25a3 mRNA expression levels 
when compared to control (Fig 4.6B).  However, protein expression of Slc25a3 was significantly 
decreased (50%) in miR-141 HEK293 cells 72 hours post transfection when compared to control 
(Fig 4.6C and D).  These results recapitulate the findings within the diabetic heart that miR-141 
action is through translational repression. Functionally, ATP synthase activity was also 
significantly decreased within miR-141 cells (Fig 4.7), indicating overexpression of miR-141 has 
functional implications upon mitochondrial ATP production through a mechanism of decreased 
phosphate transport.     
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DISCUSSION 
Mitochondrial dysfunction is known to play an active role in the pathogenesis of diabetic 
cardiomyopathy.  Specifically, mitochondrial proteomic dysregulation has been shown to be 
correlative with mitochondrial dysfunction and cardiac dysfunction seen type 1 diabetic models 
of diabetic cardiomyopathy (9, 40).  However, the mechanisms involved in promoting diabetic 
induced mitochondrial dysfunction remain limited.  miRNAs have the capability of 
transcriptional and translational repression, thus are an attractive potential mechanism for 
mitochondrial proteomic dysregulation.   Therefore, the goal of this study was to determine the 
impact of miRNAs on the mitochondrial proteome in a diabetic setting.  In order to accomplish 
this goal, we performed a broad scale RTQ-PCR miRNA analysis from the hearts of control and 
STZ-treated mice to evaluate miRNA dysregulation during a diabetic insult. 
miRNAs have the ability to modulate physiological and pathological pathways through 
the regulation of specific target genes.  Recently, studies have begun to elucidate how miRNAs 
regulate essential processes within the heart, including cardiomyocyte hypertrophy through a 
mechanism of miR133a dysregulation (11).  However, no study to date has examined the 
ramifications of miRNA regulation of mitochondrial proteins in a type 1 diabetic model.    RTQ-
PCR analysis of 375 of the most abundant mouse miRNA revealed significant increases in 26 of 
the 29 dysregulated miRNAs in the diabetic group compared control (Fig 4.1).  Specifically, four 
miRNAs displayed the highest fold change increases including miR-329, miR-208b, miR-200c, 
and miR-141.  The miR-208 family has been identified as regulators of cardiac contractility 
through the regulation of β-MHC expression within the heart (37).  Interestingly, cardiac myosin 
heavy chain (MHC) switching from α to β has been shown in multiple type 1 and type 2 diabetic 
models during times of oxidative stress, implicating miR-208b as a potential key regulator of 
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heart function during diabetic cardiomyopathy (3).  Further research into the impact of miR-208 
expression on cardiac MHC switching could potentially be a mechanism as to why MHC 
switching occurs in diabetes mellitus. 
miRNA family members miR-141 and miR-200c, located in mouse chromosome 6, were 
significantly increased in the diabetic heart compared to control by 5 fold and 2.9 fold 
respectively.  With miR-141 displaying the highest fold increase, we decided to identify nuclear-
encoded mitochondrial genes likely regulated by the miRNA.  Through the use of multiple 
miRNA targeting databases (Microcosm, TargetScan, Pictar), IMM phosphate carrier Slc25a3 
was identified as a likely target due to perfect seed region matching and high sequence homology 
between vertebrates (Fig 4.2).   Further, luciferase inhibition after co-incubation of Slc25a3 3’ 
UTR target region housed in a luciferase plasmid with miR-141 confirmed binding between the 
Slc25a3 target mRNA and miR-141 (Fig 4.3).  Recently, miR-141 and miR-200c have been 
shown to be activated within oxidative stress settings (21, 22).  Exposing both human umbilical 
vein endothelial cells and C2C12 myoblasts to hydrogen peroxide, Magenta et. al. noted 
increases in both miR-141 and miR-200c expression (21).  Further, acute hindlimb ischemia, 
known to foster a potent oxidative stress environment, also elevated both miR-141 and miR-200c 
(21).  Our laboratory and others have shown the diabetic myocardium, specifically mitochondria, 
to display high levels of reactive oxygen species (ROS) production and ROS damage, potentially 
elucidating a plausible theory for the elevation of miR-141 during a diabetic insult (9, 14, 30).    
miR-141 overexpression studies were carried out within HEK293 cells to validate target 
gene (Slc25a3) repression.  As expected, enhanced levels of miR-141 significantly decreased 
Slc25a3 protein content by 50% (Fig 4.6) and decreased mitochondrial ATP synthesis rates (Fig 
4.7).  Multiple studies have linked detriments to Slc25a3 with decreased ATP synthesis within 
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mitochondria, highlighting the critical role phosphate transport plays for proper mitochondrial 
energy production (2, 25, 29).   Most notably, patients with mitochondrial phosphate-carrier 
deficiency displayed decreased ATP synthesis in mitochondria isolated from muscle tissue which 
also correlated with hypertrophic cardiomyopathy and low cardiac output (23).   
Cardiac and skeletal muscle contain two spatially distinct mitochondrial subpopulations 
that exist within the myocardium, the SSM, located beneath the sarcolemma, and IFM, situated 
between myofibrils that are suggested to produce ATP for  subsarcolemmal metabolite transport 
and myofibrillar contraction respectively (26).  Interestingly, miR-141 overexpression within the 
diabetic heart correlated with decreased protein content of Slc25a3 as well as decreased ATP 
synthase activity only within cardiac IFM (Figs 4.4C, 4.5C).   These results were somewhat 
unexpected as we hypothesized Slc25a3 would be decreased within both mitochondrial 
subpopulations.  However, mitochondrial dysfunction within cardiac and skeletal subpopulations 
has varied within many different physiological and pathological states including but not limited 
to obesity, diabetes, aging, and apoptotic initiation (1, 4, 9, 15, 19).  Further, other mechanisms 
of dysfunction can’t currently be ruled out as contributors to mitochondrial proteomic 
dysregulation including altered nuclear-encoded mitochondrial protein import or enhanced post 
translational modifications as previously described (4).  Nevertheless, future studies dedicated to 
elucidating the regulatory role of miRNAs in context to individual mitochondrial subpopulations 
is necessary and absolutely warranted. 
In conclusion, these finding indicate that pathologies, such as diabetic cardiomyopathy, 
have the ability to alter mitochondrial specific proteins through differential expression of 
miRNAs. Specifically, we report for the first time that miR-141 is upregulated within the 
diabetic heart and is capable of regulating mitochondrial phosphate carrier Slc25a3.  Perturbation 
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of mitochondrial energy production via miR-141 could potentially be a mechanism for 
mitochondrial dysfunction leading to cardiac dysfunction present within diabetic 
cardiomyopathy.   
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Fig 4.1 
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Figure 4.1.  miRNA regulation in type 1 diabetic heart.  (A) Heat map represents miRNA 
modulation in type 1 diabetic mouse hearts when compared with controls using RTQ-PCR 
analyses.  Modulations are expressed using a log2 scale (-ΔΔCt).  Green indicates down-
regulation, red indicates up-regulation. (B)  Graphical representation of highest miRNA fold 
increases in the diabetic heart miRNA compared to control.  All values represented were 
statistically significant.  Values are represented as mean ± SEM; N=4 per group. *p<0.05 for all 
miRNA presented.     
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Fig 4.2 
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Figure 4.2.  miR-141 binding to Slc25a3.  (A)  Sequence homology between Slc25a3 3’-UTR 
(top) and miR-141 (bottom).  Black lines represent perfect match, grey lines represent G-U 
wobbles.  (B)  miR-141 recognition sequence of Slc25a3 gene in Mus musculus, Rattus 
norvegicus, Homo sapien, and Cavia porcellus as indicted from TargetScan.org.  Red characters 
represent the seed sequence for miR-141.   
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Fig 4.3 
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Figure 4.3.  miR-141 specific binding to Slc25a3 3’ UTR target sequence.  (A)  Sequence 
homology between miR-141 and family member miR-200c.  Red characters indicate differences 
in miR-200c nucleotide sequence.  (B)  Relative luciferase activities of Slc25a3 3’ reporter co-
expressed with miR-141, miR-200c, or scrambled plasmid (PmirGlo) control in HEK293 cells 24 
hours post transfection.  Firefly luciferase activity was normalized to Renilla luciferase activity. 
Values are represented as mean ± SEM; N=4 per group. *p<0.05 for miR-141 vs. all other 
groups.   
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Fig 4.4 
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Figure 4.4.  Slc25a3 expression levels.  (A) Relative mRNA levels of Slc25a3 in control and 
diabetic heart tissue.  RNU6 was used as an internal control.  Western blots and densitometry 
analysis for Slc25a3 protein expression in (B) SSM, and (C) IFM from control and diabetic 
hearts (N = 4). Control for protein loading was confirmed with Ponceau staining.  Values are 
represented as mean ± SEM; N=4 per group. *p<0.05 for Diabetic IFM vs Control IFM.   
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Fig 4.5 
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Figure 4.5.  Mitochondrial subpopulation ATP synthase activity. (A) General schematic of 
how ATP synthase produces ATP with the aid of Slc25a3 (phosphate transport) and ANT (ADP 
transport) within the mitochondria.  ATP synthase activity was assessed in SSM (B) and IFM (C) 
from hearts of control and diabetic animals using an assay coupled with pyruvate kinase which 
converts ADP to ATP and produces pyruvate from phosphoenolpyruvate. Final values are 
expressed as nanomoles/NADH/min/mg of protein ± SEM; N=4 for each group. *P<0.05 for 
Diabetic IFM vs. Control IFM. 
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Fig 4.6 
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Figure 4.6.  miR-141 overexpression.  (A)  Fold increase of miR-141 in HEK293 cells 72 hours 
post transfection with control or miR-141 expression plasmid.   (B)  Relative mRNA levels of 
Slc25a3 in HEK293 control and miR-141 cells.  RNU6 was used as an internal control.  Western 
blots and densitometry analysis for Slc25a3 protein expression in HEK293 control and miR-141 
cells.  GAPDH was used as an internal control.  Values are represented as mean ± SEM; N=4 per 
group. *p<0.05 where applicable. 
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Fig 4.7 
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Figure 4.7.  miRNA-141 ATP synthase activity. ATP synthase activity was assessed in 
HEK293 control and miR-141 cells using an assay coupled with pyruvate kinase which converts 
ADP to ATP and produces pyruvate from phosphoenolpyruvate.. Final values are expressed as 
nanomoles/NADH/min/mg of protein ± SEM; N=4 for each group. *P<0.05 for miR-141 vs 
Control groups. 
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Chapter 5: 
General Discussion 
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GENERAL DISCUSSION 
 The overall objective of this dissertation was to determine the mechanisms involved in 
mitochondrial proteomic dysregulation that occurs in the diabetic heart. Specifically, we sought 
to determine the effect of a diabetic insult on (1) nuclear-encoded mitochondrial protein import 
in mitochondrial subpopulations; (2) to test the therapeutic benefit of overexpressing 
mitochondrial specific antioxidant mPHGPx on protein translocation into individual 
mitochondrial subpopulations during a diabetic insult; (3) to evaluate the effect of diabetes 
induced miRNA modulation upon mitochondrial proteomic makeup.  Our long term goal is to 
better understand the mechanisms involved in the pathogenesis of diabetic cardiomyopathy as a 
prerequisite to the development of therapeutic interventions designed to lessen cardiac 
complications associated with diabetes mellitus.  The central hypothesis of this dissertation is 
that type 1 diabetic insult will cause dysfunction of the mitochondrial protein import process 
leading to a loss of key proteins required for adequate mitochondrial function and structure.  
These effects will be most pronounced in the IFM, influencing cardiac contractile processes.   
Our rationale for the proposed research is based upon the notion that the understanding of 
mitochondrial subpopulation response and identification of key factors that contribute to 
mitochondrial dysfunction will aid in the development of therapeutics that can address specific 
mitochondrial subpopulations at greatest risk from diabetes mellitus.      
 Cardiac complications are the leading cause of morbidity and mortality within diabetic 
patients.  A significant amount of literature has linked mitochondrial dysfunction with cardiac 
abnormalities seen within the diabetic heart (4, 9, 32, 34, 36, 38).  Specifically, abnormalities 
include, but are not limited to, altered substrate utilization, enhanced ROS production, increased 
apoptotic susceptibility, and altered mitochondrial structure during a diabetic insult (4, 9, 47).  
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Complicating cardiac mitochondrial studies, two spatially-distinct mitochondrial subpopulations 
exist within the myocardium and respond differently to various physiological and pathological 
stimuli (1, 20, 21, 33).  I/R injury was shown to decrease SSM abundance, increase ROS 
production from ETC complexes I and III, and decrease IMM phospholipid cardiolipin (22).  
Likewise, Judge et al. reported increased oxidative damage in aged mice correlating with 
increased lipid peroxidations and enhanced antioxidant defense within the IFM subpopulation 
(17).  Similar to the Judge study, previous research from our laboratory has highlighted IFM as 
the most dysfunctional subpopulation within the type 1 diabetic heart citing enhanced ROS 
production, enhanced ROS damage, and decreased size and internal complexity, whereas the 
diabetic SSM were relatively unaffected within these experimental parameters (9).  Although it 
has been suggested IFM are the primary pathological loci of interest within a type 1 diabetic 
setting, the mechanisms driving such manifestations remain limited.   
 Cardiac and mitochondrial proteomic studies within type 1 diabetic models have shown 
the mitochondrial proteome to be dramatically altered in the presence of the pathology (13, 18, 
41).  STZ-treated rats 4 weeks post diabetic induction displayed elevated levels of FAO proteins, 
decreases in ETC proteins from complex I, and a decrease in mitochondrial protein import 
constituent, MtHsp70 in cardiac tissue (41).  Similarly, Hamblin et al. analyzed cardiac tissue 
from 8 week STZ-treated diabetic rats, which revealed similar results of enhanced FAO as well 
as decreases in antioxidant defense proteins (13).  Using multiple proteomic approaches (2D-
DIGE and iTRAQ), we were able to identify IFM as the primary cardiac mitochondrial 
subpopulation most impacted by diabetes mellitus within STZ-treated mice (Chapter 2).  
Essentially all major processes occurring within IFM were significantly altered including those 
from the ETC (complex I, III, IV, V), FAO, the TCA cycle, and mitochondrial protein import 
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(MtHsp70).  Interestingly, we saw FAO proteins significantly decreased within the diabetic IFM, 
which was an unexpected finding.  Because of the inability of the heart to utilize glucose in a 
diabetic setting, it is intuitive to think that β-oxidation would be increased to allow for proper 
mitochondrial ATP production.   Although it is unclear as to why we see these discrepancies, it is 
important to point out that mitochondrial subpopulations were evaluated, there were differences 
in animal models, and different STZ protocols (high vs. low dose) were used.  Nevertheless, the 
contradictory findings are certainly interesting and warrant future experimentation.   
We next sought to understand mechanistically why the proteome of the IFM was severely 
impacted while the SSM subpopulation was not.  MtHsp70, a key component to nuclear-encoded 
mitochondrial import and essential protein of the PAM complex, has been shown in multiple 
proteomic platforms to be decreased in a diabetic insult (4, 41).  Temperature sensitive 
knockdown of MtHsp70 yeast homolog (ssc1) severely inhibited mitochondrial matrix import (8) 
and ssc1 knockout models have proven to be lethal (39).  Interestingly, both proteomic analyses 
conducted from our laboratory highlighted decreased content of MtHsp70 within the diabetic 
IFM.  Therefore, we decided to elucidate the impact of diabetes on nuclear-encoded 
mitochondrial import within cardiac mitochondrial subpopulations.  Fluorometric and Western 
blot analyses both revealed decreased ability of mitochondrial matrix import protein (MitoGFP1) 
to translocate into diabetic IFM compared to control, with no change in the SSM.  These results 
show for the first time that dysfunctional nuclear-encoded mitochondrial protein import is a 
potential mechanism for the proteomic dysregulation evident within diabetic IFM.  Nuclear-
encoded mitochondrial protein import is a complicated process in which multiple 
proteins/protein complexes must work in uniform for successful protein translocation into the 
mitochondria (19, 31, 46).  Because of this, we attempted to clarify what part of the protein 
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import process was dysfunctional within diabetic IFM.  Western blot analyses of several of the 
most important OMM (Tom20, Tom40), IMM (Tim23), and matrix (Tim44, MtHsp70) 
translocases were analyzed.  Interestingly, only MtHsp70 protein content was decreased within 
the diabetic IFM, which validated our proteomic data.  Mitochondrial membrane potential has 
been shown not only to be a critical component for mitochondrial OXPHOS but also as a driving 
force for preprotein translocation from the IMS into the mitochondrial matrix (15).  Interfibrillar 
mitochondria saw a modest 19% reduction in membrane potential during a diabetic insult, which 
may contribute to altered mitochondrial protein import.  However, previous studies examining 
aged skeletal muscle elicited reductions in mitochondrial membrane potential by as much as 
50%, which had no impact on mitochondrial import dynamics (14). Therefore, it is possible 
slight reductions in membrane potential may not be able to reduce mitochondrial import 
mechanics alone.   
There are other potential mechanisms that can account for mitochondrial proteomic 
dysregulation within the diabetic heart, including alterations to gene expression, detriments to 
cytoplasmic transport, and/or enhanced cytoplasmic proteasomal activity. In order to determine 
whether IFM proteomic dysfunction occurred due to upstream mechanisms prior to 
mitochondrial protein import, we examined multiple cytoplasmic chaperones directly involved in 
the transport of preproteins from the ribosomes to the mitochondria (Appendix 7.1).  The most 
thoroughly characterized mitochondrial chaperones are constitutive heat shock protein 70 
(Hsc70), inducible heat shock protein 70 (Hsp70i), and heat shock protein 90 (Hsp90).  
Mitochondrial transport chaperones hsc70, hsp70i, and hsp90 protein content were unaffected in 
diabetic IFM compared to control (Appendix 7.1).  Dysregulation of mitochondrial transport 
specific chaperones have been shown in various pathologies, including significant increases of 
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Hsp90 within skeletal muscle of aging rats (14).  Further, although we did not see changes in 
Hsc70 within our diabetic model, it is important to note Chen et al. saw a significant decrease in 
Hsc70 abundance in the diabetic rat myocardium of singular high-dose STZ injected rats as late 
as 21 days post injection (6).  The discrepancies between studies remain unclear; however, 
previously mentioned differences in experimental procedures may be the cause. 
 Another potential mechanism of proteomic dysregulation within mitochondria is 
enhanced cytoplasmic derived protein degradation due to elevated proteasomal abundance and/or 
activity.  Therefore, we sought to determine if diabetes mellitus has an influence on this 
cytoplasmic process, leading to downstream effects upon mitochondrial proteomic makeup.  
Enhanced protein degradation has indeed been shown within the cytoplasm of senescent rat 
skeletal muscle (14).  Further, the ubiquitin-proteasomal system has been implicated in multiple 
pathologies including cardiac hypertrophy, desmin-related cardiomyopathies, and numerous 
neurodegenerative diseases (10, 24, 37).  To determine whether ubiquitin-proteasomes have a 
detrimental role within the diabetic myocardium, we evaluated the activity level of its 20S 
catalytic subunit.  Interestingly, we saw no significant difference in activity level of the 
proteasomal 20S subunit in diabetic IFM compared to control IFM (Appendix 7.4).  Further, we 
also quantified the abundance of the primary alpha and beta subunits of the proteasome and 
again, saw no significant increases in either group analyzed (Appendix 7.4).  The results shown 
are in agreement with work presented from Liu et al. in which diabetic rat hearts displayed 
elevated levels of ubiquitin mRNA, but saw no change in free ubiquitin levels or proteasome 
chemotrypsin like peptidase activity (25).   From these results we concluded that diabetic 
induced proteomic dysregulation within the diabetic IFM was not a consequence of alterations to 
protein degradation within the cytoplasm.   
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Taken together, the data compiled from Chapter 2 indicates that diabetes-induced IFM 
proteomic dysregulation may be a consequence of altered nuclear-encoded mitochondrial protein 
import.  Further, mitochondrial protein import decrements are directly impacted by decreased 
protein content of matrix chaperone MtHsp70.   
Previous findings from our laboratory have suggested that the IMM of IFM may be 
particularly at risk within a type 1 diabetic setting (9).  Further, although the IMM constitutes 
only 21% of the total protein content within mitochondria, our proteomics data revealed greater 
than 50% of proteins identified and dysregulated within the IFM were of IMM origin.  
Additionally, a significant amount of mitochondrial import proteins reside within or are directly 
in contact with the IMM.  Therefore, we decided to employ the use of mPHGPx, an antioxidant 
potentially capable of preserving the IMM during a diabetic insult and analyze its effect upon 
diabetic IFM nuclear-encoded mitochondrial protein import.  MPHGPx is the only antioxidant 
enzyme with the ability to reduce peroxidized acyl groups in phospholipids, fatty acid 
hydroperoxides and cholesterol peroxides in mitochondrial membranes (26).  Residing within the 
mitochondrial IMS, this antioxidant has the ability to directly scavenge lipid hydroperoxides 
within mitochondrial membranes and has been implicated as the primary defense against 
mitochondrial membrane oxidations (40).  Specifically, mPHGPx is known to protect essential 
IMM phospholipid, cardiolipin from oxidative damage.  Cardiolipin is known to surround 
essential protein complexes within the IMM including the ETC complexes I, III and IV of the 
ETC as well as IMM import complex, TIM (23).   
No study to date has evaluated the impact of antioxidant overexpression on the 
preservation of the mitochondrial proteome in a diabetic setting within any organelle, including 
the heart.  Therefore, we decided to take mPHGPx transgenic mice, induce diabetes through STZ 
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treatment, isolate cardiac IFM and evaluate how mPHGPx overexpression impacted the 
mitochondrial proteome and mitochondrial import process.  Remarkably, mPHGPx 
overexpression was able to preserve a significant portion (60%) of proteins originally decreased 
within the diabetic IFM (Chapter 3).  Further, Ingenuity Pathway Analyses highlighted the 
preservation of proteins involved in processes such as OXPHOS, the TCA cycle, FAO, and 
mitochondrial protein import in mPHGPx diabetic IFM.  A breakdown of the percentages of 
proteins preserved within the mPHGPx diabetic IFM revealed the vast majority of proteins 
resided within the IMM (61%) and the mitochondrial matrix (36%).  Due to mPHGPx location 
within the IMS, we were surprised to see such a large preservation of mitochondrial matrix 
proteins.  ETC complexes I and III, known sites for electron leakage, were also highly preserved 
within the mPHGPx diabetic IFM; therefore, mPHGPx overexpression may decrease total 
electron leakage and subsequent ROS generation (7).  Given the matrix’s proximal location to 
the IMM, decreased ROS generation may be mechanism of proteomic protection within the 
mPHGPx mouse.  Indeed, our PTM data supports this notion by highlighting decreases in 
oxidations, acetylations, and deamidations within both the IMM and matrix of mPHGPx diabetic 
IFM compared to diabetic IFM (Chapter 3).  Although to a lesser extent, mPHGPx is capable of 
scavenging hydrogen peroxide, which would also lessen the oxidative environment within the 
mitochondrial matrix (42).   
 Ingenuity pathway analyses were also conducted in an effort to identify key protein 
networks of interest within  cardiac diabetic and mPHGPx diabetic IFM.  Most interestingly, 
proteins involved with nuclear-encoded mitochondrial protein import formed a central network, 
which linked other protein networks such as ETC complexes I and II, a mitofilin-based structural 
network, and an ATP-sensitive potassium channel network.  This gave us the impetus to study 
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whether nuclear-encoded mitochondrial protein import was also preserved within mPHGPx 
diabetic IFM.  As expected, mitochondrial protein import was restored within the mPHGPx 
diabetic IFM.  Further, multiple mitochondrial translocases were preserved or increased in the 
mPHGPx diabetic IFM group including Tom20, Tim50, Tim23 and MtHsp70.  In agreement, 
previous research in our laboratory has shown mPHGPx adenoviral overexpression also 
enhances Tom20 protein content within cardiac rat neonatal cardiomyocytes (48). MPHGPx 
protection of such a large portion of protein import translocases would certainly bolster protein 
import dynamics, even in times of diabetic stress.  Nevertheless, MtHsp70 was the only 
mitochondrial import protein shown to be significantly decreased within the diabetic IFM and 
therefore may act as the rate limiting step in matrix-associated mitochondrial protein import.  
This statement is supported by the fact that although Tom20, Tim50, and Tim23 were all 
increased in the mPHGPx diabetic IFM, MitoGFP1 import into the mitochondrial matrix was 
only restored, not enhanced.  Further, BN-PAGE analysis of MtHsp70 complexing within the 
PAM complex was decreased within the diabetic IFM and subsequently restored within the 
mPHGPx diabetic IFM.  These data proved conclusively that MtHsp70 protein content and 
functionality was preserved within the mPHGPx diabetic IFM.  Of note, there are additional 
mitochondrial import translocases such as OMM Tom22 and Tom40, as well as IMM Tim21 and 
Tim17 that could all potentially play a role in mitochondrial import dysfunction or preservation 
within the mPHGPx transgenic mouse.  Further, only the most highly abundant proteins, such as 
MtHsp70, were able to be identified and quantified through iTRAQ proteomic analyses, which is 
a known limitation for such experimentation.  To circumvent such a problem, an interesting 
study would be to fractionate the mitochondrial subcompartments (OMM, IMS, IMM, matrix) 
and then perform proteomic analyses.  This approach would allow for a much greater chance for 
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less abundant proteins, such as the aforementioned translocases, to be identified and/or 
quantified.  Scientific approaches such as this would certainly be warranted in the future.  
 Taken together, the results gathered from Chapter 3 highlight the unique ability of the 
antioxidant mPHGPx to protect cardiac IFM from proteomic decrements associated with type 1 
diabetes mellitus.  Further, restitution of the mitochondrial import processes, including essential 
protein import constituents, correlated with IFM proteomic preservation.  Studies such as these 
give the impetus for the development of therapeutics targeting mitochondrial proteomic 
preservation and/or restitution of nuclear-encoded mitochondrial protein import, which may 
provide protection in the diabetic heart.      
 Regulation of nuclear gene transcription/translation is another potential mechanism of 
mitochondrial proteomic regulation within the diabetic heart.  miRNAs are short (18-24nt) 
nucleotide molecules found within all vertebrate species that have the ability to cause gene 
silencing through mechanisms of mRNA degradation or translational repression (3, 5).  Recently, 
a wealth of literature has shown miRNAs to be directly implicated in cardiac pathologies, most 
notably cardiac hypertrophy (3, 43-45).  However, to date, research regarding miRNA 
modulation via diabetic insult remains limited.  Further, no study has evaluated the impact of 
diabetes mellitus on miRNA regulation of the mitochondrial proteome.  Therefore, using a broad 
scale RTQ-PCR approach, we evaluated 375 of the most prevalent mouse miRNAs in control 
and diabetic hearts to determine how miRNA are modulated within the pathology (Chapter 4).  
Interestingly, we saw upregulation of 26 miRNAs including miR-208b, miR-329, as well as 
family members miR-141 and miR-200c. These 4 miRNAs were the most highly upregulated 
with miR-141 being the highest at 5 fold.  Interestingly, Van Rooij et al. has identified miR-208b 
as a primary regulator of MHC switching within the heart, which has the functional ability to 
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repress α-MHC and promote β-MHC expression (45).  Given the context of this dissertation, we 
did not pursue whether miR-208b has similar effects within the diabetic heart.  However, 
research does suggest MHC switching can occur during a diabetic insult, implicating miR-208b 
as a potential regulator of such a phenomenon, warranting future investigation (2).  
miRNA targeting databases such as TargetScan.org, miRbase.org, and PicTar.org are 
becoming widely popular for their ability to predict miRNA binding partners within target genes 
3’ UTR’s.  Generally, the criteria for mRNA target prediction involves analyzing “seeding” 
region matches (nt 2-7), the number of miRNA target binding regions within the 3’ UTR, and the 
sequence homology between vertebrates (11, 12).  Remarkably, miR-141 was highly predicted to 
target mitochondrial inorganic phosphate carrier, Slc25a3, in all three of the aforementioned 
targeting databases.  Previous proteomic analyses (Chapter 2 and 3) highlighted Slc25a3 to be 
significantly decreased within the diabetic IFM giving us the impetus to determine whether miR-
141 is capable of repressing Slc25a3 within a diabetic setting.  Experiments were conducted in 
which the 3’ UTR target region of Slc25a3 was transfected downstream of a firefly luciferase 
plasmid.  Co-expression of this vector with miR-141 elicited a decrease in luciferase activity, 
confirming miR-141/Slc25a3 3’ UTR binding.  Further, overexpression studies (transient and 
stable transfections) of miR-141 within HEK293 cells caused a dramatic decrease in Slc25a3 
protein content, further validating miR-141 regulation upon the mitochondrial inorganic 
phosphate carrier.  Decrement to Slc25a3 has shown to cause significant decreases in ATP 
synthase activity and subsequent ATP production.  Specifically, a human genetic mutation to 
Scl25a3 led to decreased ATP synthase activity correlating with hypertrophic cardiomyopathy 
and decreased cardiac output (29, 30).  Similarly, overexpression of miR-141 also led to 
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decreased ATP synthase production in HEK293 cells and diabetic IFM, confirming the 
downstream functional impact of matrix phosphate reduction within mitochondria.   
Although the mechanism of miR-141 regulation upon Slc25a3 is clearly defined above, it 
is unclear why miR-141 is upregulated within a diabetic context.  Recent literature has begun to 
identify oxidative stress, in particular hydrogen peroxide production, as a causative agent for 
miR-141 overexpression (27, 28).  Our laboratory and others have shown significant elevations 
in ROS generation and damage within the diabetic myocardium; therefore, this scenario of 
enhanced miR-141 within diabetes mellitus is plausible (9, 34, 35).  Interestingly, Slc25a3 has 
been implicated as a primary member of the mPTP, which when formed, will induce 
mitochondrially-driven apoptosis through activation of a death-caspase cascade (16).  Previously, 
we have shown the diabetic IFM to have increased susceptibility to mPTP opening and 
subsequent death-caspase activation (47).  It could be speculated that increases in miR-141 in a 
diabetic setting is a protective mechanism aimed at decreasing mitochondrially-driven apotosis 
occurring within the diabetic IFM through inhibition of mPTP opening.  Experimentation in this 
regard is necessary in the future to give a better understanding of why miR-141 is upregulated 
within the diabetic myocardium.  
In summary, miRNAs are significantly altered within the diabetic heart and these 
modulations have the ability to influence nuclear-encoded mitochondrial proteins.  Further, 
modulation of essential mitochondrial proteins, such as Slc25a3, may impact mitochondrial 
functionality in a diabetic setting.  Therefore, experimentation examining miRNA regulation of 
other mitochondrial proteins of interest will allow for greater understanding of miRNAs and their 
effect upon the myocardium.  
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Utilizing the supporting evidence from the studies, it is clearly evident that diabetes-
induced mitochondrial proteomic dysregulation occurs through a multitude of coexisting 
mechanisms including decreased functionality of nuclear-encoded mitochondrial protein import 
(Chapter 2 and 3), enhanced PTM’s (Chapter 2 and 3), and increased miRNA regulation 
(Chapter 4).  We have also ruled out other potential mechanisms of mitochondrial proteomic 
dysregulation including detriments to mitochondrial transport chaperones (Appendix 7.3) and 
enhanced proteasomal degradation (Appendix 7.4).  Further, mPHGPx overexpression was able 
to preserve a large portion of the mitochondrial proteome, protect the nuclear-encoded 
mitochondrial protein import process and reverse PTMs within diabetic IFM.   Table 5.1 
summarizes the mechanisms analyzed in this dissertation within our type 1 diabetic model as 
well as the effect mPHGPx had upon the mechanisms.           
 
Table 5.1.  Mechanisms involved in IFM proteomic dysregulation in a diabetic setting 
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The initial finding in Chapter 2 that nuclear-encoded mitochondrial import was 
dysfunctional in the diabetic IFM served as a springboard for the subsequent chapters of the 
dissertation.  Because nearly all proteins must be imported into the mitochondrion, dysfunctional 
mitochondrial protein import seems to be the most logical explanation for the dysregulated 
mitochondrial proteome present in the diabetic IFM.  This led us to examine mechanisms of 
proteomic restitution through overexpression of mPHGPx, which was analyzed in Chapter 3 of 
the dissertation.  We had an inclination that mPHGPx would be able to restore mitochondrial 
protein import because of previous research in our laboratory in which mPHGPx overexpression 
in rat neonatal cardiomyocytes increased the protein content of OMM import protein Tim20.  
Remarkably, mPHGPx overexpression in diabetic mice corrected not only nuclear-encoded 
mitochondrial protein import, but also preserved 60% of the IFM proteome originally decreased 
in the diabetic IFM.  Therefore, the information accrued from both Chapter 2 and 3 strongly 
suggest alterations to nuclear-encoded mitochondrial protein import was a likely mechanism of 
mitochondrial proteomic dysregulation.  The research conducted in Chapter 4 was performed to 
give a better overall prospective of gene regulation within the diabetic heart.  With no supporting 
data to indicate miRNAs were modulated within the diabetic hearts, the preliminary results of 26 
altered miRNAs came as a pleasant surprise.  Interestingly, no mitochondrial import translocases 
were predicted to be regulated within the diabetic IFM, which was the original hypothesis to the 
aim.  Nevertheless, alterations to Slc25a3 via miR-141 upregulation allowed us to identify a 
novel method of mitochondrial proteomic modulation within the diabetic heart completely 
independent from the results compiled in Chapters 2 and 3.  Further, I believe it allowed for an 
overall broader prospective of how the mitochondrial proteome can be manipulated beyond acute 
mitochondrial specific mechanisms.   
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 In summary, the data presented suggests that multiple mechanisms must be taken into 
account when analyzing mitochondrial proteomic deficits that occur within the diabetic heart.  In 
particular, nuclear-encoded mitochondrial import plays a critical role in maintaining proper 
protein content within mitochondria, specifically the IFM subpopulation during a diabetic insult.  
Further, enhanced miRNA regulation may also contribute to mitochondrial proteomic 
abnormalities present within diabetic IFM.  Finally, therapeutics targeted at maintaining proper 
mitochondrial import function and/or miRNA regulation may be of clinical benefit in context to 
the type 1 diabetic heart. 
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Chapter 6: 
Future Directions 
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FUTURE DIRECTIONS 
 Although much headway has been made concerning the evaluation of type 1 diabetes 
mellitus on the nuclear-encoded mitochondrial protein import processes within this dissertation, 
there are still many questions that remained to be answered.  Most notably, our evaluation of the 
import process only analyzed matrix-associated mitochondrial protein import.  Among the many 
reasons for this was because MtHsp70, shown to be deficient within diabetic IFM, is absolutely 
essential for matrix preprotein import into mitochondria.  MtHsp70 is also known to influence 
IMM and IMS transport, albeit to a lesser extent.  Though import into other areas of the 
mitochondria (IMM, IMS, and OMM) are seemingly more complicated and much less defined 
within the literature, we have created novel plasmid constructs designed specifically to allow us 
to analyze protein import efficiency into the other subcompartments of the mitochondria.   
IMM protein import uses the TIM23 complex in a similar fashion to matrix import.  
However, these proteins contain a C-terminal hydrophobic region that locks the protein into the 
pore.  Through a controversial mechanism, these proteins are then laterally sorted into the IMM 
(3).  Similar to matrix preproteins, these proteins also contain N-terminal presequences, which 
are subsequently removed once properly inserted into the inner membrane.  OMM proteins must 
enter through the TOM40 pore and with the help of small IMS translocases, reinsert themselves 
into the OMM using the sorting and assembly machinery (SAM) complex (3). It is important to 
note that OMM proteins do not contain N-terminal presequences.  Experimentally, we cloned 
known proteins that reside within each submitochondrial location into an expression vector, 
expressed the protein using a reticulocyte lysate system and imported the proteins into their 
respective subcompartments.  The specific proteins used for each subcompartment are described 
below: 
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1. Matrix -  TCA cycle enzyme, MDH2 
2.  IMM  -  Complex I protein, NDUFS3 
3. OMM  -  OMM translocase, TOM22 
As shown in Fig 6.1, we were able to successfully import each protein into isolated 
mitochondria.  Within figure 6.1, L = protein lysate, M = isolated mitochondria, L + M = protein 
lysate added to mitochondria.  In order to confirm each specific protein reached their anticipated 
destinations, we imported the proteins into mitochondria, subfractioned the mitochondria, and 
then confirmed the protein resided in the correct subfraction through Western blot analyses.  
Mitochondrial IMS protein import was not analyzed because the exact mechanism of import has 
yet to be properly identified. 
 
Figure 6.1.  Mitochondrial protein import into the OMM, IMM, and Matrix. 
Pertaining to future directions, the most obvious first step is to analyze the import of these 
proteins within type 1 diabetic mitochondrial subpopulations.  Previous research from our 
laboratory has shown the IMM of IFM to be a primary site of dysfunction during a diabetic 
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insult.  Specifically, our results revealed decreased mitochondrial respiration correlating with 
decreased ETC complex activities (complex I, III, and IV) and decrements to ATP synthase 
activity.  Further, proteomic analyses (Chapter 2 and 3) revealed that of all the dysregulated 
proteins within the diabetic IFM, over 50% were of IMM origin.  Additionally, significant 
decreases in numerous ETC and ATP synthase proteins were evident, further validating the 
detrimental influence diabetes mellitus has upon the IMM of IFM.  Examining the impact 
diabetes mellitus has upon IMM protein import may reveal a novel mechanism of dysfunction 
within this key submitochondrial region.  Although we have not closely examined the influence 
diabetes mellitus has upon OMM proteins/protein complexes, many critical receptors (Tom20, 
Tom22) and channels (Tom40, VDAC) exist that are essential for proper mitochondrial 
functionality and viability.  Insight into OMM protein import mechanics would be a critical first 
step in elucidating potential negative effects within this relatively understudied mitochondrial 
locale.       
The research conducted in Chapter 3 highlighted the beneficial effect antioxidant mPHGPx 
had upon the mitochondrial proteome. Because we believe nuclear-encoded mitochondrial 
protein import efficiency is directly linked to mitochondrial proteomic homeostasis, we launched 
a full investigation to determine whether mPHGPx overexpression influenced protein import 
mechanics.  Interestingly, much of the data presented highlighted the absolute impact MtHsp70 
had upon matrix-associated protein import.  Decrements or preservation of this critical protein 
directly correlated with the functionality of the mitochondrial import process (Chapter 2 and 3).  
Therefore one of the long term studies proposed within the laboratory is to determine the 
therapeutic effect of MtHsp70 transgenic overexpression on the diabetic heart.  To accomplish 
this goal, I inserted human MTHSP70 into transgenic plasmid construct pCAGGS (Fig 6.2).  We 
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used this plasmid to create an MtHsp70 transgenic mouse line through pronuclear injection.  
Finally, genotypic (RTQ-PCR) and phenotypic (Western blot) experimentation was performed to 
confirm MtHsp70 overexpression within the mouse. 
 
        Figure 6.2. MtHsp70 transgenic construct 
Through overexpression of MtHsp70, future researchers will be able to critically evaluate the 
role that both MtHsp70 and protein import has upon cardiac and mitochondrial functionality 
during a diabetic insult.  Methodologies conducted in Chapter’s 2 and 3 of this dissertation, as 
well as in this future directions section can serve as an experimental jumping point to begin to 
answer some of these critical questions.  A topic currently being debated within the scientific 
community is the exact role MtHsp70 has pertaining to protein import into this key 
submitochondrial locale. Specifically, conflicting reports exist debating the extent MtHsp70 
facilitates IMM protein import.  Proteomic analyses evaluating IMM protein content derived 
from MtHsp70 overexpressing animals would help to elucidate whether MtHsp70 has a critical 
role in IMM protein import.   
Interestingly, MtHsp70 has been shown to have additional functions within mitochondria 
beyond assisting with protein import into the matrix, which includes aiding in the folding of 
proteins into their mature form or helping in the degradation of dysfunctional proteins.  Studies 
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designed to analyze the impact pathologies, such as diabetes mellitus, have upon these lesser 
studied mitochondrial processes as well as the potential protective effects MtHsp70 
overexpression elicits could all be explored in the immediate future.    
 Finally, the miRNA analyses within this dissertation were a definite step in the right 
direction in understanding how the mitochondrial proteome can be impacted by these small 
transcriptional/translational regulators.  However, the results were compiled analyzing total heart 
tissue from control and diabetic mice.  Most recently, literature has suggested that miRNAs 
potentially reside within the mitochondrion.  From these manuscripts, it is clearly evident 
miRNAs are able to be isolated from liver mitochondria.  However, why miRNA exist within the 
organelle is currently unknown (1, 2).  The most logical explanation would be that these 
miRNAs modulate transcription/translation of the mitochondrial genome.  Researchers have also 
speculated that mitochondria can potentially serve as reservoirs for miRNAs, expelling them 
under certain physiological or pathological conditions (1). Giving credence to such claims, use of 
bioinformatics approaches such as MiRanda and TargetScan algorithms determined 
mitochondrial miRNAs are likely involved in regulation of apoptosis, cell proliferation, and 
differentiation.  However, solid evidence pertaining to mitochondrial miRNA functionality 
remains limited.   
We have undertaken preliminary studies in which we examined miRNAs within cardiac 
mitochondrial subpopulations and analyzed the effect diabetes mellitus has upon mitochondrial 
miRNA modulation.  As shown in Fig 6.3, not only was a distinct subpopulation of miRNA 
present within cardiac SSM and IFM, but diabetes had a completely opposite effect upon their 
miRNA makeup.  Remarkably, in general, miRNAs were significantly reduced in the diabetic 
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IFM whereas diabetic SSM had significant increases in miRNA content.  Red indicates a 
significant increase in the miRNA, green indicates a significant decrease diabetic IFM.   
 
Figure 6.3 Mitochondrial miRNAs impacted by diabetes mellitus 
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This preliminary data indicates for the first time that cardiac mitochondria possess a distinct 
mitochondrial subpopulation and miRNAs within mitochondrial subpopulations are differentially 
impacted by diabetes mellitus.  Future directions within our laboratory would be to identify why 
miRNAs exist within cardiac mitochondria.  Further, elucidating why miRNAs are dysregulated 
within the diabetic mitochondrial subpopulations is absolutely essential.  We have begun to 
evaluate the impact of the mitochondrial miRNA subpopulation upon the mitochondrial genome 
and we believe this is a good start in understanding why these miRNA exist within mitochondria.  
Fig. 6.4 is a map of the mitochondrial genome and indicates potential miRNA binding partners 
within SSM and IFM subpopulations that may influence mitochondrial-encoded protein 
generation.  A red line indicates a miRNA that is upregulated in diabetes mellitus and green lines 
indicates a miRNA that is downregulated in diabetes mellitus. 
  
Figure 6.4. Mitochondrial miRNAs and their impact on the mitochondrial genome 
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Future research in context to the preliminary miRNA data presented in this section could 
elucidate a novel mechanism of mitochondrial genomic regulation within the mitochondria.  As 
stated above, it is also possible for mitochondria to act as holding chambers for cytoplasmic 
miRNAs.  It could be speculated that opening or rupturing of the mitochondria would cause 
miRNA to efflux out of the damaged organelle.  Interestingly, diabetic IFM have an increased 
propensity for mPTP opening, which coincides with decreased miRNA content as shown above. 
Therefore, increased mitochondrial pore opening may be a plausible mechanism as to why we 
see decreased miRNA within this select subpopulation.  Experimentation concerning the 
influence of membrane stability on mitochondrial miRNA content should be examined in the 
future.  In summary, findings derived from a study such as this has the potential to be highly 
impactful within scientific community and may lead to the identification of novel roles that both 
miRNA and mitochondria play in various physiological and pathological conditions.   
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Fig 7.1 
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Figure 7.1.  Mitochondrial protein import.   Effect of type 1 diabetes mellitus and mPHGPx 
overexpression on MitoGFP1 import in SSM. Cardiac mitochondrial subpopulations from 
control, diabetic, mPHGPx, and diabetic mPHGPx mice were isolated and incubated with 2µl of 
MitoGFP1 protein lysate at 1 and 2 minute time points.  Representative Western blots from SSM 
(A) protein import assay.  Graphical representation of mitochondrial protein import performed in 
control (C), diabetic (STZ), mPHGPx (M), and diabetic mPHGPx IFM (M + STZ) (B).  The 
relative amount of imported MitoGFP1 was determined by densitometry. Dashed line denotes 
control levels.  Import efficiency was based off of percent control at the 1 and 2 minute time 
points.  Both time point percentages were then averaged to show total import efficiency.  Control 
for protein loading was confirmed by Ponceau staining.  Values are presented as means ± SE.  
N=5 per group.   
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Fig 7.2 
 
 
 
 
 
 
 
 
 
 
 
 235 
 
Figure 7.2.  MtHsp70 content.  Western blot analysis of protein import constituent MtHsp70 in 
control (C), mPHGPx (M), diabetic (STZ) and diabetic MPHGPx (M + STZ) SSM. Control for 
protein loading was confirmed by Ponceau staining. Values are presented as means ± SE; P < 
0.07 for SSM mPHGPx + STZ vs. all groups; N=4 per group.   
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Fig 7.3 
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Figure 7.3.  Cytoplasmic Chaperones.  Western blot analysis of cytoplasmic chaperones 
involved mitochondrial preprotein translocation (Hsc70, Hsp70i, and Hsp90) from control and 
diabetic cytoplasm.  Values are presented as means ± SE; Control for protein loading was 
confirmed with GAPDH. N = 4 per group. 
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Fig 7.4 
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Figure 7.4. Proteosomal analysis.  Effect of type 1 diabetes mellitus on proteosomal abundance 
and activity within the cytoplasm.   20S proteosomal activity was measured fluorometrically in 
control and diabetic cytoplasm (A).  Data was expressed as enzymatic events.  Western blot 
analyses of α and β subunits of the 20S proteasome in the cytoplasm of control and diabetic 
samples containing 30 µg of protein (B).  Control for protein loading was confirmed with 
GAPDH.  Values are presented as means ± SE.  N = 4 per group. 
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